---
document_datetime: 2023-09-21 19:47:42
document_pages: 93
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/tecentriq-h-c-004143-ii-0018-epar-assessment-report-variation_en.pdf
document_name: tecentriq-h-c-004143-ii-0018-epar-assessment-report-variation_en.pdf
version: success
processing_time: 257.0626813
conversion_datetime: 2025-12-24 00:25:48.854506
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 July 2019 EMA/CHMP/557475/2019 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Tecentriq

International non-proprietary name: atezolizumab

Procedure No. EMEA/H/C/004143/II/0018

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................6                                                                                              |
|-----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6  |                                                                                                                                              |
| 1.2. Steps taken for the assessment of the product.........................................................6                |                                                                                                                                              |
| 2. Scientific discussion                                                                                                    | ................................................................................7                                                            |
| 2.1. Introduction.........................................................................................................7 |                                                                                                                                              |
| 2.1.1. Disease or condition...........................................................................................7     |                                                                                                                                              |
| 2.1.2. Epidemiology                                                                                                         | ....................................................................................................7                                        |
| 2.1.3. Biologic features................................................................................................7   |                                                                                                                                              |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis                                                                 | ..............................................8                                                                                              |
| 2.1.5. Management.....................................................................................................8     |                                                                                                                                              |
| 2.2. Non-clinical aspects                                                                                                   | ..............................................................................................9                                              |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | .........................................................10                                                                                  |
| 2.2.2. Discussion and conclusion on non-clinical aspects................................................10                  |                                                                                                                                              |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................10                                         |
| 2.3.1. Introduction....................................................................................................10   |                                                                                                                                              |
| 2.3.2. Pharmacokinetics.............................................................................................10      |                                                                                                                                              |
| 2.3.3. Discussion on clinical                                                                                               | pharmacology...................................................................14                                                            |
| 2.3.4. Conclusions on clinical pharmacology.................................................................15              |                                                                                                                                              |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................15                                         |
| 2.4.1. Dose response study(ies)                                                                                             | .................................................................................15                                                          |
| 2.4.2. Main study......................................................................................................16   |                                                                                                                                              |
| 2.4.3. Discussion on clinical efficacy............................................................................55        |                                                                                                                                              |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................57          |                                                                                                                                              |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................57                                       |
| 2.5.1. Discussion on clinical safety                                                                                        | ..............................................................................79                                                             |
| 2.5.2. Conclusions on clinical safety                                                                                       | ............................................................................81                                                               |
| 2.5.3. PSUR cycle                                                                                                           | .....................................................................................................81                                      |
| 2.6. Risk management plan........................................................................................81         |                                                                                                                                              |
| 2.7. Update of the Product information                                                                                      | ........................................................................88                                                                   |
| 2.7.1. User consultation.............................................................................................88     |                                                                                                                                              |
| 3. Benefit-Risk Balance..............................................................................89                     |                                                                                                                                              |
| 3.1. Therapeutic Context                                                                                                    | ...........................................................................................89                                                |
| 3.1.1. Disease or condition.........................................................................................89      |                                                                                                                                              |
| 3.1.2. Available therapies and unmet medical need.......................................................89                  |                                                                                                                                              |
| 3.1.3. Main clinical studies                                                                                                | .........................................................................................89                                                  |
| 3.2. Favourable effects                                                                                                     | ..............................................................................................89                                             |
| 3.3. Uncertainties and limitations about favourable effects.............................................90                  |                                                                                                                                              |
| 3.4. Unfavourable effects...........................................................................................90      |                                                                                                                                              |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | .........................................90                                                                                                  |
| 3.6. Effects Table......................................................................................................91  |                                                                                                                                              |
| 3.7. Benefit-risk assessment and discussion.................................................................91              |                                                                                                                                              |
| 3.7.1. Importance of favourable and unfavourable 3.7.2. Balance of benefits and                                             | effects..............................................91 risks.............................................................................91 |

<div style=\"page-break-after: always\"></div>

| 3.7.3. Additional considerations on the benefit-risk balance ...........................................92                 |
|----------------------------------------------------------------------------------------------------------------------------|
| 3.8. Conclusions .......................................................................................................92 |
| 4. Recommendations.................................................................................92                      |
| 5. EPAR changes........................................................................................92                  |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADA

anti-drug antibody, also called anti-therapeutic antibody

ADR

adverse drug reaction

AE

adverse event

AESI

adverse event of special interest

Atezo

Atezolizumab

CCOD

clinical cut-off date

CD47

Cluster of Differentiation 47

CE

Carboplatin + Etoposide

CI

confidence interval

CMC

chemistry, manufacturing, and control

Cmin

minimum serum or plasma concentration

CNS

central nervous system

CR

complete response

CSR

Clinical Study Report

DOR

Duration of response

ECOG PS

Eastern Cooperative Oncology Group Performance status

eCRF

electronic Case Report Form

EMA

European Medicines Agency

EORTC QLQ-C30

European Organization for the Research and Treatment of Cancer Quality of Life

Questionnaire Core 30

EORTC QLQ-LC13

European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module

ES-SCLC

extensive-stage small cell lung cancer

EU

European Union

FNA

fine needle aspiration

HR

hazard ratio

HRQoL

Health-Related Quality of Life

iDMC

Independent Data Monitoring Committee

IgG1

immunoglobulin G1

IHC

immunohistochemistry

IL-10

Interleukin 10

ITT

intent-to-treat

IV

intravenous

IxRS

Interactive Voice/Web Response System

KM

Kaplan-Meier

MAA

Marketing Authorisation Application

mAb

monoclonal antibody

NPT

non-prior anti-cancer therapy

NSCLC

non-small cell lung cancer

ORR

objective response rate

OS

overall survival

PBO

placebo

<div style=\"page-break-after: always\"></div>

| PCI    | prophylactic cranial irradiation              |
|--------|-----------------------------------------------|
| PD     | progressive disease                           |
| PD-1   | programmed death-1                            |
| PD-L1  | programmed death-ligand 1                     |
| PFS    | progression-free survival                     |
| PK     | Pharmacokinetic                               |
| PopPK  | population pharmacokinetics                   |
| PR     | partial response                              |
| PRO    | patient-reported outcome                      |
| q3w    | every three weeks                             |
| RECIST | Response Evaluation Criteria for Solid Tumors |
| RMP    | Risk Management Plan                          |
| SAE    | serious adverse event                         |
| SAP    | Statistical Analysis Plan                     |
| SBP    | Summary of Biopharmaceutics                   |
| SCE    | Summary of Clinical Efficacy                  |
| SCLC   | small cell lung cancer                        |
| SCP    | Summary of Clinical Pharmacology              |
| SCS    | Summary of Clinical Safety                    |
| SmPC   | Summary of Product Characteristics            |
| TGF- β | transforming growth factor beta               |
| Ttd    | time to deterioration                         |
| UC     | urothelial carcinoma                          |
| US     | United States                                 |
| VALG   | Veterans Administration Lung Study Group      |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Roche Registration GmbH submitted to the European Medicines Agency on 11 October 2018 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication to include, in combination with carboplatin and etoposide, first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) for Tecentriq; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. RMP version 8.0 has also been submitted.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0220/2015 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0220/2015 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication.

## Scientific advice

The applicant did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Sinan B. Sarac

Co-Rapporteur:

Jan Mueller-Berghaus

<div style=\"page-break-after: always\"></div>

| Timetable                                                                                                                                          | Actual dates     |
|----------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| Submission date                                                                                                                                    | 11 October 2018  |
| Start of procedure:                                                                                                                                | 3 November 2018  |
| CHMP Rapporteur Assessment Report                                                                                                                  | 20 December 2018 |
| CHMP Co-Rapporteur Assessment Report                                                                                                               | 20 December 2018 |
| PRAC Rapporteur Assessment Report                                                                                                                  | 4 January 2019   |
| PRAC members comments                                                                                                                              | 9 January 2019   |
| Updated PRAC Rapporteur Assessment Report                                                                                                          | 10 January 2019  |
| PRAC Outcome                                                                                                                                       | 17 January 2019  |
| CHMP members comments                                                                                                                              | 21 January 2019  |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report                                                                                               | 24 January 2019  |
| Request for supplementary information (RSI)                                                                                                        | 31 January 2019  |
| Extension of timetable adopted by the CHMP on:                                                                                                     | 28 February 2019 |
| CHMP Rapporteur Assessment Report                                                                                                                  | 3 June 2019      |
| CHMP members comments                                                                                                                              | 17 June 2019     |
| Request for supplementary information (RSI)                                                                                                        | 27 June 2019     |
| CHMP Rapporteur Assessment Report                                                                                                                  | 9 July 2019      |
| CHMP members comments                                                                                                                              | 15 July 2019     |
| Updated CHMP Rapporteur Assessment Report                                                                                                          | n/a              |
| The CHMP adopted a report on the novelty of the indication/significant clinical benefit in comparison with existing therapies on date (Appendix 1) | 25 July 2019     |
| Opinion                                                                                                                                            | 25 July 2019     |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Disease or condition

## 2.1.2. Epidemiology

Lung cancer remains the leading cause of cancer death worldwide.  NSCLC is the predominant subtype, accounting for approximately 85% of all cases (Molina et al. 2008; Howlader et al. 2014). Small cell lung cancer accounts for approximately 15% of all cases, and is distinguished from NSCLC by its rapid growth, early development of metastatic disease, and initial responsiveness to platinum-based doublet chemotherapy (Govindan et al. 2006).

## 2.1.3. Biologic features

SCLC is characterised by uniform round to spindled-shaped small cells, sparse cytoplasm, high mitotic index, necrotic areas (ESMO, 2013).

<div style=\"page-break-after: always\"></div>

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

SCLC is characterised by a rapid doubling time, high growth fraction, and early development of widespread metastases. The majority of the patients with SCLC present with hematogenous metastases. One third of the patients present with limited disease confined to the chest (NCCN, 2019).

The Veterans Administration Lung Group (VALG) proposed a clinical two-stage system for SCLC that distinguishes limited stage and extensive stage. Limited-stage is defined as being limited to one hemithorax, including mediastinal, contralateral hilar and ipsilateral supraclavicular lymph nodes, whereas extensive-stage represents tumour spread beyond these regions (Zelen 1973). Poor prognostic factors for survival in patients with SCLC include extensive-stage (ES) disease, poor ECOG PS, weight loss, and markers associated with excessive bulk of disease (e.g., elevated lactate dehydrogenase) (Yip et al. 2000; Foster et al. 2009).

## 2.1.5. Management

Patients with limited-stage SCLC can be treated with chemotherapy and radiation with the potential for long-term survival (Stinchcombe et al. 2010).  However, the majority (approximately 70%) of patients with SCLC are diagnosed with ES-SCLC, which has poor survival prospects: the median OS is approximately 10 months with a 1-year OS rate of approximately 40% (Socinski et al. 2009). Chemotherapy alone can palliate symptoms and prolong survival for patients with ES-SCLC; however, long-term survival is rare (Johnson et al. 2004; DeMets et al. 2010).

The current standard first-line treatment for patients with ES-SCLC is platinum-based chemotherapy with etoposide, a topoisomerase II inhibitor (NCCN 2018, Fruh et al. 2013). The combination of cisplatin or carboplatin with etoposide has shown response rates ranging from 60% to 70% in patients with ES-SCLC (Rossi et al. 2012).  Several studies using cisplatin or carboplatin with etoposide (at various doses) have shown consistent outcomes, suggesting their efficacy is equivalent in patients with ES-SCLC. A meta-analysis of four randomized studies compared cisplatin-based versus carboplatin based regimens in patients with SCLC (Rossi et al. 2012).  Of the 663 patients included in this meta-analysis, 68% had extensive-stage disease. In patients receiving cisplatin- versus carboplatin-containing regimens, there was no significant difference observed in response rate (67% vs. 66%), PFS (median: 5.5 vs. 5.3 months; hazard ratio [HR]: 1.10; 95% confidence interval [CI]: 0.94, 1.29) or OS (median: 9.6 vs. 9.4 months; HR: 1.08; 95% CI: 0.92, 1.27), suggesting equivalent efficacy in patients with ES-SCLC. Carboplatin is frequently substituted for cisplatin in clinical practice as it reduces the risk of emesis, neuropathy, nephropathy and fluid overload from cisplatin intravenous (IV) hydration protocols that patients may not tolerate. Etoposide in combination with cisplatin or carboplatin is nationally authorised for the treatment of SCLC

Despite the impressive response rates observed with first-line chemotherapy regimens, most patients with ES SCLC develop chemotherapy resistant disease and their prognosis is poor. Therefore, there is need for improved treatment options for patients with ES-SCLC (Chute et al 1999).

## About the product

Atezolizumab  is  an  Fc-engineered  humanized  immunoglobulin  (IgG1)  monoclonal  antibody  (MAb) targeting  the  programmed  death-ligand  1  (PD-L1).  Binding  of  atezolizumab  to  PD-L1  inhibits  the interaction of the PD-1 and B7.1 receptors. Both of these interactions are reported to provide inhibitory signals to T cells.

<div style=\"page-break-after: always\"></div>

Tecentriq is currently authorised as 840 mg concentrate for solution for infusion (positive opinion adopted by CHMP but pending EC decision at the time of adoption of this procedure) and 1,200 mg concentrate for solution for infusion.

Tecentriq is currently authorised in the following indications:

- Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):

- after prior platinum-containing chemotherapy, or
- who are considered cisplatin ineligible, and whose tumours have a PDL1 expression ≥ 5%.

- Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment  of  adult  patients  with  metastatic  non-squamous  non-small  cell  lung  cancer  (NSCLC).  In patients  with  EGFR  mutant  or  ALK-positive  NSCLC,  Tecentriq,  in  combination  with  bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies .

- Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq.

-  Tecentriq  in  combination  with  nab-paclitaxel  is  indicated  for  the  treatment  of  adult  patients  with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

The current application is submitted to extend the authorised indication to the use of atezolizumab in combination with carboplatin and etoposide for the treatment of ES-SCLC in  patients who have not received previous systemic therapy. The evidence comes from pivotal study IMpower133, a phase III, multicentre, randomised, double-blind, placebo-controlled study.

The following new indication is recommended by the CHMP:

Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

During the induction phase, the recommended dose of Tecentriq is 1,200 mg administered by intravenous infusion followed by carboplatin, and then etoposide administered by intravenous infusion on day 1. Etoposide is also administered by intravenous infusion on days 2 and 3. This regimen is administered every three weeks for four cycles.

The induction phase is followed by a maintenance  phase without chemotherapy in which 1,200 mg Tecentriq is administered by intravenous infusion every three weeks.

It is recommended that patients are treated with Tecentriq until disease progression or unmanageable toxicity. Treatment beyond disease progression may be considered at the discretion of the physician (see section 4.2 of the SmPC).

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

<div style=\"page-break-after: always\"></div>

## 2.2.1. Ecotoxicity/environmental risk assessment

Atezolizumab is an IgG1 monoclonal antibody produced by recombinant DNA technology, a protein with a molecular mass of ~150 kDa. As an unaltered protein, being extensively degraded in the patient's body by regular proteolytic mechanisms before excretion, atezolizumab is unlikely to result in a significant environmental exposure. Atezolizumab is expected to biodegrade in the environment and does not pose a  significant  risk  to  the  environment.  Thus,  according  to  the  'Guideline  on  the  Environmental  Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00), atezolizumab is exempt from the submission of Environmental Risk Assessment studies as the product and excipients do not pose a significant risk to the environment.

## 2.2.2. Discussion and conclusion on non-clinical aspects

No new nonclinical data has been provided to support this application. The applicant did not submit studies for the ERA. According to the relevant guideline, in the case of products containing proteins as active pharmaceutical ingredient(s), this is acceptable.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<!-- image -->

| Study                | Design                                                                  | Patient Population                                                                                                                                     | Number of Patients Enrolled                 | Treatment                                                                                                      | Primary Efficacy Endpoint                         | Timing of Primary Analysis (Clinical Cutoff Date)                                                                                                                                                                                          |
|----------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|----------------------------------------------------------------------------------------------------------------|---------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pivotal Study        |                                                                         |                                                                                                                                                        |                                             |                                                                                                                |                                                   |                                                                                                                                                                                                                                            |
| 0030081 (lMpower133) | Phase Illl, global, placebo- randomized, double-blind, controlled study | Patients 218 years with histologically or (per the VALG confirmed ES-SCLC cytologically staging system). EcOG PS 0 or 1 and no prior systemic therapy. | Total: n = 403 n-202PBO+CE n=201 Atezo + CE | Atezolizumab fixed dose of 1200 mg IV q3w and Etoposide 100 Carboplalin AUC of 5 mg'mL/min IV q3w mg/m² IV q3w | Investigator- assessed So pue PFS per RECIST v1.1 | The OS interim analysis was performed when approximately 240 OS events in the ITT population were observed. The pre- specified primary analysis of PFS was planned to be conducted at the time of the Os interim analysis. (24 April 2018) |

ECoG PS=Eastem Cooperative Oncology Group Performance Status: ES-SCLC =oxtensive-stage small celllung cancer: IV=intravenous: VALG= Veterans Administration Lung Study Group.

## 2.3.2. Pharmacokinetics

The  PK  of  atezolizumab  in  ES-SCLC  was  characterized  based  on  data  from  the  Phase  I/III  study, IMpower133.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetics in target population

The  descriptive  statistics  of  the  available  Cmax  (30  minutes  following  the  end  of  the  atezolizumab infusion) and Cmin (pre-dose) serum concentrations of atezolizumab for the Atezo + CE arm following 1200 mg q3w IV administration are summarized in the table below. A total of 195 patients had evaluable atezolizumab PK. Mean serum atezolizumab concentrations over time are shown in Figure 1. Steady-state was reached by approximately Cycle 3 based on evaluation of trough concentration (Cmin).

Table 1: Summary Statistics for Atezolizumab Cmax and Cmin Following Multiple IV Doses of Atezolizumab1200 mg, Administered Every 3 Weeks in Combination with Carboplatin and Etoposide

| Treatment   | Visit1   |   Nominal Time From First Dose (day) |   N | AM (μg/mL)   | AM SD (μg/mL)   | GM (μg/mL)   | GM %CV   | Min (μg/mL)   |   Median (μg/mL) |   Max (μg/mL) |
|-------------|----------|--------------------------------------|-----|--------------|-----------------|--------------|----------|---------------|------------------|---------------|
| Atezo + CE  | C1D1     |                               0      | 194 | NR           | NR              | NE           | NR       | NR            |              0   |             0 |
| Atezo + CE  | C1D1     |                               0.0625 | 185 | 389          | 135             | 258          | 699      | 0.03          |            395   |           779 |
| Atezo + CE  | C1D21    |                              21      | 174 | 80.6         | 32.1            | 71.6         | 84.5     | 0.03          |             79.1 |           275 |
| Atezo + CE  | C2D21    |                              42      | 166 | 120          | 52.3            | 112          | 39.7     | 33            |            114   |           528 |
| Atezo + CE  | C3D21    |                              63      | 156 | 138          | 56.4            | 119          | 102      | 0.03          |            130   |           333 |
| Atezo + CE  | C7D21    |                             147      |  88 | 186          | 73.5            | 171          | 44.5     | 49.1          |            177   |           364 |

AM = Arithmetic Mean; Atezo + CE = atezolizumab in combination with carboplatin and etoposide; Cmax = maximum serum concentration;

Cmin = trough or minimum serum concentration; CV = coefficient of variation; GM = Geometric Mean; IV = intravenous; Max = maximum;

Min = minimum; N = number of patients included in summary statistics; SD = standard deviation; NE = Not Evaluable; NR = Not Reported.

1Visit is denoted by Cycle abbreviated by \"C\" and Day abbreviated by \"D\". For example, C1D1 corresponds to Cycle 1, Day 1. Predose Cycle 1 is C1D1, 0 days. Cmax is C1D1 30 minutes post end of infusion. Predose Cycle 2 is C1D21, predose Cycle 3 is C2D21, Cmax is C3D1 30 minutes postend of infusionetc.

Datasource:IMpower133CSR,Table31

<!-- image -->

Atezo + CE = atezolizumab in combination with carboplatin and etoposide; SD =standard deviation

Data source: IMpower133 CSR, Figure 11

Figure 1: Mean ( ± SD) Plot of Atezolizumab Serum Concentrations versus Time Following Multiple IV Doses of Atezolizumab 1200 mg, Administered Every 3 Weeks in Combination with Carboplatin and Etoposide

## Carboplatin Pharmacokinetics

A total of 30 patients had evaluable carboplatin PK (16 patients from the Atezo + CE arm and 14 patients from the PBO + CE arm). The mean plasma carboplatin concentrations over time are presented in Figure 2, and show that the concentration-time profiles of carboplatin are similar between treatment arms.

<div style=\"page-break-after: always\"></div>

Atezo + CE = atezolizumab in combination with carboplatin and etoposide; AUC = area under the concentration-time curve; PBO + CE = placebo in combination with carboplatin and etoposide;

<!-- image -->

SD=standard deviation

Data source: IMpower133 CSR, Figure 12

Figure 2: Mean (±SD) Plot of Carboplatin Plasma Concentrations versus Time Following Multiple IV Doses of Carboplatin AUC 5 mg/mL*min, Administered Every 3 Weeks in Combination with Etoposide, with or without Atezolizumab

## Etoposide Pharmacokinetics

A total of 30 patients had evaluable etoposide PK (16 patients from the Atezo + CE arm and 14 patients from the PBO + CE arm). The mean plasma etoposide concentrations over time are presented in Figure 3, and show that the concentration-time profiles of etoposide are similar between treatment arms. The data suggest administration of carboplatin and atezolizumab in combination with etoposide do not impact the PK of etoposide.

<!-- image -->

Atezo + CE = atezolizumab in combination with carboplatin and etoposide;IV= intravenous;

PBO+ CE=placebo in combination with carboplatin and etoposide;SD=standard deviation

Datasource:IMpower133CSR,Figure13

Figure 3: Mean (±SD) Plot of Etoposide Plasma Concentrations versus Time Following Multiple IV Doses of Etoposide 100 mg/m2, Administered on Days 1, 2, and 3 of Every 3 Week Cycle in Combination with Carboplatin, with or without Atezolizumab

## Pharmacokinetics by Treatment-Emergent ADA Status

Atezolizumab concentrations up to Cycle 7 Day 21 (or pre-dose Cycle 8) by treatment-emergent ADA status are summarized in Table 2 for all atezolizumab patients who were both PK and ADA-evaluable. The geometric mean Cmin estimates for Cycle 7 Day 21 (or pre-dose Cycle 8) in the Atezo + CE arm were 135 μg/mL and 179 μg/mL for ADA -positive and ADA-negative patients, respectively.

<div style=\"page-break-after: always\"></div>

Mean  serum  atezolizumab  concentrations  over  time  by  ADA  status  are  shown  in  Table  2.  Average atezolizumab  Cmin  for  both  ADA-positive  and  ADA-negative  patients  approached  a  plateau  (or steady-state) between 4-8 cycles of dosing.

Table 2: Summary Statistics for Atezolizumab Cmax and Cmin Following Multiple IV Doses of Atezolizumab 1200 mg Given Every 3 Weeks in Combination with Carboplatin and Etoposide by Treatment-Emergent ADA status

| ADA Status   | Visit1   |   Nominal Time From First Dose (day) |   N | AM (μg/mL)   | AM SD (μg/mL)   | GM (μg/mL)   | GM %CV   | Min (μg/mL)   |   Median (μg/mL) |   Max (μg/mL) |
|--------------|----------|--------------------------------------|-----|--------------|-----------------|--------------|----------|---------------|------------------|---------------|
| Negative     | C1D1     |                               0      | 152 | NR           | NR              | NE           | NR       | NR            |              0   |             0 |
| Negative     | C1D1     |                               0.0625 | 144 | 389          | 136             | 262          | 628      | 0.03          |            393   |           779 |
| Negative     | C1D21    |                              21      | 141 | 80.3         | 28.7            | 71.1         | 92.8     | 0.03          |             79.5 |           156 |
| Negative     | C2D21    |                              42      | 136 | 123          | 55.3            | 114          | 40.9     | 33            |            115   |           528 |
| Negative     | C3D21    |                              63      | 128 | 141          | 57.4            | 122          | 107      | 0.03          |            130   |           333 |
| Negative     | C7D21    |                             147      |  74 | 193          | 74.2            | 179          | 43.9     | 49.1          |            186   |           364 |
| Positive     | C1D1     |                               0      |  35 | NR           | NR              | NE           | NR       | NR            |              0   |             0 |
| Positive     | C1D1     |                               0.0625 |  34 | 404          | 83.4            | 395          | 21.7     | 237           |            396   |           577 |
| Positive     | C1D21    |                              21      |  33 | 81.8         | 44.1            | 73.8         | 46.2     | 34.7          |             73.2 |           275 |
| Positive     | C2D21    |                              42      |  30 | 108          | 33.5            | 103          | 33       | 56            |            110   |           173 |
| Positive     | C3D21    |                              63      |  28 | 126          | 50.4            | 108          | 79.3     | 6.88          |            130   |           212 |
| Positive     | C7D21    |                             147      |  14 | 144          | 55.4            | 135          | 40       | 65.9          |            137   |           261 |

ADA=anti-drug antibodies; AM=Arithmetic Mean; Cmax = maximum serum concentration; Cmin = trough or minimum serum concentration; CV=coefficient of variation; GM= Geometric Mean; IV = intravenous; Max = maximum; Min = minimum; N=number of patients included in summary statistics;NE=NotEvaluable;NR=NotReported;SD=standard deviation.

1 Visit is denoted by Cycle abbreviated by \"C\" and Day abbreviated by \"D\". For example, C1D1 corresponds to Cycle 1, Day 1, etc. Predose Cycle infusion etc.

Datasource:IMpower133CSR,Table67

<!-- image -->

ADA=anti-drug antibodies; Atezo + CE = atezolizumab in combination with carboplatin and etoposide; SD =standard deviation

Data source:IMpower133CSR,Figure16

Figure 4: Mean ( ± SD) Plot of Atezolizumab Concentrations versus Time Following Multiple IV Doses of Atezolizumab 1200 mg Given Every 3 Weeks in Combination with Carboplatin and Etoposide by Treatment-Emergent ADA Status

<div style=\"page-break-after: always\"></div>

## Population PK analysis

The  Phase  I  popPK  Model  was  subjected  to  an  external  validation  for  mUC,  NSCLC,  and  ES-SCLC separately, using PK data collected in IMvigor210 and IMvigor211 for mUC, data collected in BIRCH, POPLAR, FIR, OAK and IMpower150 for NSCLC and data collected in IMpower133 for ES-SCLC.

The prediction-corrected visual predictive check suggested that the median, 95th, and 5 th percentiles of observed Cmax and Cmin were generally within the prediction intervals of the Phase I popPK Model (Figure 5). Covariate effects (i.e., BWT, gender, ADA status, albumin levels and tumor burden) in the IMpower133 data were generally consistent with those identified in the popPK Model. Both Cycle 1 and steady-state  exposure  metrics  were  similar  to  those  estimated  in  other  atezolizumab  monotherapy studies.

popPK=population pharmacokinetics; VPC =visual predictive check.

<!-- image -->

Source: IMpower133 extermal-validation popPK Report 1090018, Figure 2

Figure 5: Predicted-Corrected Visual Predictive Check Atezolizumab Concentration in IMpower133 Using the Phase I PopPK Model

## 2.3.3. Discussion on clinical pharmacology

The  recommended  dose  of  atezolizumab  is  1200  mg  administered  as  an  IV  infusion  q3w.  Study IMpower130 evaluated atezolizumab at this dose level and schedule in chemotherapy-naïve patients with NSCLC, in combination with carboplatin and nab- paclitaxel.  The rationale for the recommended dose was  based  on  data  from  nonclinical  studies  and  available  clinical  data  from  Study  PCD4989g  (see European Public Assessment Report for the initial marketing authorisation). In addition, results from the studies OAK, BIRCH and POPLAR support the selection of the 1200 mg q3w dose level in patients with locally advanced or metastatic NSCLC.

The starting point for the population PK analysis submitted in the current variation application was the previous  population  PK  analysis  based  on  dataset  including  subjects  from  phase  I  clinical  studies

<div style=\"page-break-after: always\"></div>

PCD4989g  and  JO28944).  This  'Phase  I  popPK  Model'  was  subsequently  subjected  to  an  external evaluation with the use of atezolizumab PK data collected in Study IMpower133.

The  goodness-of-fit  plots  for  population  and  individual  predictions  appeared  adequate.  The  Phase  1 popPK Model is suitable to describe the individual PK data from the IMpower130 Study and seems suitable for determination of atezolizumab exposure metrics. The co-administration of chemotherapy (carboplatin +  etoposide)  did  not  seem  to  influence  atezolizumab  PK.  The  data  submitted  also  suggest  that administration of etoposide and atezolizumab in combination with carboplatin do not impact the PK of carboplatin.

In general, the observed concentrations in this setting fall within the range of predicted concentrations, at least during the first cycle, indicating that the definitive population PK model developed on monotherapy data provides an adequate description of the pharmacokinetics of atezolizumab in combination with carboplatin and etoposide. The data available support the use of the same dose of 1200 mg q3w for atezolizumab.

Since  atezolizumab  is  cleared  from  the  circulation  through  catabolism,  no  metabolic  drug-drug interactions are expected. Based on PK data from IMpower133, there is no evidence of a PK drug-drug interaction with the co-administration of atezolizumab with carboplatin and etoposide.

While PK and ADA samples had to be collected from patients assigned to the comparator arm to maintain the blinding of treatment assignment, PK and ADA assay results for atezolizumab in these patients were generally not needed for the safe conduct or proper interpretation of this study. Sponsor personnel responsible for performing PK and ADA assays were unblinded to patients' treatment assignment to identify appropriate samples to be analyzed. Samples from patients assigned to the comparator arm were not analyzed for atezolizumab concentration except by request (e.g., to evaluate a possible error in dosing). Atezolizumab ADA samples collected on Day 1 of Cycle 1 could be analysed for all patients, while subsequent samples from patients assigned to the comparator arm were not to be analyzed for ADA unless requested.

The baseline prevalence of atezolizumab ADAs was 2.0% in the atezolizumab - CE arm for atezolizumab-treated patients with a baseline ADA sample. The post-baseline treatment-emergent ADA incidence was 18.6%. The rates of treatment emerged ADA are considered to be high. Treatment emergent ADAs did not appear to have a clinically meaningful impact, the number of ADA positive subjects is too small (n=35) to draw firm conclusions.  There was a trend for slightly lower exposure in ADA-positive patients; however the Cmin in all ADA-positive patients was in excess of the target serum concentration of 6 μg/mL. The MAH is recommended to further investigate the effect of neutralizing antibodies on atezolizumab pharmacokinetics and efficacy of atezolizumab (see also clinical efficacy).

## 2.3.4. Conclusions on clinical pharmacology

The clinical pharmacology of atezolizumab has previously been characterized and the PK investigations in IMPower133 overall confirm previous findings. The PK of atezolizumab is similar when administered in combination with carboplatin and etoposide without evidence of drug-drug interactions, no unexpected interactions with covariates have been identified and the proposed dose of 1200 mg q3w seems to be appropriate and is endorsed.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

No additional dose-response study was performed.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study

IMpower133 (study GO30081): A Phase I/III, randomized, double-blind, placebo-controlled study of carboplatin plus etoposide with or without atezolizumab (anti-PD-L1 antibody) in patients with untreated extensive-stage small cell lung cancer

<!-- image -->

ECOG PS = Eastern Cooperative Oncology Group performance status; PCI = prophylactic cranial irradiation; PD = progressive disease; SCLC = small cell lung cancer

Figure 6: Overview of Study Design for IMpower133

The study included a Phase I safety run-in period in order to establish tolerability of the study treatment. After a minimum of 12 patients were enrolled in each treatment arm and received at least two cycles of study treatment, unblinded safety data were reviewed by an independent data monitoring committee (iDMC). Subsequently, the iDMC reviewed safety data approximately every 6 months during the study.

## Methods

## Study participants

Patients enrolled into this study were unselected for PD-L1 expression. A baseline tissue sample was required to be submitted during the study; however, PD-L1 testing was not required during screening.

## Inclusion criteria:

- Signed Informed Consent Form.
- Male or female, 18 years of age or older.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Histologically or cytologically confirmed ES-SCLC per the Veterans Administration Lung Study Group (VALG) staging system.
- No prior systemic treatment for ES-SCLC.
- Patients who received prior chemoradiotherapy for limited-stage SCLC must have been treated with curative intent and experienced a treatment-free interval of at least 6 months since last chemotherapy, radiotherapy, or chemoradiotherapy cycle from diagnosis of extensive-stage SCLC.
- Patients with a history of treated asymptomatic central nervous system (CNS) metastases were eligible, provided they met all of the following criteria:
- o Only supratentorial and cerebellar metastases allowed (i.e., no metastases to midbrain, pons, medulla or spinal cord)
- o No ongoing requirement for corticosteroids as therapy for CNS disease
- o No evidence of interim progression between the completion of CNS-directed therapy and randomization
- o Patients with new asymptomatic CNS metastases detected at the screening scan had to receive radiation therapy and/or surgery for CNS metastases. Following treatment, these patients could be eligible without the need for an additional brain scan prior to randomization, if all other criteria were met.
- Measurable disease, as defined by RECIST v1.1. Previously irradiated lesions could only be considered as measurable disease if disease progression had been unequivocally documented at that site since radiation and the previously irradiated lesion was not the only site of disease.
- Adequate hematologic and end organ function.
- Patients had to submit a pre-treatment tumor tissue sample. Any available tumor tissue sample could be submitted. The tissue sample should have been submitted before or within 4 weeks after randomization; however, patients could be enrolled into the study before the pre-treatment tumor tissue sample was submitted.
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of &lt;1% per year during the treatment period and for at least 5 months after the last dose of study treatment.
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures.

<div style=\"page-break-after: always\"></div>

## Exclusion criteria:

- Active or untreated CNS metastases as determined by computed tomography (CT) or MRI evaluation during screening and prior radiographic assessments.
- Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease had been clinically stable for ≥ 1 week prior to randomization.
- Leptomeningeal disease.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters (e.g., PleurX®) were allowed regardless of drainage frequency.
- Uncontrolled or symptomatic hypercalcemia. Patients who were receiving denosumab prior to randomization had to be willing and eligible to discontinue its use and replace it with a bisphosphonate while in the study.
- Malignancies other than SCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year OS &gt; 90%) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous-cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent).
- Women who were pregnant, lactating, or intending to become pregnant during the study.
- History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
- o Patients with a history of autoimmune-related hypothyroidism on thyroid replacement hormone therapy were eligible.
- o Patients with controlled Type I diabetes mellitus on an insulin regimen were eligible.
- o Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis were excluded).
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) was permitted.
- Positive test result for human immunodeficiency virus (HIV). All patients were tested for HIV; patients who tested positive for HIV were excluded.
- Patients with active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen [HBsAg] test result at screening) or hepatitis C virus (HCV).
- Active tuberculosis.
- Severe infections at the time of randomization, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.
- Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction &lt; 50% must have been on a stable medical regimen that was optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate.
- Major surgical procedure other than for diagnosis within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study.
- Prior allogeneic bone marrow transplantation or solid organ transplant.
- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicated the use of an investigational drug or that could affect the interpretation of the results or render the patient at high risk for treatment complications.
- Patients with illnesses or conditions that interfered with their capacity to understand, follow, and/or comply with study procedures.
- Treatment with any other investigational agent with therapeutic intent within 28 days prior to randomization.
- Administration of a live, attenuated vaccine within 4 weeks before randomization or anticipation that such a live attenuated vaccine would be required during the study Patients could not receive live, attenuated influenza vaccines within 4 weeks prior to randomization, during treatment, and for 5 months following the last dose of atezolizumab/placebo.
- Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-PD-1, and anti-PD-L1 therapeutic antibodies.
- Treatment with systemic immunosuppressive medications (including, but not limited to corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 1 week prior to randomization.
- History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
- Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation.
- History of allergic reactions to carboplatin or etoposide.

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## Treatments

The induction phase of the study consisted of four cycles of atezolizumab/placebo plus chemotherapy, with each cycle being 21 days in duration. On Day 1 of each cycle, study drug infusions were administered in the following order:

Arm A: atezolizumab → carboplatin → etoposide (ATZ + CE)

Arm B: placebo → carboplatin → etoposide (PBO + CE)

During the induction phase, study treatment was administered in the following manner:

- Day 1: Atezolizumab 1200 mg or placebo administered intravenously over 60 minutes
- Day 1: Carboplatin to reach AUC 5 mg/mL/min administered intravenously over 30-60 minutes
- Day 1-3: Etoposide 100 mg/m 2  administered intravenously over 60 minutes.

If one component of study treatment was discontinued permanently because of tolerability concerns, the patient was allowed to continue with other components of study treatment until disease progression if agreed upon by the investigator and patient.

Following the induction phase, patients continued maintenance therapy with either atezolizumab or placebo (21 day-cycles). During the maintenance phase, prophylactic cranial irradiation was permitted per local standard-of-care. Thoracic radiation with curative intent or the intent to eliminate residual disease was not permitted. Palliative thoracic radiation was allowed. Treatment had to be discontinued in all patients (in both treatment arms) who exhibited evidence of disease progression per RECIST v1.1.

Table 3: Intravenous Treatment Regimen (IMpower133)

<div style=\"page-break-after: always\"></div>

| Treatment regimen   | Induction (Four 21-Day Cycles)                                                    | Maintenance (21-Day Cycles)   |
|---------------------|-----------------------------------------------------------------------------------|-------------------------------|
| A                   | atezolizumab (1,200 mg) a + carboplatin (AUC 5) b + etoposide (100 mg/m 2 ) b,c b | atezolizumab (1,200 mg) a     |
| B                   | placebo + carboplatin (AUC 5) + etoposide (100 mg/m 2 ) b,c                       | placebo                       |

a Atezolizumab was administered until loss of clinical benefit as assessed by investigator

b Carboplatin and etoposide were administered until completion of 4 cycles, or progressive disease or unacceptable toxicity, whichever occurs first

c Etoposide was administered on day 1, 2 and 3 of each cycle

## Treatment beyond progression:

Conventional response criteria may not adequately assess the activity of immunotherapeutic agents since progressive disease (PD) by initial radiographic evaluation may not necessarily reflect therapeutic failure. In order to better accommodate standard clinical practice which is guided by the fact that patients with ES-SCLC whose disease progresses after first-line treatment have limited treatment options and such options have limited efficacy and significant toxicity, patients could be considered for treatment beyond radiographic disease progression per RECIST v1.1, at the discretion of the investigator and after appropriate discussion with the patient and obtaining informed consent, only if all of the following criteria were met:

- Evidence of clinical benefit as assessed by the investigator
- No decline in ECOG PS that could be attributed to disease progression
- Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal disease) that could not be managed by protocol-allowed medical interventions
- Patients must provide written consent to acknowledge deferring other treatment options in favor of continuing study treatment at the time of initial progression

Patients were fully informed of the risk of continuing study treatment in spite of apparent radiographic progression, and consent was documented appropriately before study treatment could continue. Investigators made a careful assessment of the potential benefit of continuing study treatment beyond radiographic disease progression, considering radiographic data and the clinical status of the patient.

Patients who continued treatment beyond radiographic disease progression per RECIST v1.1 were closely monitored clinically and with a follow-up scan in 6 weeks or sooner if symptomatic deterioration occurred. Treatment had to be discontinued if clinical deterioration due to disease progression occurred at any time, or if persistent disease growth was confirmed in a follow-up scan. In addition, patients had to be discontinued for unacceptable toxicity or for any other signs or symptoms of deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status.

## Dose modification:

No dose reductions for atezolizumab/placebo were permitted. Patients could temporarily suspend treatment with atezolizumab/placebo for up to 105 days beyond the last dose if they experienced an AE that required a dose to be withheld. If atezolizumab/placebo was withheld because of AEs for more than 105 days beyond the last dose, then the patient was discontinued from atezolizumab/placebo treatment. Exceptions required Medical Monitor approval. If a patient had to be tapered off steroids used to treat AEs, atezolizumab could be withheld for additional time beyond 105 days from the last dose until steroids were discontinued or reduced to prednisone dose (or dose equivalent) ≤ 10 mg/day. The acceptable length of interruption depended on agreement between the investigator and the Medical Monitor.

<div style=\"page-break-after: always\"></div>

Dose modifications for carboplatin and etoposide were permitted for toxicity according to the prescribing information and local standard-of-care. Once reduced, the dose could not be increased back to 100%. Treatment with carboplatin or etoposide was recommended to be discontinued if a patient experienced any hematologic or non-hematologic Grade 3 or Grade 4 toxicity after two dose reductions or treatment was delayed for more than 63 days due to toxicities.

## Tumour assessments:

Tumour assessments were conducted every 6 weeks for the first 48 weeks following Cycle 1, Day 1 and then every 9 weeks thereafter. Patients who met established criteria and who agreed to be treated beyond disease progression had tumour assessments conducted every 6 weeks until treatment discontinuation.

## Objectives

## Co-primary efficacy objectives:

- To evaluate the efficacy of Atezo + CE compared with PBO + CE in the intent-to-treat (ITT) patient population as measured by investigator-assessed PFS according to RECIST v1.1
- To evaluate the efficacy of Atezo + CE compared with PBO + CE in the ITT patient population as measured by OS

## Secondary efficacy objectives:

- To evaluate the efficacy of Atezo + CE compared with PBO + CE in the ITT population as measured by investigator-assessed objective response rate (ORR) according to RECIST v1.1
- To evaluate the efficacy of Atezo + CE compared with PBO + CE in the ITT population as measured by investigator-assessed duration of response (DOR) according to RECIST v1.1
- To evaluate the PFS rate at 6 months and at 1 year in each treatment arm for the ITT population
- To evaluate the OS rate at 1 and 2 years in each treatment arm for the ITT population
- To determine the impact of atezolizumab as measured by time to deterioration (TTD) in patient-reported lung cancer symptoms of cough, dyspnea (single-item and multi-item subscales), chest pain, arm/shoulder pain, or fatigue using the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) and the supplemental lung cancer module (QLQ-LC13) in patients treated with Atezo + CE compared with PBO + CE in the ITT population

## Safety objectives:

- To evaluate the safety and tolerability of Atezo + CE compared with PBO + CE
- To evaluate the incidence and titers of anti-therapeutic antibodies (anti-drug antibodies; ADA) against atezolizumab and to explore the potential relationship of the immunogenicity response with pharmacokinetics (PK), safety, and efficacy

## Pharmacokinetic objective:

- To characterize the pharmacokinetics of atezolizumab, carboplatin, and etoposide in patients with chemotherapy-naive ES-SCLC.

## Exploratory objectives:

<div style=\"page-break-after: always\"></div>

- To evaluate investigator-assessed PFS, ORR, and DOR according to immune-modified RECIST for the atezolizumab-containing treatment arm in the ITT population
- To evaluate the relationship between tumor biomarkers (including but not limited to PD-L1, PD-1, somatic mutations, blood tumour mutation burden [bTMB], and others), as defined by immunohistochemistry (IHC) or quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR), next generation sequencing (NGS), and/or other methods and measures of efficacy
- To assess predictive, prognostic, and pharmacodynamic exploratory biomarkers in archival and/or fresh tumor tissue, blood, plasma and serum and their association with disease status, mechanisms of resistance, and/or response to study treatment
- To evaluate and compare patient's health status as assessed by the EuroQoL 5 Dimensions 5-Level (EQ-5D-5L) questionnaire to generate utility scores for use in economic models for reimbursement
- To determine the impact of Atezo + CE compared with PBO + CE as measured by change from baseline in patient-reported outcomes (PRO) of health-related quality of life (HRQoL), lung cancer-related symptoms, physical functioning, and health status as assessed by the EORTC QLQ-C30 and LC13
- To evaluate the impact of chemotherapy (both carboplatin and etoposide) on peripheral and tumor-specific T-cell populations during and after induction therapy and its relationship to efficacy and safety outcomes

## Outcomes/endpoints

| Endpoint/ SAP Section                               | Definition                                                                                       | Censoring                                                                                                                                                                                                                        | Methodology                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------------------------------------------------|--------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Co-Primary Endpoints                                | Co-Primary Endpoints                                                                             | Co-Primary Endpoints                                                                                                                                                                                                             | Co-Primary Endpoints                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| PFS per RECIST v1.1 by investigator Saction 4.4.1.1 | Time from randomization to first documenled PD or death from any cause, whichever occurred first | Patients who were alive and who did not experience PD at time of analysis were censored at dale of the last tumor assessment. Patients with no post-baseline tumor assessment were censored at date of randomization plus 1 day. | Kaplan-Meier methodology, stratified log-rank test and stratified Cox regression model. Slratification faclors should be the same as for randomization including: sex [male vs. female]. ECoG performance status [0 vs. 1]. and brain metastasis [Yes vs. No], as recorded in the IxRS,unless at least one stratum had less than 10 events. If that happened, the slratification factor which contained the level with the smallest number of patients was removed from the stratified analyses until there was no stratum with less than 10 events. |
| 0S Section 4.4.1.2                                  | Time from randomization to death from any cause                                                  | Patients who were not reported as having died at time of analysis were censored at the date last known to be alive. Patients who did not have posl- baseline information were censored at the date of randomization plus 1 day.  | Same methods as for PFS co-primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| ORR (confirmation not required) per RECIST v1.1 by investigator Section 4.4.2.1   | Proportion of patients with an objective response, either CR or PR                                                   | NIA                                                                                                                                                                                                                                                                                                                                              | Clopper-Pearson method for 95% Cl of response rates 95% Cl for the difference in ORRs betweenthetwo treatmentarmswas estimated using the normal approximation to the binomial distribution method                           |
|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DOR (confimmation nol required) per RECIST v1.1 by investigator Section 4.4.2.2   | Time from the first documented objective response to documented PD or death from any cause, whichever occurred first | Palients who were alive and who did not experience PD at time of analysis were censored at the date of the last tumor assessment. If no tumor assessments were performed after the date of the first occurrence of the objective response (CR or PR). DoR was censored at the dale of the first occurrence of the objective response plus 1 day. | Same melhods as for PFS co-primary endpoint                                                                                                                                                                                 |
| OS at 1- and 2-year landmark timepoints                                           | Same as above                                                                                                        | Same as above                                                                                                                                                                                                                                                                                                                                    | Kaplan-Meier methodology with 95% Cl calculated with the standard error derived from the Greenwood formula 95% Cl tor the difference In OS rates between the two treatment armswas estimated using the normal approximation |
| PFS at 6 monthand 1 yearSame as above landmark timepoints                         |                                                                                                                      | Same as above                                                                                                                                                                                                                                                                                                                                    | Same as above                                                                                                                                                                                                               |

Cl=confidence interval; CR = complete response; DoR = duration of response; ECOG = Eastern Cooperative Oncology Group; IRF = independent review facility; ITT = intent-to-treat; IxRS=interactive voice/Web response system; N/A = not applicable; ORR = objective response rate; OS = overall survival; PD = progressive disease: PFS = progresslon-tree survival: PR = partial response; RECiST =Response Evaluation Criteria in Solid Tumors; SAP = statistical analysis plan.

## Sample size

Approximately 400 patients were to be randomized into the global enrollment phase of this study to the ATZ+CE arm and the PBO+CE arm in a 1:1 ratio.

There are two co-primary efficacy endpoints: PFS and OS. To control the overall two-sided Type I error rate at 0.05, the two-sided significance levels of 0.005 and 0.045 were allocated to the primary comparisons for PFS and OS, respectively.

The following sample size calculation applies to the global enrollment phase, excluding the China extension cohort, unless otherwise noted.

The sample size of the study is determined by the analysis of OS. To detect an improvement of HR = 0.68 in OS using a log-rank test, approximately 306 deaths in the ITT population will be required to achieve 91% power at a two-sided significance level of 0.045. One OS interim analysis will be performed when approximately 240 OS events in the ITT population are observed, which by estimation will occur at approximately 25 months after the first patient is randomized. The final analysis of OS will be performed when approximately 306 OS events in the ITT population have been observed, which is expected at approximately 36 months after the first patient is randomized.

The primary analysis of PFS is planned to be conducted at the time of the OS interim analysis, and is estimated to be when approximately 295 PFS events in the ITT population have occurred, which is expected at approximately 25 months after the first patient is randomized. This provides 99% power to detect an improvement of HR = 0.55 in PFS at a two-sided significance level of 0.005. There will be no interim analysis for PFS.

The calculation of sample size and estimates of the analysis timelines are based on the following assumptions:

<div style=\"page-break-after: always\"></div>

- PFS and OS are exponentially distributed.
- The median duration of PFS in the control arm is 6 months.
- The median duration of OS in the control arm is 10 months.
- The interim and final analyses of OS use the Lan-DeMets alpha spending function to approximate the O'Brien-Fleming boundary.
- The dropout rate is 5% over 12 months for PFS and OS.

Table 4: Power and minimum detectable difference for the proposed design of each primary endpoint

| Primary Endpoint   |   Expected No. of Events |   TargetHR |   Two-Sided TypeI | Power   | MDD HR   |
|--------------------|--------------------------|------------|-------------------|---------|----------|
| PFS                |                      295 |       0.55 |             0.005 | %66     | 0.721    |
| PFS                |                      295 |       0.55 |             0.05  | %6'66   | 0.796    |
| OS                 |                      306 |       0.68 |             0.045 | 91%     | 0.790    |
| OS                 |                      306 |       0.68 |             0.05  | 92%     | 0.794 a  |

HR=hazard ratio; MDD=minimum detectable difference;PFS=progression-free survival;

OS =overall survival.

At final analysis conditional on interim analysis with 78% information fraction.

## Randomisation

Eligible patients were stratified by sex (male vs. female), ECOG PS (0 vs. 1), and presence of brain metastases (yes vs. no) and randomized 1:1 to receive either ATZ+CE or PBO+CE. Randomization occurred in a 1:1 ratio using a permuted-block randomization method.

## Blinding (masking)

This was a double-blind study. The Sponsor and its agents (with the exception of the IxRS service provider [the external independent statistical coordinating center responsible for verifying patient randomization and study treatment kit assignments], PK/pharmacodynamic laboratory personnel, and the iDMC members); the study site personnel, including the investigator; and the patient were blinded to treatment assignment.

## Statistical methods

## Analysis populations:

- ITT population: Defined as all randomized patients, regardless of whether the patient received the assigned treatment. ITT patients were analyzed according to the treatment assigned at randomization by the IxRS.
- Pharmacokinetic-Evaluable Population: PK analyses were based on PK observations from all patients who had received atezolizumab, carboplatin, or etoposide treatment and who provided at least one evaluable atezolizumab PK sample.
- Safety Population: Included all treated patients, defined as patients who received any amount of any component of study treatment. For the safety analyses, patients who received any amount of atezolizumab were analyzed as part of the Atezo + CE arm, even if atezolizumab was given in error.
- ADA-Evaluable Population: ADA analyses were based on ADA observations from patients who had received atezolizumab treatment and were evaluated for immunogenicity.

<div style=\"page-break-after: always\"></div>

## Efficacy analyses:

The co-primary efficacy outcome measures for this study are:

- PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever occurs first

OS, defined as the time from randomization to death from any cause The null and alternative hypotheses regarding PFS or OS in the ITT population can be phrased in terms of the PFS or OS survival functions SA(t) and SB(t) for Arm A (ATZ+CE) and Arm B (PBO+CE), respectively: H0: SA(t) = SB(t) versus H1: SA(t) ≠ SB(t) The Kaplan-Meier approach will be used to estimate median PFS for each treatment arm. The Brookmeyer-Crowley methodology (Brookmeyer and Crowley 1982) will be used to construct the 95% CI for the median PFS for each treatment arm. Cox proportional-hazards models, stratified by sex (male vs. female), ECOG performance status (0 vs. 1), and presence of brain metastases (yes vs. no) will be used to estimate the HR and its 95% CI. The unstratified HR will also be presented. Treatment comparisons will be based on the stratified log-rank test. Use of the stratification factors implemented at randomization in the Cox model for OS and PFS: The Study GO30081 Statistical Analysis Plan (SAP) Version 2 was amended (27 February 2018)due to the potential risk of over-stratification (Akazawa et al. 1997). If at least one stratum (i.e., a combination of stratification factor levels across sex [male vs female], Eastern Cooperative Oncology Group [ECOG] performance status [0 vs 1], and brain metastasis [Yes vs No] per interactive voice/Web response system [IxRS]) has less than 10 events (progression-free survival [PFS] or overall survival [OS] events), the stratification factor (one of 3 stratification factors: sex, ECOG performance status, and brain metastasis per IxRS) which contains the level with the smallest number of patients will be removed from the stratified analyses. The removal of the stratification factor will continue until there is no stratum with less than 10 events (PFS or OS events). The final set of stratification factors used in stratified analyses will be applied to all endpoints where stratified analyses are planned. Censoring rules: OS: Patients who are alive at the time of the analysis data cutoff will be censored at the last date they were known to be alive. Patients with no post-baseline information will be censored at the date of randomization plus 1 day. PFS: Patients who have not experienced disease progression or death at the time of analysis will be censored at the time of the last tumor assessment. Patients without a date of disease progression will be analyzed as censored observations on the date of the last tumor assessment. Patients with no post-baseline tumor assessment will be censored at the date of randomization plus 1 day. Sensitivity analyses: OS: The impact of non-protocol-specified anti-cancer therapy on OS will be assessed, in which data from patients who receive non-protocol-specified anti-cancer therapy before a PFS event will be censored at the date before receipt of non-protocol-specified anti-cancer therapy.

<div style=\"page-break-after: always\"></div>

The impact of loss to follow-up on OS will be assessed depending on the number of patients who are lost to follow-up. If &gt; 5% of patients are lost to follow-up for OS in either treatment arm, a sensitivity analysis will be performed for the comparisons between two treatment arms in which patients who are lost to follow-up will be considered as having died at the last date they were known to be alive. PFS: One sensitivity analysis will be performed to evaluate the potential impact of missing scheduled tumor assessments on the primary analysis of PFS, as determined by the investigator using a PFS event imputation rule 1. If a patient misses two or more assessments scheduled immediately prior to the date of the PFS event, the patient will be counted as having progressed on the date of the first of these missing assessments. 2. Patients with a PFS event who missed two or more scheduled assessments immediately prior to the PFS event will be censored at the last tumor assessment prior to the missed visits. The imputation rule will be applied to patients in both treatment arms. Statistical methodologies that are analogous to those used in the primary analysis of PFS will be used for this sensitivity analysis. Analyses were also presented to assess the impact of non-prior anti-cancer therapy (NPT) on PFS for patient who switched to other treatment before a PFS event. Control of the type 1 error due to two co-primary endpoints: To adjust for multiplicity due to having two co-primary endpoints, a group sequential Holm's procedure will be implemented: initially the hypothesis test for PFS will be conducted at a two-sided alpha of 0.005 and OS will be tested at a two-sided alpha of 0.045. Once a null hypothesis is rejected, the test mass predefined for that endpoint becomes available and can be recycled to the other unrejected test. 2-sidedα=0.05 ifrejected,o=0.005will be passed to Os OS (α=0.045) PFS (α=0.005) if rejected，α=0.045will be passed to PFS

<!-- image -->

## Table 5: Group sequential Holm procedure

Interim analyses: One interim efficacy analysis of OS is planned for when approximately 240 OS events have been observed. The primary analysis of PFS will be conducted at the same time as the interim OS analysis, and the exact timing of the analysis depends on when 240 OS events in the ITT population have occurred. The final OS analysis will be conducted when approximately 306 OS events in the ITT population have been observed. This is expected to occur approximately 36 months after the first patient is randomized, but the exact timing of this analysis will depend on the actual number of OS events. To control the type I error for OS, the stopping boundaries for OS interim and final analyses are to be computed with use of the Lan-DeMets approximation to the O'Brien-Fleming boundary. An external independent Data Monitoring Committee (iDMC) will be set up to evaluate safety data on an ongoing basis. All summaries/analyses by treatment arm for the iDMC's review will be prepared by an independent Data Coordinating Center. Members of the iDMC will be external to the Sponsor and will follow a charter that outlines their roles and responsibilities. Any outcomes of these safety reviews that affect study conduct will be communicated in a timely manner to the investigators for notification of the institutional review boards/ethics committees. A detailed plan will be included in the iDMC Charter. Secondary efficacy endpoints Objective Response Rate (ORR) is defined as the proportion of patients who had an objective response by the investigator using RECIST v1.1. An estimate of ORR and its 95% CI will be calculated with the Clopper Pearson method for each treatment arm. CIs for the difference in ORRs between the two treatment arms will be determined with use of the normal approximation to the binomial distribution. Patients without any post-baseline assessment will be considered non-responders. Confirmation of response according to RECIST v1.1 was not required, but for the exploratory purposes, ORR with confirmation was to be reported as needed. Duration or Response (DOR) was to be assessed for patients who had an objective response as determined by the investigator using RECIST v1.1. Patients whose disease has not progressed and who have not died at the time of analysis will be censored at the time of last tumor assessment date. If no tumor assessments were performed after the date of the first occurrence of a CR or PR, DOR will be censored at the date of the first occurrence of a CR or PR plus 1 day. DOR is based on a non-randomized subset of patients (specifically, patients who achieved an objective response); therefore, formal hypothesis testing will not be performed for this endpoint. Comparisons between treatment arms will be made for descriptive purposes. The methodologies detailed for the PFS analysis was used for the DOR analysis. PatientReported Outcomes. PROs of HRQoL, lung cancer-related symptoms w as measured using EORTC QLQC30 and EORTC QLQ-LC13. The ITT population was used for TTD analyses and to document completion rates. Missing PRO scores were not imputed. Patients whose symptoms have not deteriorated before the last PRO a ssessment is completed were to be censored at the date of the last PRO assessment. Patients with no baseline assessment or post-baseline assessments were to be censored at the date of randomization plus 1 day. TTD according to the EORTC QLQ-C30 and EORTC QLQ-LC13 measures will be evaluated in each of the following linearly transformed symptom scores: cough, dyspnea (single item), dyspnea (multi-item subscale), chest pain, or arm/shoulder pain. The linear transformation gives each individual symptom subscale a possible score of 0 to 100. For the symptom to be considered ' deteriorated, ' a score increase of ≥ 10 points above baseline must be held for at least two consecutive assessments or an initial score increase of ≥ 10 points is followed by death within 3 weeks from the last assessment. A ≥ 10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998). The methodologies outlined for the analysis of PFS will be used for the analyses of TTD of the pre-specified symptoms of the EORTC QLQ-C30 and EORTC QLQ-LC13 measures. The estimated Kaplan-Meier plots will be provided for each symptom separately. Subgroup analyses: The consistency of PFS and OS results was investigated by estimating the treatment effect in predefined subgroups based on key demographics (age, sex, race/ethnicity), baseline disease characteristics (ECOG PS, smoking status, brain, liver and other metastases at enrollment), and pre-specified TMB biomarker expression cutoffs ( ≥ 10 or

<div style=\"page-break-after: always\"></div>

## &lt;10 and ≥ 16 or &lt;16). Results

## Participant flow

<!-- image -->

*One Safety Population patient randomized to the PBO + CE arm received Atezo and was therefore counted in the Atezo + CE arm.

Table 6: Patient disposition (screened patients)

Failed screening: A total of 123 patients failed screening based on information collected in the IxRS system. The most common reasons for screen failure were active or untreated CNS metastases (25 patients), withdrawal by subject (13 patients), and lack of evidence of histologically or cytologically confirmed ES-SCLC per the VALG staging system (Inclusion Criterion 4; 10 patients). A listing of all patients who failed screening, including the reason for screening failure, was provided in the appendix of the CSR.

No treatment received: Overall, 9 patients did not receive any study treatment (5 patients in the PBO + CE arm and 4 patients in the Atezo + CE arm). As of the CCOD of 24 April 2018, all 9 untreated patients had discontinued the study due to withdrawal by subject (4 patients), death (4), and physician decision (1).

Patients Unblinded During the Study: At the time of the CCOD, treatment allocation had been unblinded for 4 patients for safety reasons (2 patients in each arm) and for 6 patients for other reasons, for example to inform subsequent treatment decisions after disease progression (2 patients in the Atezo + CE arm and 4 patients in the PBO + CE arm). These were individual patient unblindings that occurred at the site level, and the Sponsor continued to remain blinded to the treatment assignment. Patients who were unblinded were included in the analysis populations.

<div style=\"page-break-after: always\"></div>

Table 7: Patient disposition from study (ITT population)

<!-- image -->

|                       | PBO + CE (Randomized) (N=202)   | PBO + CE (Randomized) (N=202)   | Atezo+CE (Randomi zed) (N=201)   | Atezo+CE (Randomi zed) (N=201)   | All Fatients (N=403)   | All Fatients (N=403)   |
|-----------------------|---------------------------------|---------------------------------|----------------------------------|----------------------------------|------------------------|------------------------|
| Received Treatment    |                                 | 197(97.56)                      |                                  | 197(98.06)                       |                        | 394(97.84)             |
| Om-study Status       |                                 | 60(29.76)                       | 77                               | (38.36)                          |                        | 137(34.09)             |
| Alive: On Treatment   |                                 | 11 ( 5.4%]                      | 23                               | (11.48)                          |                        | 34(8.4%)               |
| Alive: In Follow-Up   | 49                              | (24.3%)                         |                                  | 54(26.95)                        |                        | 103 (25.6%)            |
| Discontinued Study    | 142                             | (70.35)                         | 124                              | (61.74)                          | 266                    | (66.05)                |
| Death                 |                                 | 132 (65.36)                     | 101                              | 192'051                          | 233                    | 148*L5)                |
| Lost To Follow-Up     | 1                               | 10.55]                          | 3                                | ( 1.5%]                          | 4                      | ( 1.0%)                |
| Phvsician Decision    | 0                               |                                 | C1                               | (1.08)                           | 1                      | (0.54)                 |
| withdrawal By Subiect | 9                               |                                 | 18                               | [80*6)                           | 27                     | (6.76)                 |

Table 8: Patient disposition (safety evaluable population)

|                                    | IMpowerl33     | IMpowerl33     | IMpowerl33       | IMpowerl33       |                            |                            |                     |                     |
|------------------------------------|----------------|----------------|------------------|------------------|----------------------------|----------------------------|---------------------|---------------------|
|                                    | PBO+CE (N=196) | PBO+CE (N=196) | Atezo+CE (N=198) | Atezo+CE (N=198) | Atezo+Chemo Combo (N=2421) | Atezo+Chemo Combo (N=2421) | Atezo Mono (N=3178) | Atezo Mono (N=3178) |
| End of Study Status                |                |                |                  |                  |                            |                            |                     |                     |
| n                                  |                | 196 (100%)     | 861              | (100%)           |                            | 2421 (100%)                |                     | 3178(100号)          |
| Discontinued study                 | 137            | (69.9%)        | 128              | 60.6%)           | 1363                       | (56.3%)                    | 2070                | (65.18)             |
| Ongoing                            | 59             | (30.1%)        |                  | 39.4%)           | 1058                       | (43.7%)                    | 1108                |                     |
| Reason_for Study Discontinuation   |                |                |                  |                  |                            |                            |                     |                     |
| All Reasons                        | 137            | (69.98)        | 120              | (60.68)          | 1363                       | (56.38)                    | 2070(               | (65.18)             |
| Death                              | 129            | (65.8%)        | 100              | (50.58)          | 1251                       | (51.78)                    | 1887                | (59.48)             |
| Progressive disease                | 010007         |                |                  |                  |                            | 0                          | 3                   | (<0.1%)             |
| Lost to follow-up                  |                | (0.58)         | 3                | (1.58)           | 10                         | (0.4%)                     | 70                  | (2.28)              |
| Other                              |                |                | 0                |                  |                            | (<0.18)                    | 1                   | (<0.1%)             |
| Physician decision                 |                |                |                  | (0.58)           |                            | ( 0.1%)                    | 1                   | (<0.1%)             |
| Protocol violation                 |                |                | 10               |                  |                            | 230                        | 11                  | 0.3%)               |
| Withdrawal by subject              |                | (3.68)         | 16               | (8.18)           | 96                         | (4.0%)                     | 97                  | 3.1%)               |
| Non-compliance                     | 0              |                | 0                |                  | 1                          | (<0.18)                    | 0                   |                     |
| Patients Discontinued from Atezo   |                |                |                  |                  |                            |                            |                     |                     |
| All Reasons                        | 0              |                | 175              | (88.48)          | 1912                       | (79.0%)                    | 2627                | (82.78)             |
| Adverse event                      | 0              |                | 21               | (10.6%)          | 329                        | (13.6%)                    | 213                 | 6.7%)               |
| Death                              | 0              |                | 8                | (4.0%)           | 69                         | (2.98)                     | 15                  | (0.58)              |
| Progressive disease                | 0              |                | 126              | (63.6%)          | 1145                       | (47.3%)                    | 1862                | (58.68)             |
| Progression of disease             | 0              |                |                  |                  |                            | 0                          | 371                 | (11.78)             |
| Lost to follow-up                  | 0              |                |                  |                  | 5                          | 0.28)                      | 2                   | (<0.1%)             |
| Other                              | 0              |                | 000              |                  | 12                         | 0.5%)                      | 10                  | 0.38)               |
| Physician decision                 | 0              |                | 2                | (1.0号)           | 92                         | 3.8%)                      | 34                  | 1.18)               |
| Protocol yiolation                 | 0              |                |                  |                  | 2                          | (<0.1:)                    | 14                  | 0.48)               |
|                                    | 0              |                |                  | 0.58)            | 1                          | (<0.1%)                    | 0                   |                     |
| Protocol Deviation                 | 00             |                | 06               | 4.58)            |                            | 3.8%)                      |                     |                     |
| Withdrawalbysubject Non-compliance |                |                |                  |                  | 92 3                       | 0.18)                      | 94 8                | 3.0%) 0.3%)         |
| Non-compliance with study drug     |                |                |                  | 0.58)            | 1                          | (<0.1%)                    | 0                   |                     |
| Symptomatic Deterioration          | 0:0            |                |                  | 3.58)            | 161                        | (6.7%)                     |                     | (0.1%)              |

Table 9: Patient disposition from study treatment (safety evaluable population)

|                                           | PBO+CE (Actual) (N=196)   | PBO+CE (Actual) (N=196)   | Atezo + CE (Actual) (N=198)   | Atezo + CE (Actual) (N=198)   |
|-------------------------------------------|---------------------------|---------------------------|-------------------------------|-------------------------------|
| Received at least one study treatment Yes |                           | 196 (100.0%)              |                               | 198 (100.0%)                  |
| Treatment Status                          |                           |                           |                               |                               |
| Ongoing                                   | 1                         | 0.5%)                     | 13                            | 6.6%)                         |
| Withdrawn from treatment                  | 195                       | 99.5%)                    |                               | 185 (93.48)                   |
| Withdrawn from Treatment Reason           |                           |                           |                               |                               |
| NON-COMPLIANCE WITH STUDY DRUG            | 0                         |                           | 1                             | 0.5%)                         |
| PROTOCOLDEVIATION                         | 0                         |                           | 1                             | 0.5%)                         |
| DEATH                                     | 10                        | 5.1%)                     | 8                             | ( 4.0%)                       |
| ADVERSE EVENT                             | 6                         | 3.1%)                     | 24                            | (12.1%)                       |
| SYMPTOMATICDETERIORATION                  | 1                         | 0.5%)                     | 7                             | 3.5%)                         |
| PROGRESSIVE DISEASE                       | 160                       | 81.6%)                    | 135                           | 68.2%)                        |
| PHYSICIAN DECISION                        | 10                        | 5.1%)                     | 2                             | 1.0%)                         |
| WITHDRAWALBYSUBJECT                       | 8                         | 4.1%)                     | 10                            | 5.1%)                         |
| LOST TOFOLLOW-UP                          | 1                         | 0.5%)                     | 0                             |                               |

All reasons across study treatments are displayed.Multiple occurrences of the reason within a patient is counted once.

<div style=\"page-break-after: always\"></div>

## Recruitment

The first patient was randomized on 6 June 2016.

The last patient was randomized on 31 May 2017.

Data cut-off was on 24 April 2018.

The study was conducted across 106 sites in 21 countries.  The number of patients randomized per country, followed by the number of centers (in parentheses) was: United States of America 86 (22), Poland 45 (6), Japan 42 (13), Russia 30 (6), Spain 25 (6), Austria 20 (4), Hungary 19 (4), Czech Republic 17 (3), South Korea 17 (4), Italy 15 (6), Serbia 15 (3), Australia 11 (3), Greece 11 (3), United Kingdom 10 (4), Germany 9 (5), Taiwan 9 (3), France 7 (4), Chile 6 (2), Brazil 4 (3), Mexico 4 (1), China 1 (1).

## Conduct of the study

## Protocol amendments:

The original protocol dated 08 December 2015 was amended on four times (v2, 08 June 2016; v3, 25 August 2016; v4, 29 August 2017; v5, 27 February 2018). Only relevant protocol amendments are included in the following section:

Protocol Amendment 1 (Version 2) - 08 June 2016

- The phase of this study was changed from Phase III to Phase I/III throughout the protocol.
- It was added that in the case of an early termination of the study, patients who were deriving clinical benefit from treatment with atezolizumab would be permitted to continue treatment with atezolizumab at the discretion of the investigator.

Protocol Amendment 2 (Version 3) - 25 August 2016

- The phase of the study was changed from Phase III to Phase I/III where applicable throughout.
- A secondary efficacy objective and corresponding outcome measure were added to evaluate the efficacy of Atezo + CE compared with PBO + CE as measured by investigator-assessed time to response (TTR). TTR will be assessed in the ITT population for patients who had an objective response as determined by the investigator according to RECIST v1.1.
- Clarification was made that during the maintenance phase, prophylactic cranial irradiation was permitted as per local standard-of-care and its use was to be reported on the Prophylactic Cranial Irradiation eCRF page.
- Clarification was made that thoracic radiation with curative intent or the intent to eliminate residual disease was not permitted but that palliative thoracic radiation was allowed.
- The criteria for continuing study treatment beyond radiographic disease progression per RECIST v1.1 was modified to remove the criterion for absence of symptoms and signs including worsening of laboratory vitals indicating unequivocal progression of disease.
- It was added that in the case of an early termination of the study, patients who were deriving clinical benefit from treatment with atezolizumab would be permitted to continue treatment with atezolizumab at the discretion of the investigator.
- Clarification was made that cycles in which no chemotherapy was given did not count toward the total number of induction chemotherapy cycles.
- The screening assessments were revised, clarifying that either a CT or MRI scan of the pelvis was required at screening.
- Clarification was made that biomarker blood samples should not be taken during screening. The baseline biomarker blood sample should be collected on Cycle 1, Day 1, and the samples should be taken prior to administration of any study treatment.
- Revision was made to clarify that a pre-treatment tumor tissue sample could be archival or freshly obtained and should be submitted before or within 4 weeks after randomization. This specimen was expected to be accompanied by the associated pathology report. Additionally, although any available tumor tissue sample could be submitted, preferred sample types were included. It was strongly encouraged that representative tumor specimens in paraffin blocks (preferred) or 10 (or more) serial, freshly cut, unstained slides were submitted for exploratory biomarker analysis, including but not limited to PD-L1 status. NGS may be performed by Foundation Medicine on evaluable pre-treatment tissue if requested by the investigator.
- Clarification was made that pre-treatment tumor tissue samples from patients who were deemed ineligible to enroll into the study were returned no later than 6 weeks after eligibility determination.
- Preferred sample types for optional tumor samples after completion of induction treatment were added. In addition, language was added to specify that NGS may be performed by Foundation Medicine on evaluable tissue if requested by the investigator.
- Revision was made to clarify that if clinically feasible, it was recommended that a tumor biopsy be performed at the time of radiographic progression, preferably within 40 days of radiographic progression or prior to the start of the next anti-cancer treatment, whichever was sooner. Preferred sample types were also added. In addition, language was added to specify that NGS could be performed by Foundation Medicine on evaluable tissue if requested by the investigator.
- The frequency of the EORTC QLQ-C30, EORTC QLQ-LC13, and EQ-5D-5L questionnaires were modified. Patients who discontinued study treatment for any reason other than disease progression per RECIST v1.1 (e.g., toxicity) were to complete these questionnaires at each tumor assessment visit until disease progression per RECIST v1.1, unless the patient withdrew consent or the Sponsor terminated the study, whichever occurred first.
- Revision was made to clarify that if, in the opinion of the investigator, a toxicity was considered to be due solely to one component of the study treatment and the dose or administration of that component was delayed or modified, the dose or administration of the other study treatment components did not require modification and could be administered if there was no contraindication.
- The length of time that atezolizumab could be withheld was clarified to be a maximum of 105 days beyond the last dose of atezolizumab and that exceptions required Medical Monitor's approval.
- Dose modification guidelines for carboplatin and etoposide were revised for clarity and consistency.
- Clarification was made that a hospitalization that was necessary because of patient requirement for outpatient care outside of normal outpatient clinic operating hours were not considered to be SAEs, but should be reported as AEs.
- The requirement for a tumor response assessment at the treatment discontinuation visit was removed.

<div style=\"page-break-after: always\"></div>

## Protocol Amendment 3 (Version 4) - 29 August 2017

- Modifications were made to the SAP and the timing for the efficacy analyses for PFS and OS in the global study. The OS event-patient ratio for the interim OS analysis was increased from 45% to 55%;

<div style=\"page-break-after: always\"></div>

for the final OS analysis, the ratio was reduced from 74% to 70%. Additionally, the second OS interim analysis at the time when 258 OS events had occurred was removed. As a result of the changes, 280 deaths were required for the final OS analysis, estimated to be achieved at approximately first patient randomized plus 31 months, compared to 298 OS events with 37 months under a 74% event-patient ratio. These changes were implemented to be consistent with other studies in the atezolizumab first-line lung cancer program. The multiplicity strategy was adjusted from splitting alpha to a group sequential Holm procedure so that alpha spent on PFS could be recycled to OS when PFS was significant, and vice versa, to most efficiently use alpha and maximize power.

- The secondary objectives and outcome measures regarding investigator-assessed time in response (TIR) and TTR according to RECIST v1.1 were removed to be consistent with other studies in the atezolizumab first line lung cancer program.
- The exploratory objectives and outcome measures regarding disease control rate (DCR), TIR, and TTR according to modified RECIST v1.1, PFS, OS, ORR, DOR, TIR, TTR, and DCR in the PD-L1 selected population, and investigator-assessed DCR according to RECIST v1.1 were removed to be consistent with other studies in the atezolizumab first line lung cancer program.
- The definition of the end of the study was updated. The end of study was to occur when all of the following criteria had been met: the last patient last visit (LPLV) had occurred (i.e., last patient in the global and extended China enrollment phases combined); approximately 280 deaths had been observed among the randomized patients in the global enrollment phase; and there were sufficient OS events in the ITT population enrolled in the China enrollment phase.
- Language was modified to clarify the process for reporting deaths and for reporting events that occurred after the AE reporting period.
- The reporting procedures for death were modified to prohibit use of the term \"sudden death\" on the AE eCRF unless it was combined with the presumed cause of death (e.g., \"sudden cardiac death\"), as use of the term \"sudden death\" required the Sponsor to query the site for clarification on the cause of death.
- The reporting instructions for AEs leading to hospitalization were clarified.
- Language was added to clarify that AE reports were not to be derived from PRO data by the Sponsor and sites were not expected to review the PRO data for AEs.
- PFS defined by additional censoring rule for missed visits was changed to a sensitivity analysis to be consistent with other studies in the atezolizumab first line lung cancer program.
- The impact of non-protocol-specified anti-cancer therapy on OS was to be assessed as a sensitivity analysis by using censoring date cutoff at the date before receipt of non-protocol-specified anti-cancer-therapy to be consistent with other studies in the atezolizumab first line lung cancer program.
- Language was added to clarify that the Sponsor reviewed all protocol deviations, and prospective requests to deviate from the protocol were not allowed.

## Protocol Amendment 4 (Version 5) - 27 February 2018

- Protocol GO30081 Version 5 was a country-specific amendment to comply with the Spanish health authority's (Agencia Española de Medicamentos y Productos Sanitarios) requirement to include guidelines on the management of atezolizumab-specific AEs, which were also included in the Atezolizumab Investigator's Brochure, in the protocol.

## Protocol deviations:

<div style=\"page-break-after: always\"></div>

Table 10: Summary of major protocol deviations (ITT population)

| Protocol Deviation Category Protocol Deviation Description   | PBO + CE (Randomized) (N=202)   | Atezo + CE (Randomized) (N=201)   | All Patients (N=403)   |
|--------------------------------------------------------------|---------------------------------|-----------------------------------|------------------------|
| Total number of patients with at least one deviation         | 74 (36.6%)                      | 79(39.3%)                         | 153 (38.0%)            |
| Overall total number of deviations                           | 104                             | 118                               | 222                    |
| Procedural                                                   |                                 |                                   |                        |
| Total number of patients with at least one deviation         | 64(31.7%)                       | 65 (32.3%)                        | 129 (32.0%)            |
| Total number of events                                       | 80                              | 91                                | 171                    |
| ICF - other (e.g. procedural issues)                         | 23 (11.4%)                      | 28 (13.9%)                        | 51 (12.7%)             |
| Other proc. deviation for safety and/or efficacy             | 19 (9.4%)                       | 19 (9.5%)                         | 38 (9.4%)              |
| Error with stratification                                    | 8 (4.0%)                        | 12 6.0%)                          | 20 5.0%)               |
| Omission of safety labs required by protocol                 | 9 (4.5%)                        | 9 4.5%)                           | 18 4.5%)               |
| Failure to report sAEs or pregnancy per protocol             | 6 (3.0%)                        | 5 ( 2.5%)                         | 11 2.7%)               |
| Tumor assessment significantly out of window                 | 3 (1.5%)                        | 8 (4.0%)                          | 11 2.7%)               |
| Omission of tumor assessment                                 | A (2.0%)                        | 4 (2.0%) 0                        | 8 (2.0%)               |
| No pre-treatment tumor tissue sample submitted               | 1 (0.5%)                        |                                   | 1 0.2%)                |
| Inclusion criteria                                           |                                 |                                   |                        |
| Total number of patients with at least one deviation         | 9 (4.5%)                        | 15 (7.5%)                         | 24 (6.0%)              |
| Total number of events                                       | 9                               | 16                                | 25 20 (5.0%)           |
| Incl/Excl-relatedtest not done/outof window                  | 7 (3.5%)                        | 13 (6.5%) 2                       | 3 (0.7%)               |
| Ineligible history or current sCLC stage                     | 1 (0.5%)                        | (1.0%)                            |                        |
| Inclusion lab values outside allowed limits                  | 1 (0.5%)                        | 0                                 | 1 0.2%)                |
| Received prior treatment for Es-sCLc                         | 0                               | 1 (0.5%)                          | 1 (0.2%)               |
| Medication                                                   |                                 |                                   |                        |
| Total number of patients with at least one deviation         | 9 (4.5%)                        | 7 (3.5%)                          | 16 (4.0%)              |
| Total number of events                                       | 10                              | 7                                 | 17                     |
| Sigmificant deviation from planned study drug dose           | (3.5%)                          | 5 (2.5%)                          | 12 ( 3.0%)             |
| Induction treatment not given as per protocoi                | 1 (0.5%)                        | 1 (0.5%)                          | 2 (0.5%)               |
| Received incorrect study drug or wrong dose                  | 1 (0.5%)                        | 1 (0.5%)                          | 21 (0.5%)              |
| Exclusion criteria                                           |                                 |                                   |                        |
| Total number of patients with at least one deviation         | 5 (2.5%)                        | (2.0%)                            | 9 (2.2%)               |
| Totalnumber of events                                        | 5                               | 4                                 | 9                      |
| Active or umtreated CNs metastases                           | 4 (2.0%)                        | 0                                 | 4 (1.0%)               |
| Other exclusion criteria                                     | (0.5%)                          | 3 (1.5%)                          | 4 (1.0%)               |
| Excluded positive viral test (HIV, HBV, HCV, TB)             | 0                               | 1 ( 0.5%)                         | 1 ( 0.2%)              |

<div style=\"page-break-after: always\"></div>

## Baseline data

## Table 11: Demographic and baseline disease characteristics (ITT population)

Age (years)

Age group (years)

Sex (eCRF)

Sex (IxRS)

Race

Ethnicity

Weight (kg) at baseline

Baseline ECOG (eCRF)

Baseline ECOG (IxRS)

Tobacco Use History

Brain Metastases (eCRF)

Brain Metastases (IxRS)

bTMB Biomarker Expression bTMB Biomarker Expression

SLD at Baseline

Atezo=Atezolizumab, CE=Carboplatin + Etoposide, PBO=Placebo

Data Cutoff: 24APR2018

|                                      | PBO + CE (Randomized)                        | Atezo + CE (Randomized)    | All Patients (N=403)         |
|--------------------------------------|----------------------------------------------|----------------------------|------------------------------|
| Age (years)                          | (N=202)                                      | (N=201)                    |                              |
| American Indian or Alaska Native     | 1 ( 0.5%) 36                                 | 0 33                       | 1 ( 69 (17.1%)               |
| Asian African American               | (17.8%) 2 ( 1.0%)                            | (16.4%) 1                  | 403 63.7 (8.9)               |
| n Mean (SD)                          | 202 63.6 (9.0)                               | 201 63.8 (8.8)             |                              |
| Median                               | 64.0                                         | 64.0                       | 64.0                         |
| Min - Max                            | 26 - 87                                      | 28 - 90                    | 26 - 90                      |
| Age group (years)                    |                                              |                            |                              |
| n                                    | 202                                          | 201                        | 403                          |
|                                      | 106 (52.5%)                                  | (55.2%)                    | 217 (53.8%)                  |
| < 65 >= 65                           | 96 (47.5%)                                   | 111 90 (44.8%)             | 186 (46.2%)                  |
| 65 - 74                              | 74 (36.6%)                                   | 71 (35.3%)                 | 145 (36.0%)                  |
| 75 - 84                              | 21 (10.4%)                                   | 18 (                       | 39 ( 9.7%)                   |
| >=85                                 | 1 ( 0.5%)                                    | 9.0%) 1 ( 0.5%)            | 2 ( 0.5%)                    |
| Sex (eCRF)                           |                                              |                            |                              |
| n                                    | 202                                          | 201 129                    | 403                          |
| Male                                 | 132 (65.3%)                                  | (64.2%)                    | 261 (64.8%)                  |
| Female                               | 70 (34.7%)                                   | 72 (35.8%)                 | 142 (35.2%)                  |
| Sex (IxRS)                           |                                              | 201                        | 403                          |
| n Male Female                        | 202 132 (65.3%) 70 (34.7%)                   | 130 (64.7%) 71 (35.3%)     | 262 (65.0%) 141 (35.0%)      |
| Race                                 |                                              |                            |                              |
| n                                    | 202                                          | 201                        | 403                          |
|                                      |                                              |                            | 0.2%)                        |
|                                      |                                              | ( 0.5%)                    | 3 ( 0.7%)                    |
| Black or White                       | 159                                          | 163                        |                              |
| Unknown                              | (78.7%) 4 ( 2.0%)                            | (81.1%) 4 ( 2.0%)          | 322 (79.9%) 8 ( 2.0%)        |
| Ethnicity                            |                                              |                            |                              |
| n                                    | 202 4.0%)                                    | 201                        | 403 16 (                     |
| Hispanic or Latino                   | 8 (                                          | 8 ( 4.0%)                  | 4.0%)                        |
| Not Hispanic or Latino               | 185 (91.6%)                                  | 187 (93.0%)                | 372 (92.3%) 8 2.0%)          |
| Not Stated Unknown                   | 4 ( 2.0%) 5 ( 2.5%)                          | 4 ( 2.0%) 2 ( 1.0%)        | ( 7 ( 1.7%)                  |
| Weight (kg) at baseline              |                                              |                            |                              |
| n Mean (SD)                          | 196 75.71 (17.81)                            | 197 75.36 (19.74)          | 393 75.53 (18.78)            |
|                                      |                                              | 73.00                      | 73.00                        |
| Median Min - Max                     | 73.50 39.0 - 129.0                           | 45.0 - 181.0               | 39.0 - 181.0                 |
| Baseline ECOG (eCRF)                 |                                              |                            |                              |
| n                                    | 202 (33.2%)                                  | 201 73                     | 403 140                      |
| 0 1                                  | 67 135 (66.8%)                               | (36.3%) 128 (63.7%)        | (34.7%) 263 (65.3%)          |
| Baseline ECOG (IxRS) n 0 1           | 202 72 (35.6%) 130 (64.4%)                   | 201 73 (36.3%) 128 (63.7%) | 403 145 (36.0%) 258 (64.0%)  |
| Tobacco Use History n                | 202 3 (                                      | 201 9 (                    | 403 12 (                     |
| Never Current                        | 1.5%) 75 (37.1%)                             | 4.5%)                      | 3.0%) 149                    |
|                                      | 124 (61.4%)                                  | 74 (36.8%)                 | (37.0%)                      |
| Previous                             |                                              | 118 (58.7%)                | 242 (60.0%)                  |
| Brain Metastases (eCRF)              |                                              |                            |                              |
| n                                    | 202 18 ( 184 (91.1%)                         | 201 ( 8.5%) 184 (91.5%)    | 403 35 ( 8.7%) 368 (91.3%)   |
| Yes No                               | 8.9%)                                        | 17                         |                              |
| Brain Metastases (IxRS)              | 202                                          | 201 16 ( 185               | 403 32 (                     |
| n Yes No                             | 16 (                                         | 8.0%) (92.0%)              | 7.9%) 371 (92.1%)            |
| bTMB Biomarker Expression n <10 >=10 | 7.9%) 186 (92.1%) 178 68 (38.2%) 110 (61.8%) | 173 71 (41.0%) 102 (59.0%) | 351 139 (39.6%) 212 (60.4%)  |
| n <16                                | 178 138 40                                   |                            |                              |
|                                      |                                              | 133 40                     |                              |
| >=16                                 |                                              |                            | 351 (77.2%)                  |
| SLD at Baseline n                    |                                              | 173                        |                              |
| Mean (SD) Median                     |                                              | (76.9%) (23.1%)            | (22.8%)                      |
| Min - Max                            | (77.5%) (22.5%) 202 116.58 (58.28)           | 201 120.90 (58.88)         | 271 80 403                   |
|                                      | 105.50 15.0 - 353.0                          | 113.00 12.0 - 325.0        | 118.73 (58.55) 111.00 12.0 - |
| Atezo=Atezolizumab,                  |                                              |                            |                              |
|                                      | + Etoposide,                                 |                            |                              |
|                                      |                                              |                            | 353.0                        |
| CE=Carboplatin                       |                                              |                            |                              |
|                                      |                                              | PBO=Placebo                |                              |

<div style=\"page-break-after: always\"></div>

Table 12: SCLC History, Intent-to-Treat Patients

|                                                                                                                                                                                            | PBO+ CE (Randomized) (N=202)                                                               | Atezo + CE (Randomi zed) (N=201)                                                              | All Patients (N=403)                                             |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|------------------------------------------------------------------|
| Initially diagnosed with Limited Stage SCLC prior n Yes                                                                                                                                    | to 202                                                                                     | progressing 200                                                                               | to Extensive stage SCLC 402                                      |
| No n                                                                                                                                                                                       | 1 4 6.98) 188 93.18)                                                                       | 13 (6.5%) 187 (93.0%)                                                                         | 27(6.7%) 375 (93.18)                                             |
| Current Disease Status Limited Stage SCLC                                                                                                                                                  | 202 0 202                                                                                  | 200 1 （0.5%) 199 (99.08)                                                                      | 402 1 401                                                        |
| Extensive Stage SCLC Time since Limited Stage SCLC Diagnosis (months) n                                                                                                                    | (100.0%)                                                                                   |                                                                                               | (0.2%) (99.58) 27                                                |
| Mean (SD) Median Min - Max Time since Extensive Stage SCLc Diagnosis n Mean (SD) Median Min - Max Brain Metastasis at Enrollment (per eCRF) n Yes No                                       | 1 4 15.74 (9.39) 13.83 0.9-33.7 (months) 202 0.76 (0.46) 0.66 0.1 -2.8 202 18 ( 184 91.18) | 13 16.33_(19.81) 13.34 0.5-76.0 199 1.00 (1.34) 0.72 0.1 12.4 201 8.9%) 17 (8.5%) 184 (91.5%) | 16.02_(15.01) 13.63 0.5 -76.0 401 0.88 (1.00) 0.69 403 35 (8.7%) |
| Number of brainmetastases n Mean (SD) Median Min - Max BrainMetastasis Treatment Whole Brain Radiation SBRT/GammaKnife Surgical Resection Liver Adrenal Gland Lung Lymph Nodes Breast Bone | 35 172 ( 168 ( 1 ( 42 (                                                                    | 0 0 6 (3.0%) 0 15 (7.5%)                                                                      | 0.1 -12.4                                                        |
| Locationof brain metastases Supratentorial Cerebellum Non-cerebellar Infratentorial                                                                                                        | 1 6 6 ( 1 ( 18 1.28 (0.46) 1.00 1.0 -2.0 1 2 ( 5.98) 3 ( 1.5%)                             | 7.98) 9 (4.58) 3.0%) 8(4.0%) 0.5%) 0 17 1.00 (0.00) 1.00 1.0 - 1.0 13(6.5%)                   | 368 (91.38) 25 (6.28) 1 4 (3.5%) (0.2%)                          |
| Metastatic Site at Enrollment                                                                                                                                                              | 1                                                                                          | 2 (1.0%)                                                                                      | 35 1.14 (0.36) 1.00 1.0 - 2.0 25 (6.2%)                          |
|                                                                                                                                                                                            | 0.5%) 72 ( 35.6%)                                                                          | 3 (1.58)                                                                                      | 5 1.2%) 4                                                        |
|                                                                                                                                                                                            | 17.38)                                                                                     | 77 (38.38) 37 (18.48)                                                                         | 1.0%) 149                                                        |
|                                                                                                                                                                                            | 85.1%)                                                                                     | (79.68)                                                                                       | (37.0%) 72 (17.98) 349 (86.6%)                                   |
|                                                                                                                                                                                            | 1 (                                                                                        | 0 6 (                                                                                         | 81 1 16                                                          |
|                                                                                                                                                                                            | 83.2%) 0.5%)                                                                               | 177 (88.18)                                                                                   | 328                                                              |
|                                                                                                                                                                                            | 1 0 (                                                                                      | 39                                                                                            | 1 0.2%)                                                          |
|                                                                                                                                                                                            |                                                                                            | 160 0                                                                                         |                                                                  |
| Bronchus                                                                                                                                                                                   | 1 (                                                                                        |                                                                                               |                                                                  |
|                                                                                                                                                                                            | 20.8%) 0.5%)                                                                               | (19.48)                                                                                       |                                                                  |
|                                                                                                                                                                                            | 5.0%) 0.5%)                                                                                |                                                                                               | (20.1%) 0.2%) 4.0%)                                              |
| Chest                                                                                                                                                                                      |                                                                                            | 3.0%)                                                                                         | 1                                                                |
| Esophagus                                                                                                                                                                                  | 0                                                                                          |                                                                                               | 0.2%) 0 10 2.58)                                                 |
| Head                                                                                                                                                                                       |                                                                                            |                                                                                               |                                                                  |
| Kidney                                                                                                                                                                                     | 4                                                                                          |                                                                                               |                                                                  |
|                                                                                                                                                                                            | 0                                                                                          |                                                                                               |                                                                  |
| Bone Marrow Mediastinum                                                                                                                                                                    | 2.0%)                                                                                      |                                                                                               | 31                                                               |
|                                                                                                                                                                                            | 16 ( 7.98)                                                                                 | 0                                                                                             |                                                                  |
|                                                                                                                                                                                            | (                                                                                          |                                                                                               | 2                                                                |
|                                                                                                                                                                                            |                                                                                            |                                                                                               | 0                                                                |
| Neck Ovary                                                                                                                                                                                 | 2 1.0%) 0                                                                                  |                                                                                               | (7.7%) (0.5%)                                                    |
| Pancreas Pelvis                                                                                                                                                                            | 9 ( 4.5%)                                                                                  | 1 8 1                                                                                         | 1 0.2%) 17 1                                                     |
|                                                                                                                                                                                            |                                                                                            | （0.5%) (4.0%) 0.5%)                                                                           |                                                                  |
| Pericardial Cavity                                                                                                                                                                         | 0 5                                                                                        |                                                                                               | 4.2%) 0.2%)                                                      |
| Peritoneum                                                                                                                                                                                 | 3 (                                                                                        | 9 4.5%) 4                                                                                     | 1 4 3.58) 7 (                                                    |
|                                                                                                                                                                                            | 2.5%) 1.5%)                                                                                | 2.0%) (25.9%)                                                                                 | 1.7%)                                                            |
| Pleura                                                                                                                                                                                     | 53 (                                                                                       | 52                                                                                            | 105 (26.1%)                                                      |
|                                                                                                                                                                                            | 26.28)                                                                                     | 1                                                                                             | 3                                                                |
| Skin Soft Tissue                                                                                                                                                                           | 2 1.0%) 2 1.0%)                                                                            | 0.5%) 4 (                                                                                     | 6                                                                |
|                                                                                                                                                                                            |                                                                                            |                                                                                               | 0.7%) 1.58)                                                      |
| Stomach                                                                                                                                                                                    | 0                                                                                          | 0                                                                                             | 0                                                                |
|                                                                                                                                                                                            | 0                                                                                          | 3                                                                                             | 3                                                                |
| Trachea                                                                                                                                                                                    |                                                                                            | 1.5%)                                                                                         |                                                                  |
|                                                                                                                                                                                            | 5.4%)                                                                                      | 20 (10.0%)                                                                                    | 0.7%)                                                            |
|                                                                                                                                                                                            |                                                                                            |                                                                                               | 31                                                               |
|                                                                                                                                                                                            | 1 1                                                                                        |                                                                                               | 7.7%)                                                            |
| Other                                                                                                                                                                                      |                                                                                            |                                                                                               |                                                                  |
|                                                                                                                                                                                            |                                                                                            | 2.0%)                                                                                         |                                                                  |

<div style=\"page-break-after: always\"></div>

Subject1o042hadsquamouscellcarcinomaandwasrandomizedintothe studywithoutmeetingdiseaseeligibilitycriteria，therefore noSCLchistoryisavailableforthissubject. Subject 103oohadNon-cerebellar Infratentorialbrain metastasis andwas randomizedintothe studywithout meeting eligibility criteria. Subject 10365had limited-stage SCLC andwas randomized into the study without meeting eligibility criteria，therefore no ES-SCLC history isavailablefor this subject. PartialDiagnosis date is imputed withlstof the monthif the dayis missing in the calculations of time since LimitedStageor Extensive Stage. Atezo=Atezolizumab,CE=Carboplatin+Etoposide,PBo=Placebo DataCutoff:24APR2018

## Table 13: Prior cancer therapy (Intent-to-Treat patients)

| Therapy Setting                                     | PBO+ CE (Randomized) (N=202)   | Atezo + CE (Randomi zed) (N=201)   | All Patients (N=403)   |
|-----------------------------------------------------|--------------------------------|------------------------------------|------------------------|
| Limited-Stage                                       |                                |                                    |                        |
| Line of Therapy                                     |                                |                                    |                        |
| 1ST LINE                                            | 12(5.98)                       | 8 (4.0%)                           | 20(5.0%)               |
| 2ND LINE                                            | 1 （0.5%)                       | 0                                  | 1(0.28)                |
| Therapy Type                                        |                                |                                    |                        |
| Totalnumber of patients withat leastonetreatment    | 12 (5.98)                      | 8(4.0%)                            | 20(5.0%)               |
| Total number of treatments                          | 13                             | 8                                  | 21                     |
| CHEMOTHERAPY/NON-ANTHRACYCLINE                      | 12 (5.9%)                      | 8(4.0%)                            | 20 (5.0%)              |
| Regimen Name                                        |                                |                                    |                        |
| Total number of patients withat least one treatment | 12 (5.98)                      | 8(4.0%)                            | 20 (5.0%)              |
| Totalnumber of treatments                           | 13                             | 8                                  | 21                     |
| CISPLATIN，ETOPOSIDE,PLUS CONCURRENT RADIATION       | (3.58)                         | 6(3.0%)                            | 13( 3.28)              |
| CARBOPLATIN,ETOPOSIDE,PLUS CONCURRENT RADIATION     | (3.0%)                         | 2 (1.0%)                           | 8(2.0%)                |
| other                                               |                                |                                    |                        |
| 1ST LINE                                            | 0                              | 1(0.58)                            | 1(0.28)                |

setting for a patient were counted once in the frequency for the therapy setting A patient was counted more than once if received more than one therapy types under each line and regimen. Subject 10242 received a dose of etoposide for the first-line treatment of ES-SCLC prior tobeing randomizedintothe study. Atezo=Atezolizumab，CE=Carboplatin + Etoposide，PBO=Placebo Data Cutoff:24APR2018

## Numbers analysed

## Table 14: Overview of analysis populations

|                                                                            |   PBO+CE |     |   Atezo + CEAll Patients |
|----------------------------------------------------------------------------|----------|-----|--------------------------|
| AllRandomizedIntent-to-Treat Patients                                      |      202 | 201 |                      403 |
| Measurable Disease at Baseline perInvestigator in Intent-to-Treat Patients |      202 | 201 |                      403 |
| AllSafetyEvaluablePatients                                                 |      196 | 198 |                      394 |
| ADAEvaluable AtezoPatients                                                 |        0 | 188 |                      188 |
| PRO Evaluable Patients for EORTC QLQ-C30                                   |      177 | 170 |                      347 |
| PROEvaluable Patients for EORTCQLQ-LCl3                                    |      169 | 166 |                      335 |
| PROEvaluablePatientsforEQ-5D-5L                                            |      169 | 165 |                      334 |
| AllPKEvaluableAtezolizumabTreatedPatients                                  |        0 | 192 |                      192 |

Safety, ATAandPK Evaluablepopulations are actualtreatment received.Allother populations are randomized treatment.

Atezo=Atezolizumab,CE=Carboplatin+Etoposide，PBO=Placebo

DataCutoff:24APR2018

## Outcomes and estimation

Co-primary efficacy endpoints:

## OS in ITT

At the time of the primary analysis(data cutoff 24 April 2018), patients had a median survival follow up time of 13.9 months. At the final analysis (data cutoff 24 January 2019), median survival follow up time was 22.9 months.

<div style=\"page-break-after: always\"></div>

Table 15: Duration of survival follow-up (ITT population)

<!-- image -->

<!-- image -->

Table 16: Overview of overall survival results (ITT population)

| Parameter                                                        | Interim os Analysis (CCOD24April2018)       | Interim os Analysis (CCOD24April2018)       | Updated os Analysis (CCOD24January2019)     | Updated os Analysis (CCOD24January2019)     |
|------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
|                                                                  | PBO+CE                                      | Atezo+CE                                    | PBO+CE                                      | Atezo+CE                                    |
| Co-PrimaryEfficacyObjective:OverallSurvival                      | Co-PrimaryEfficacyObjective:OverallSurvival | Co-PrimaryEfficacyObjective:OverallSurvival | Co-PrimaryEfficacyObjective:OverallSurvival | Co-PrimaryEfficacyObjective:OverallSurvival |
| ITT Population                                                   | N=202                                       | N=201                                       | N = 202                                     | N = 201                                     |
| Patients with event (%)                                          | 134 (66.3)                                  | 104 (51.7)                                  | 160 (79.2)                                  | 142 (70.6)                                  |
| Median duration of survival - months (95% CI)                    | 10.3 (9.3, 11.3)                            | 12.3 (10.8, 15.9)                           | 10.3 (9.3, 11.3)                            | 12.3 (10.8, 15.8)                           |
| Stratified Hazard Ratio (95% Cl) p-value (log-rank)              | 0.701 (0.541, 0.909) 0.0069a                | 0.701 (0.541, 0.909) 0.0069a                | 0.755 (0.601, 0.949) 0.0154b                | 0.755 (0.601, 0.949) 0.0154b                |
| Patients remaining at risk 12-month event-free rate - % (95% CI) | 59 38.2 (31.2, 45.3)                        | 74 51.7 (44.4, 59.0)                        | 74 39.0 (32.1, 45.9)                        | 93 51.9 (44.6, 59.1)                        |
| Patients remaining at risk 18-monthevent-freerate-% (95% CI)     | 3 20.2 (11.1, 29.4)                         | 5 25.0 (11.2, 38.7)                         | 39 21.0 (15.2, 26.8)                        | 61 34.0 (27.1, 40.9)                        |
| Patients remaining at risk 24-month event-free rate - % (95% CI) | NE NE (NE, NE)                              | NE NE (NE, NE)                              | 8 16.8 (11.3, 22.2)                         | 21 22.0 (15.7, 28.3)                        |

Atezo=atezolizumab;CcoD=clinicalcut-off date;CE=carboplatin+etoposide;Cl=confidence interval; DoR = duration of response; ITT = intent-to-treat; OS = overall survival; NE = not estimable;PBO=placebo a Interim Analysis OS was tested at two-sided α of 0.0193 (with 238 observed OS events at CCoD) to control the overall two-sided type I error for OS at 0.045 by Lan DeMets function approximating O'Brien-Fleming boundary.

b Descriptive purposes only

Source:Table 17Primary CSR,and t\\_ef\\_tet01\\_IT\\_os\\_24JAN2019

<div style=\"page-break-after: always\"></div>

<!-- image -->

Stratification factors are: Sex(male vs female) and ECoG (0 vs T) per (XR.5.

Figure 7: Kaplan-Meier curves for overall survival - final analysis (ITT population)

## INV-PFS in ITT

Data from the primary analysis with cutoff on 24 April 2018.

Table 17: Time to event summary for progression free survival per RECIST v1.1 - Investigator (Intent-to-treat patients)

<div style=\"page-break-after: always\"></div>

<!-- image -->

* Censored, ^ Censored and event, NE = Not estimable. Summaries  of  Time-to-Event  (median,  percentiles)  are  Kaplan-Meier  estimates.  95%  CI  for  median  was  computed  using the  method  of  Brookmeyer  and  Crowley.  Hazard  ratios  were  estimated  by  Cox  regression.  Stratification  factors  are: Sex (male vs female) and ECOG (0 vs 1) per IXRS. Atezo=Atezolizumab, CE=Carboplatin + Etoposide, PBO=Placebo

Figure 8: Kaplan-Meier plot of progression free survival with stratified analysis (Intent-to-treat patients)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Secondary efficacy endpoints:

## Unconfirmed ORR

## Table 18: Summary of ORR (ITT population patients with unconfirmed response assessed by investigator per RECIST v1.1)

|                                                                                                                                           | PBO + CE (Randomized) (N=202)   | Atezo + CE (Randomized) (N=201)   |
|-------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|-----------------------------------|
| _____________________________________________________________________________________________________________ ______________              |                                 |                                   |
| Responders                                                                                                                                | 155 (76.7%)                     | 149                               |
| (74.1%) Non-Responders                                                                                                                    | 47 (23.3%)                      | 52                                |
| (25.9%) 95% CI for Response Rate (Clopper-Pearson) 80.03)                                                                                 | (70.29, 82.38)                  | (67.50,                           |
| Difference in Response Rates 95% CI for Difference in Response Rates (Wald with Continuity Correction) p-Value* (Cochran-Mantel-Haenszel) | -2.60 (-11.50, 6.30) 0.5412     | -2.60 (-11.50, 6.30) 0.5412       |
| Odds Ratio* 95% CI for Odds Ratio* Complete Response (CR)                                                                                 | 0.87 (0.55, 3 ( 1.5%) 5 (       | 1.37) 2.5%) (0.81,                |
| 95% CI 5.71) Partial Response (PR)                                                                                                        | (0.31, 4.28) 152 (75.2%)        | 144                               |
| (71.6%) 95% CI 77.76)                                                                                                                     | (68.70, 81.04)                  | (64.87,                           |
| Stable Disease (SD)                                                                                                                       | 22 (10.9%)                      | 24                                |
| (11.9%) 95% CI                                                                                                                            | (6.95, 16.02)                   | (7.80,                            |
| 17.24)                                                                                                                                    | 5.4%)                           | 15 ( 7.5%)                        |
| Progressive Disease (PD) 95% CI                                                                                                           | 11 ( (2.75, 9.53)               | (4.24,                            |
| 12.01) Missing or unevaluable ( 6.5%)                                                                                                     | 14 ( 6.9%)                      | 13                                |

Patients were classified as missing or unevaluable if no post-baseline response assessments were available or all post-baseline response baseline assessments were unevaluable.  Responders refer to patients with &lt;CR/PR&gt;. 95% CI for rates were constructed using the Clopper Pearson method.Wald is the normal approximation for 95% CI of difference in rates. * Stratification factors are Sex and ECOG per IxRS.

Data Cutoff: 24APR2018

Atezo=Atezolizumab, CE=Carboplatin + Etoposide, PBO=Placebo

<div style=\"page-break-after: always\"></div>

## Unconfirmed DoR

Table 19: Summary of DOR (ITT population patients with unconfirmed response assessed by investigator per RECIST v1.1)

|                                                            | PBO + CE (Randomized) (N=155)   | Atezo + CE (Randomized) (N=149) ________________________________________________________________________________   |
|------------------------------------------------------------|---------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Patients with event (%)                                    | 148 (95.5%)                     | 129 (86.6%)                                                                                                        |
| Earliest contributing event                                | 9                               | 8                                                                                                                  |
| Death Disease Progression                                  | 139                             | 121                                                                                                                |
| Patients without event (%)                                 | 7 ( 4.5%)                       | 20 (13.4%)                                                                                                         |
| Time to Event (Months) Median 95% CI                       | 3.1 (2.9, 3.9)                  | 4.1 (3.5, 4.2)                                                                                                     |
| Unstratified Analysis Event Free Rate (%)                  | 2.8, 4.5                        | 2.8, 6.6 0.731 (0.571, 0.935)                                                                                      |
| 25% and 75%-ile Range                                      | 0.3 to 16.1*                    | to 19.5                                                                                                            |
| Stratified Analysis p-value (log-rank)                     |                                 | 0.0* 0.0125                                                                                                        |
| Hazard Ratio 95% CI p-value (log-rank) Hazard Ratio 95% CI |                                 | 0.0063 0.715 (0.562, 0.911)                                                                                        |
| Time Point Analysis 6 Months Patients remaining at risk    | 22                              | 39                                                                                                                 |
|                                                            | 14.34                           | 27.13                                                                                                              |
| 95% CI                                                     | (8.80, 19.89)                   | 34.40)                                                                                                             |
|                                                            |                                 | (19.87,                                                                                                            |

* Censored, ^ Censored and event, NE = Not estimable.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Summaries  of  Time-to-Event  (median,  percentiles)  are  Kaplan-Meier  estimates.  95%  CI  for  median  was  computed  using the  method  of  Brookmeyer  and  Crowley.  Hazard  ratios  were  estimated  by  Cox  regression.  Stratification  factors  are: Sex (male vs female) and ECOG (0 vs 1) per IXRS.

Atezo=Atezolizumab, CE=Carboplatin + Etoposide, PBO=Placebo Data Cutoff: 24APR2018

## PROs

Table 20: Baseline patient-reported outcome scores

|                               | PBO+CE (N=202)   | Atezo+ CE (N=201)   |
|-------------------------------|------------------|---------------------|
|                               | Mean scores (SD) | Mean scores (SD)    |
| SelectEORTC QLQ-LC13 scales   | n =168           | n = 176             |
| Coughing                      | 42.9 (29.2)      | 42.2 (27.7)         |
| Pain in chest                 | 22.2 (25.7)      | 22.9 (26.6)         |
| Dyspnea                       | 29.6 (25.9)      | 34.3 (25.9)         |
| Pain in arm or shoulder       | 19.4 (27.4)      | 22.2 (30.6)         |
| Select EORTC QLQ-C30 scales   | n = 175          | n = 179             |
| Fatigue                       | 38.7 (26.9)      | 42.0 (26.4)         |
| Appetite loss                 | 27.4 (31.9)      | 28.9 (32.3)         |
| Physical functioning          | 71.9 (23.5)      | 70.7 (22.7)         |
| Role funclioning              | 66.4 (32.9)      | 67.1 (31.3)         |
| Social functioning            | 73.3 (28.8)      | 71.1 (29.1)         |
| Emotional functioning         | 69.9 (24.0)      | 68.6 (23.9)         |
| Cognitive functioning         | 83.3 (20.6)      | 81.8 (21.1)         |
| Global health status or HRQoL | 53.7 (23.4)      | 51.6 (22.4)         |

Atezo - atezolizumab, CE - carboplatin and etoposide, HRQoL = health-related quality of life.

PBO =placebo; PRO =palient-reported outcome, SD = standard deviation

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 9: Kaplan-Meier plot of time to confirmed deterioration of cough with stratified analysis (ITT patients)

<!-- image -->

Figure 11: Kaplan-Meier plot of time to confirmed deterioration of pain in arm or shoulder with stratified analysis (ITT patients)

<!-- image -->

## Ancillary analyses

## Efficacy according to PD-L1 IHC status

Table 21: IMpower133 PD-L1 IHC (SP263) prevalence from patients with available tissue (ITT patients)

|                            | PBO+ CE (Randomized) (N=202)   | Atezo + CE (Randomized) (N=201)   | Atezo + CE (Randomized) (N=201)   | All Patients (N=403)   |
|----------------------------|--------------------------------|-----------------------------------|-----------------------------------|------------------------|
| BEP1 (Section age <=lYR) n | 73 (36.1%)                     |                                   | 64 (31.8%)                        | 137 (34.0%)            |
| TC>=50% or IC>=50%         | 0                              |                                   | 0                                 | 0                      |
| TC>=25%0rIC>=25%           | 0                              |                                   | 1 (1.6%)                          | 1 (0.7%)               |
| TC>=5% or IC>=5%           | 14 (19.2%)                     | 15                                | (23.4%)                           | 29 (21.2%)             |
| TC>=1% or IC>=18           | 36 (49.3%)                     | 36                                | (56.3%)                           | 72 (52.6%)             |
| TC<1andIC<18               | 37 (50.7%)                     | 28                                | (43.8%)                           | 65 (47.4%)             |
| BEP2 (Any PD-L1) n         | 93 (46.0%)                     | 75                                | (37.3%)                           | 168 (41.7%)            |
| TC>=50% or IC>=50%         | 0                              |                                   | 0                                 | 0                      |
| TC>=25orIC>=25%            | 0                              | 1                                 | (1.3%)                            | 1 (0.6%)               |
| TC>=5orIC>=5%              | 22 (23.7%)                     | 17                                | (22.7%)                           | 39( (23.2%)            |
| TC>=1or IC>=18             | 51 (54.8%)                     | 42                                | (56.0%)                           | 93 (55.4%)             |
| TC<18andIC<18              | 42 (45.2%)                     | 33                                | (44.0%)                           | 75 (44.6%)             |

tissue slide sectioned&lt;= 1 year prior to IHC staining.

tissue slide, regardless of slide age at IHC staining.

Percentages in the TcIc expression rows

Percentages in the Biomarker Evaluable Populationrows arebased on the treatment columnN.

are based on the Biomarker Evaluable Population row total n.

Figure 10: Kaplan-Meier plot of time to confirmed deterioration of pain in chest with stratified analysis (ITT patients)

Figure 12: Kaplan-Meier plot of time to confirmed deterioration of dyspnoea with stratified analysis (ITT patients)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                 |         | PBO+CE (Randomized) (N=202)   | PBO+CE (Randomized) (N=202)   | PBO+CE (Randomized) (N=202)   | Atezo+CE (Randomized) (N=201)   | Atezo+CE (Randomized) (N=201)   | Atezo+CE (Randomized) (N=201)   |              |             | Atezo+CE            | PBO+CE              |
|---------------------------------|---------|-------------------------------|-------------------------------|-------------------------------|---------------------------------|---------------------------------|---------------------------------|--------------|-------------|---------------------|---------------------|
| BaselineRiskFactors:            | Total n | n                             | Events                        | Median (Months)               | n                               | Events                          | Median (Months)                 | Hazard Ratio | 95%Wald D   | (Randomized) better | (Randomized) better |
| AllPatients                     | 403     | 202                           | 160                           | 10.3                          | 201                             | 142                             | 12.3                            | 0.76         | (0.61,0.96) |                     |                     |
| ITT-BEP1                        |         |                               |                               |                               |                                 |                                 |                                 |              |             |                     |                     |
| BEP1-SlideageC=1Yr              | 137     | 73                            | 64                            | 8.9                           | 64                              | 49                              | 9.9                             | 0.70         | (0.48.1.02) |                     |                     |
| PD-L1unknownor slideage>1Yr     | 266     | 129                           | 96                            | 11.2                          | 137                             | 93                              | 14.6                            | 0.81         | (0.61,1.08) |                     |                     |
| PD-L1Expression1%-SlideageC=1YR |         |                               |                               |                               |                                 |                                 |                                 |              |             |                     |                     |
| <1                              | 65      | 37                            | 34                            | 8.3                           | 28                              | 25                              | 10.2                            | 0.51         | (0.30.0.89) |                     |                     |
| >=1                             | 72      | 36                            | 30                            | 10.6                          | 36                              | 24                              | 9.7                             | 0.87         | (0.51,1.49) |                     |                     |
| PD-L1Expression5%-Slideagec=1YR |         |                               |                               |                               |                                 |                                 |                                 |              |             |                     |                     |
| <5                              | 108     | 59                            | 53                            | 8.9                           | 49                              | 40                              | 9.2                             | 0.77         | (0.51.1.17) |                     |                     |
| S=<                             | 29      | 14                            | 11                            | 9.2                           | 15                              | 9                               | 21.6                            | 0.60         | (0.25,1.46) |                     |                     |
| ITT-BEP2                        |         |                               |                               |                               |                                 |                                 |                                 |              |             |                     |                     |
| BEP2-AnyPD-L1                   | 168     | 93                            | 79                            | 9.3                           | 75                              | 57                              | 10.5                            | 0.76         | (0.54,1.08) |                     |                     |
| PD-L1unknown                    | 235     | 109                           | 81                            | 11.1                          | 126                             | 85                              | 14.6                            | 0.78         | (0.58,1.07) |                     |                     |
| PD-L1Expression1%-AnyPD-L1      |         |                               |                               |                               |                                 |                                 |                                 |              |             |                     |                     |
| <1                              | 75      | 42                            | 38                            | 8.8                           | 33                              | 29                              | 10.5                            | 0.57         | (0.34,0.94) |                     |                     |
| >=1                             | 93      | 51                            | 41                            | 11.1                          | 42                              | 28                              | 10.6                            | 0.90         | (0.56,1.46) |                     |                     |
| PD-L1Expression5%-AnyPD-L1      |         |                               |                               |                               |                                 |                                 |                                 |              |             |                     |                     |
| <5                              | 129     | 71                            | 62                            | 9.3                           | 58                              | 47                              | 9.3                             | 0.83         | (0.56.1.21) |                     |                     |
| >=5                             | 39      | 22                            | 17                            | 9.2                           | 17                              | 10                              | 14.3                            | 0.61         | (0.28,1.35) |                     |                     |

BEP1(BiomarkerEvaluablePopulation1)=ITTpatientswithavalidPD-L1IHCresult fromatumortissueslidesectioned&lt;=1yearpriortoIHCstaining.

MedianswereestimatedfromKaplan-Meiermethod.NE=Notestimable.

BEP2（BiomarkerEvaluablePopulation2)=ITTpatientswithavalidPD-L1IHCresultfromatumortissueslide.regardlessofslideageatIHCstaining.

HazardratiosrelativetoPBo+CEandtheassociatedconfidenceintervalswereestimatedusingunstratifiedCoxregression.

Theverticaldashedlineindicatesthehazardratioforallpatients.

Thesizeofthesymbolisproportionaltothesizeofthepopulationinthesubgroup.

Figure 13 : Forest plot - subgroup analysis of OS by PD-L1 status in BEP1 and BEP2 (ITT population)

Figure 14 : Kaplan-Meier curves for overall survival in PD-L1 negative subgroup (&lt;1% TC or &lt;1% IC) of BEP2 (ITT population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Any PD-L1 means all slides sectioned and stained for PD-L1

Figure 15 : Kaplan-Meier curves for overall survival in PDL1 positive subgroup (≥1% TC or ≥1% IC) of BEP2 (ITT population)

## Subgroup analyses by selected demographics and baseline disease characteristics

## Updated subgroup analysis of OS, 24-JAN-2019

|                                        |         | PBO+CE (Randomized) (N=202)   | PBO+CE (Randomized) (N=202)   | PBO+CE (Randomized) (N=202)   | Atezo+CE (Randomized) (N=201)   | Atezo+CE (Randomized) (N=201)   | Atezo+CE (Randomized) (N=201)   |              |                           | Atezo+CE            | PBO+CE              |
|----------------------------------------|---------|-------------------------------|-------------------------------|-------------------------------|---------------------------------|---------------------------------|---------------------------------|--------------|---------------------------|---------------------|---------------------|
| Baseline Risk Factors                  | Total n | n                             | Events                        | (Months) Median               | n                               | Events                          | (Months) Median                 | Hazard Ratio | 95%Wald CI                | (Randomized) better | (Randomized) better |
| All Patients                           | 403     | 202                           | 160                           | 10.3                          | 201                             | 142                             | 12.3                            | 0.76         | (0.61, 0.96)              |                     |                     |
| Age Group 4 Categories (yr)            |         |                               |                               |                               |                                 |                                 |                                 |              |                           |                     |                     |
| <65                                    | 217     | 106                           | 79                            | 11.5                          | 111                             | 78                              | 12.1                            | 0.94         | (0.68,1.28)               |                     |                     |
| 65-74                                  | 145     | 74                            | 61                            | 9.7                           | 71                              | 53                              | 12.3                            | 0.69         | (0.47,1.00)               |                     |                     |
| 75-84                                  | 39      | 21                            | 19                            | 9.6                           | 18                              | 10                              | 17.9                            | 0.29         | (0.13,0.66)               |                     |                     |
| >=85                                   | 2       | 1                             | 1                             | 0.5                           | 1                               | 1                               | 5.4                             | <0.01        | (0.00,NE)                 |                     |                     |
| Age Group 2 Categories (yr)            |         |                               |                               |                               |                                 |                                 |                                 |              |                           |                     |                     |
| 65 >=65                                | 217 186 | 106 96                        | 79 81                         | 11.5 9.6                      | 111 90                          | 78 64                           | 12.1 14.4                       | 0.94 0.59    | (0.68, 1.28) (0.42,0.82)  |                     |                     |
| Sex(eCRF)                              |         |                               |                               |                               |                                 |                                 |                                 |              |                           |                     |                     |
| Male Female                            | 261 142 | 132 70                        | 103 57                        | 10.9 9.5                      | 129 72                          | 95 47                           | 12.2 13.6                       | 0.83         | (0.53, 1.10) (0.43, 0.94) | He                  |                     |
| Race                                   |         |                               |                               |                               |                                 |                                 |                                 |              |                           |                     |                     |
|                                        |         |                               |                               | 7.7                           |                                 |                                 |                                 | 0.64         |                           |                     |                     |
| American Indian or Alaska Native       | 1       | 1                             | 1                             |                               |                                 |                                 |                                 | NE           | (NE,NE)                   | H9                  |                     |
| Asian                                  | 69      | 36                            | 24                            | 13.2                          | 33                              | 22                              | 15.4                            | 860          | (0.55, 1.74)              |                     |                     |
| BlackorAfrican American                | 3       | 2                             | 2                             | 12.9                          | 1                               | 0                               | NE                              | <0.01        | (0.00,NE)                 |                     |                     |
| White                                  | 322     | 159                           | 129                           | 9.9                           | 163                             | 118                             | 12.1                            | 0.75         | (0.59,0.97)               |                     |                     |
| Unknown                                | 8       | 4                             | 4                             | 7.6                           | 4                               | 2                               | 10.8                            | 0.21         | (0.02, 1.88)              |                     |                     |
| Baseline ECOG (eCRF)                   |         |                               |                               |                               |                                 |                                 |                                 |              |                           |                     |                     |
| 0                                      | 140     | 67                            | 49                            | 12.6                          | 73                              | 43                              | 16.8                            | 0.73         | (0.48,1.10)               | H                   |                     |
|                                        | 263     | 135                           | 111                           | 9.3                           | 128                             | 99                              | 11.3                            | 0.78         | (0.60, 1.03)              |                     |                     |
| Tobacco Use                            |         |                               |                               |                               |                                 |                                 |                                 |              |                           |                     |                     |
| Never                                  | 12      | 3                             | 2                             | 15.8                          | 9                               | 3                               | 21.7                            | 0.40         | (0.05,2.98)               |                     |                     |
|                                        | 149     | 75                            | .57                           | 9.7                           | 74                              | 53                              | 11.4                            | 0.76         | (0.52,1.11)               |                     |                     |
| Previous                               | 242     | 124                           | 101                           | 10.9                          | 118                             | 86                              | 12.6                            | 0.79         | (0.59, 1.05)              |                     |                     |
| Brain Metastases (eCRF)                |         |                               |                               |                               |                                 |                                 |                                 |              |                           |                     |                     |
| Yes                                    | 35      | 18                            | 14                            | 9.7                           | 17                              | 15                              | 8.5                             | 0.96         | (0.46,2.01)               |                     |                     |
| No                                     | 368     | 184                           | 146                           | 10.4                          | 184                             | 127                             | 12.6                            | 0.74         | (0.58, 0.94)              |                     |                     |
| Lung Metastasis at Enrollment          |         |                               |                               |                               |                                 |                                 |                                 |              |                           |                     |                     |
| Yes                                    | 349     | 172                           | 139                           | 10.3                          | 177                             | 127                             | 12.6                            | 0.77         | (0.61, 0.99)              |                     |                     |
| No                                     | 54      | DE                            | 21                            | 10.4                          | 24                              | 15                              | 10.9                            | 0.70         | (0.36, 1.36)              |                     |                     |
| Liver Metastasis at Enrollment         |         |                               |                               |                               |                                 |                                 |                                 |              |                           |                     |                     |
| Yes                                    | 149     | 72                            | 63                            | 7.8                           | 77                              | 58                              | 9.3                             | 0.75         | (0.52, 1.07)              |                     | HO                  |
| No                                     | 254     | 130                           | 6                             | 11.2                          | 124                             | 84                              | 16.3                            | 0.76         | (0.56,1.01)               |                     |                     |
| Lymph Node Metastasis at Enrollment    |         |                               |                               |                               |                                 |                                 |                                 |              |                           |                     |                     |
|                                        | 328     | 168                           | 136                           | 10.0                          | 160                             | 115                             | 12.1                            | 0.74         | (0.57,0.95)               |                     |                     |
| No                                     | 75      |                               | 24                            | 11.2                          | 41                              | 27                              | 14.4                            | 0.91         | (0.53, 1.58)              |                     |                     |
| Yes                                    |         | 34                            |                               |                               |                                 |                                 |                                 |              |                           |                     |                     |
|                                        |         |                               |                               |                               | 37                              |                                 |                                 |              |                           |                     |                     |
| Adrenal Gland Metastasis at Enrollment |         |                               |                               |                               |                                 |                                 |                                 |              |                           |                     |                     |
| Yes                                    | 72      | 35                            | 30                            | 8.8                           |                                 | 34                              | 9.1                             | E60          | (0.57, 1.53)              |                     |                     |
| No                                     | 331     | 167                           | 130                           | 10.9                          | 164                             | 108                             | 14.9                            | 0.72         | (0.56,0.93)               |                     |                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| bTMB Biomarker Expression <10   | 134 212   | 65 110   | 53 85   | 9.4 11.2   | 69 102   | 49 71   | 11.8 14.9   | 0.73 0.73 0.91   | (0.49,1.08) (0.53,1.00) (0.50.1.66)   |
|---------------------------------|-----------|----------|---------|------------|----------|---------|-------------|------------------|---------------------------------------|
| >=10                            |           |          |         |            |          |         |             |                  |                                       |
| Unknown                         |           |          | 22      | 9.5        |          |         |             |                  |                                       |
|                                 | 57        | 27       |         |            | 30       | 22      | 7.9         |                  |                                       |
| bTMBBiomarkerExpression <16     | 266 08    | 135 40   | 106 32  | 10.0       | 131      | 94 26   | 12.5 17.1   | 0.79 0.58        | (0.60.1.04) (0.34,0.99)               |
| >=16                            |           |          |         | 11.9       | 40       |         |             | 0.91             |                                       |
| Unknown                         | 57        | 27       | 22      | 9.5        | 30       | 22      |             |                  | (0.50,1.56)                           |

MedianswereestimatedfromKaplan-Meiermethod.NE=Notestimable.

HazardratiosrelativetoPBO+CEandtheassociatedconfidenceintervalswereestimatedusingunstratifiedCoxregression.

Theverticaldashedlineindicatesthehazardratioforallpatients.

Thesizeofthesymbolisproportionaltothesizeofthepopulationinthesubgroup.

Figure 16 : Forest plot - subgroup analysis of OS by selected demographics and baseline disease characteristics updated analysis (ITT population)

## Subgroup analysis of PFS, 24-APR-2018

|                                                         |              | PBO+CE (Randomized) (N202)   | PBO+CE (Randomized) (N202)   | PBO+CE (Randomized) (N202)   | Alezo+CE (Rardomiced) (N201)   | Alezo+CE (Rardomiced) (N201)   | Alezo+CE (Rardomiced) (N201)   |                     |                                             | Alezo + CE         |
|---------------------------------------------------------|--------------|------------------------------|------------------------------|------------------------------|--------------------------------|--------------------------------|--------------------------------|---------------------|---------------------------------------------|--------------------|
| Bascline Risk Factors                                   | Tolal n      | n                            | Ewents                       | Median (Months)              | n                              | Events                         | Medion (Honths)                | Hazard Rato         | 95%Wald                                     | cRandomized) betir |
| AllPatents                                              | 403          | 202                          | 189                          | 4.3                          | 201                            | 171                            | 5.2                            | 0.76                | (0.61, 0.94)                                | 中                  |
| ( seuobee t dhoi ev 65                                  |              | 106                          |                              | 43                           | 111                            |                                |                                | 0.76                | (0.57,1.01)                                 |                    |
| 65-74 75.54 2-85                                        | 217 145 39 2 | 79 21                        |                              |                              | 71 18                          | 028                            | 4.2                            | 0.85 -0.01          | 10.60. 1.20 1.14 0.00.NEI                   |                    |
| Age Group 2 Calegories (yr) -65 59 =c                   | 217 186      | 106 96                       | 98 前                         | 43 4.6                       | 111 90                         |                                | 33                             | 0.76 0.76           | (0.57, 1.01) (0.56, 1.03)                   | 中                  |
| Sx(CRF) Male Female                                     | 261 142      | 132 70                       | 123 66                       | 4.4 4.2                      | 129 72                         | 112 59                         | 4.4 5.6                        | 0.87 0.59           | (0.67,1.13) (0.41, 0.95)                    | 中                  |
| Race American lndian or Alaska Native Whte Asidn Unkown | 1 322 69 8   | 1 159 36 2 4                 | 1 150 4                      | 5.6 43 42 43 6.5             | 103 1 4                        | 139 2                          | 4.3                            | NE 1 0.83 0.72 3.49 | (HE.NE) 00.49.1.39) 1607250 CO.0O.NE 515450 |                    |
| Bascline ECOG (eCRF)                                    |              |                              |                              |                              |                                |                                |                                | 8.9                 | 2138                                        |                    |
| Tobacco Use Never Cument Previous                       | 242          | 75 124                       | 120                          | 4.2                          | 118                            | 104                            | 5.2                            | 0.74 084 0.73       | 9.28.131 1.1 (0.56, 0.95)                   | 商                  |
| Brain Metastases (eCRF) ves No                          | 35 368       | 18 184                       | 18 171                       | 44 4.3                       | 17 184                         | 15 156                         | 42 5.3                         | 0.98 0.75           | (0.49,2.00) (0.60,0.93)                     | H                  |
| Lung Metastasis atEnrollment Yes No                     | 349 54       | 172 30                       | 162 27                       | 4.4 4.1                      | 177 24                         | 152 19                         | 52 5.4                         | 0.78 0.67           | (0.62,0.97) (0.37,1.23)                     |                    |
| Liver Metastasis at Enrollment Yes No                   | 149 15C      | 72 130                       | 69 120                       | 42 4.4                       | 77 124                         | 09 102                         | 4.3 5.6                        | 0.80 0.72           | 10.57.1.13) (0.55,0.94)                     |                    |
| Lymph Node Metastisis at Enrellment Yes No              | 328 75       | 168                          | 158 31                       | 47 5.5                       | 160 41                         | 137 34                         | 5.4 4.5                        | 0.69 1.23           | (0.54.0.87) (0.75,2.02)                     | 1 日                |
| Aeral Glra Melastasis al Enollmen Yes No                | 72 331       | 167                          | 33 156                       | 4.2 4.3                      | 37 164                         | 34 137                         | 4.5 5.3                        | 0.80 0.75           | (0.49.1.31) (0.59.0.94)                     | 1                  |

<div style=\"page-break-after: always\"></div>

Figure 17 : Forest plot - subgroup analysis of PFS per RECIST v1.1 - investigator (ITT patients)

<!-- image -->

## Sensitivity analyses

Table 23: Subsequent non-protocol anti-cancer treatments (ITT patients)

|                                                                                                                                                                                                                              | PBO + CE (Randomized) (N=202)                                     | Atezo + CE (Randomized) (N=201)                                   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|
| Patients with event (&) Earliest contributing event Death Disease Progression Patients without event (&) Time to Event (Months) Median 95 CI 25% and 75&-ile Range Stratified Analysis p-value (log-rank) Hazard Ratio 95 CI | 185 (91.6%) 19 166 17(8.4%) 4.3 (4.2, 4.5) 4.0, 5.7 0.0* to 17.3^ | 166 (82.6) 16 150 35 (17.4%) 5.1 (4.3, 5.6) 4.1, 7.1 0.0* to 21.1 |
|                                                                                                                                                                                                                              |                                                                   | 0.0209 0.777 (0.626, 0.963)                                       |

Table 22 : Time to event summary for investigator PFS censored for missing visits (ITT patients)

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                                 | PBO + CE (Randlomizedl) (N=202)   | Atezo + CE (Randlomizedl) (N=201)   | All Patients (N=403)   |
|-------------------------------------------------|-----------------------------------|-------------------------------------|------------------------|
| Line of Therapy                                 |                                   |                                     |                        |
| MAINTENANCE                                     | 0                                 | 2 (1.0%)                            | 2(0.5%)                |
| 2ND LINE                                        | 116 (57.48)                       | 101 (50.28)                         | 217 (53.8%)            |
| 3RD LINE                                        | 38 (18.8%)                        | 29 (14.48)                          | 67(16.6%)              |
| 4TH LINE                                        | 15 (7.4%)                         | 3 (1.58)                            | 18 ( 4.5%)             |
| MISSING                                         | 1 (0.5%)                          | 0                                   | 1(0.28)                |
| Therapy Type                                    |                                   |                                     |                        |
| Totalnumber ofpatientswithat least onetreatment | 116 (57.48) 176                   | 104 (51.78) 138                     | 220 (54.6%) 314        |
| Totalnumber of treatments                       | 88                                | (40.38)                             |                        |
| CHEMOTHERAPY/NON-ANTHRACYCLINE                  | (43.6%)                           | 81                                  | 169 (41.9%)            |
| CHEMOTHERAPY/ANTHRACYCLINE                      | 46 (22.88)                        | 31 (15.48)                          | 77 (19.18)             |
| IMMUNOTHERAPY                                   | 15 (7.48)                         | 6 （3.0%）                            | 21 (5.2%)              |
| OTHER                                           | 2 1.0%)                           | 2 (1.0%)                            | 4 1.0%)                |
| TARGETED THERAPY                                | 1 0.5%)                           | 2 (1.0%)                            | 3 (0.7%)               |

Multiple cases within a specific line of therapy and regimen for a patient were counted once for the frequency of line of therapy or regimen neme. Atezo=Atezolizumab,CE=Carboplatin+Etoposidle,PBo=Placebo DataCutoff:24APR2018

## Table 24: Time to event summary for PFS censoring for NPT (ITT patients)

Time to Event Summary for Investiqator Proqression-Free Survival Censored at NPT, Intent-to-Treat Patients Protocol:G030081

<!-- image -->

|                                                                                                                                                                                                        | PBO + CE (Randomized) (N=202)                       | Atezo + CE (Randomized) (N=201)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|-----------------------------------|
| Patients with event (%) Earliest contributinq event Death Disease Proqression Patientswithoutevent(%) Time to Event (Months) Median 95%CI 25% and 75&-ile Ranqe Stratified Analysis p-value (loq-rank) | 186 (92.1%) 20 166 16 ( 7.9%) 4.3 (4.2,4.5) 4.0,5.7 | 170 (84.6%) 19 151 5.2            |
| Hazard Ratio 95%CI                                                                                                                                                                                     | 0.0212 0.778 0.767 (0.621,0.947)                    | 57                                |
| Time Point Analysis                                                                                                                                                                                    |                                                     |                                   |
| 95%CI                                                                                                                                                                                                  |                                                     | 31 (15.4%)                        |
|                                                                                                                                                                                                        | 0.0* to 17.3^                                       | 0.0* to 21.1                      |
|                                                                                                                                                                                                        |                                                     | (4.4, 5.6) 4.1,7.1                |
|                                                                                                                                                                                                        | (0.628, 0.964)                                      |                                   |
| Unstratified Analysis p-value (loq-rank)                                                                                                                                                               | 0.0136                                              |                                   |
| Hazard Ratio                                                                                                                                                                                           |                                                     |                                   |
|                                                                                                                                                                                                        | 43                                                  |                                   |
| 6 Months Event Free Rate () 958CI                                                                                                                                                                      | 22.37 (16.49, 28.25)                                | (24.08,37.28)                     |
| Patients remaining at risk                                                                                                                                                                             |                                                     | 30.68                             |

Censored,^Censored and event，NE =Not estimable.

computedusinqthemethodof

Summaries of Time-to-Event (median, percentiles) are Kaplan-Meier estimates. 95&amp; CI for median was

Brookmeyer and Crowley. Hazard ratios were estimated by Cox reqression. Stratification factors are: Sex(malevs female)and ECoG(0

vs 1) per IXRS.

Data Cutoff:24APR2018

Atezo=Atezolizumab,CE=Carboplatin + Etoposide，PBO=Placebo

Table 25 : Time to event summary for OS censoring for NPT (ITT patients)

<div style=\"page-break-after: always\"></div>

|                                                | OverallSurvivalStratifiedHazardRatio (95% CI)   |
|------------------------------------------------|-------------------------------------------------|
| Discounting for NPT with 10%Benefit Reduction  | 0.690 (0.533,0.895)                             |
| Discounting for NPT with 20% Benefit Reduction | 0.691 (0.533.0.896)                             |
| Discounting for NPT with 30% Benefit Reduction | 0.694                                           |
|                                                | (0.536,0.899)                                   |

## Exploratory analyses:

Confirmed ORR and DOR

Table 26 : Summary of ORR per RECIST v1.1 by Investigator (ITT Population Patients with Confirmed Response)

| + CE                                                                                                                                    | PBO + CE (Randomized) (N=202)   | Atezo (Randomized) (N=201)   |
|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|------------------------------|
| Responders                                                                                                                              | 130 (64.4%)                     | 121                          |
| (60.2%) Non-Responders (39.8%)                                                                                                          | 72 (35.6%)                      | 80                           |
| 95% CI for Response Rate (Clopper-Pearson) 67.02)                                                                                       | (57.33, 70.95)                  | (53.07,                      |
| Difference in Response Rates 95% CI for Difference in Response Rates (Wald with Continuity Correctio p-Value* (Cochran-Mantel-Haenszel) | -4.16 (-14.11, 5.79) 0.3839     | -4.16 (-14.11, 5.79) 0.3839  |
| Odds Ratio* 95% CI for Odds Ratio* Complete Response (CR) CI                                                                            | (0.56, 2 ( 1.0%) (0.12, 3.53)   | 5 ( 2.5%) (0.81,             |
| 95% 5.71) Partial Response (PR) 95% CI 64.63)                                                                                           | 128 (63.4%) (56.32, 70.02)      | 116 (57.7%) (50.56,          |
| Stable Disease (SD) 95% CI                                                                                                              | 43 (21.3%) (15.85, 27.58)       | 42 (20.9%) (15.49, 27.18)    |
| Progressive Disease (PD) (10.9%) 95% CI                                                                                                 | (3.84, 11.36)                   | (6.99,                       |
|                                                                                                                                         | 14 ( 6.9%)                      | 22                           |
| 16.10)                                                                                                                                  |                                 |                              |
| Missing or unevaluable                                                                                                                  | 15 ( 7.4%)                      | 16 ( 8.0%)                   |

Patients were classified as missing or unevaluable if no post-baseline response assessments were available or all post-baseline response baseline assessments were unevaluable.  Responders refer to patients with &lt;CR/PR&gt;. 95% CI for rates were constructed using the Clopper Pearson method.Wald is the normal approximation for 95% CI of difference in rates. *Stratification factors are Sex and ECOG per IxRS.

Data Cutoff: 24APR2018

Atezo=Atezolizumab, CE=Carboplatin + Etoposide, PBO=Placebo

Table 27 : Summary of DOR (ITT Population Patients with Confirmed Response Assessed by Investigator per RECIST v1.1)

| _________________________________________________________________________________   | PBO + CE (Randomized) (N=130)   | Atezo + CE (Randomized) (N=121)   |
|-------------------------------------------------------------------------------------|---------------------------------|-----------------------------------|
| Patients with event (%)                                                             | 123 (94.6%)                     | 103 (85.1%)                       |
| Earliest contributing event Death                                                   | 7                               | 4                                 |
| Disease Progression                                                                 | 116                             | 99                                |
| Patients without event (%)                                                          | 7 ( 5.4%)                       | 18 (14.9%)                        |
| Time to Event (Months)                                                              |                                 |                                   |
| Median                                                                              | 3.9                             | 4.2                               |
| 95% CI                                                                              | (3.1, 4.2)                      | (4.1, 4.5)                        |

<div style=\"page-break-after: always\"></div>

| 25% and 75%-ile Range                    | 2.8, 5.3 2.0 to 16.1*   | 3.0, 7.2 1.4* to 19.5   |
|------------------------------------------|-------------------------|-------------------------|
| Stratified Analysis p-value (log-rank)   |                         | 0.0109                  |
| Hazard Ratio 95% CI                      |                         | 0.700 (0.532, 0.922)    |
| Unstratified Analysis p-value (log-rank) |                         | 0.0055                  |
| Hazard Ratio 95% CI                      |                         | 0.685 (0.524, 0.896)    |

* Censored, ^ Censored and event, NE = Not estimable.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Summaries  of  Time-to-Event  (median,  percentiles)  are  Kaplan-Meier  estimates.  95%  CI  for  median  was  computed  using the  method  of  Brookmeyer  and  Crowley.  Hazard  ratios  were  estimated  by  Cox  regression.  Stratification  factors  are: Sex (male vs female) and ECOG (0 vs 1) per IXRS.

Atezo=Atezolizumab, CE=Carboplatin + Etoposide, PBO=Placebo Data Cutoff: 24APR2018

## PFS by modified RECIST

The median duration of PFS by modified RECIST (5.6 months [95% CI: 5.5, 6.0]) was similar with RECIST v1.1 (5.2 months [95% CI: 4.4, 5.6]).

## Anti-drug antibodies (ADA)

Table 28: Baseline Prevalence and Post-Baseline Incidence of Anti-Drug Antibodies (ADA) to Atezolizumab

|                                  | Atezo+CE (N=198)   |
|----------------------------------|--------------------|
| Baselineevaluablepatients        | n=196              |
| No. of patients positive for ADA | 4 (2.0%)           |
| No. of patients negative for ADA | 192                |
| Post-baseline evaluable patients | n=188              |
| No. of patients positive for ADA | 35 (18.6%)         |
| Treatment-induced ADA 3          | 35                 |
| Treatment-enhanced ADAb          | 0                  |
| No.of patientsnegativefor ADA    | 153                |
| Treatment-unaffectedADA          | 4                  |

<div style=\"page-break-after: always\"></div>

Table 29: PFS by Investigator and OS by Atezolizumab Treatment- Emergent ADA status (ADA-Evaluable Atezolizumab Patients in Safety Evaluable Population)

|                                          | PBO+CE (N=202)   | Atezo + CE (N=188)   | Atezo + CE (N=188)   |
|------------------------------------------|------------------|----------------------|----------------------|
|                                          | All patients     | Atezo ADA-Negative   | Atezo ADA-Positive   |
| ProgressionFreeSurvival per Investigator |                  |                      |                      |
| N                                        | n=202            | n=153                | n=35                 |
| Patients with event (%)                  | 189 (93.6%)      | 135 (88.2%)          | 30 (85.7%)           |
| Median time to event (months)            | 4.3              | 5.1                  | 5.5                  |
| 95% CI                                   | (4.2, 4.5)       | (4.3, 5.6)           | (5.2, 5.6)           |
| 6 Months                                 |                  |                      |                      |
| Patients remaining at risk               | 44               | 49                   | 9                    |
| Event Free Rate (%)                      | 22.4             | 32.7                 | 27.6                 |
| 95% CI                                   | (16.6, 28.2)     | (25.2, 40.2)         | (12.3, 42.9)         |
| 1 year                                   |                  |                      |                      |
| Patients remaining at risk               | 9                | 18                   | 3                    |
| Event Free Rate (%)                      | 5.4              | 13.2                 | 12.3                 |
| 95% CI                                   | (2.1, 8.6)       | (7.7, 18.7)          | (1.0, 23.5)          |
| OverallSurvival                          |                  |                      |                      |
| N                                        | n=202            | n= 153               | n=35                 |
| Patients with event (%)                  | 134 (66.3%)      | 82 (53.6%)           | 17 (48.6%)           |
| Median time to event (months) 95% CI     | 10.3 (9.3, 11.3) | 12.6 (11.1, 16.6)    | 10.9 (9.1, NE)       |
| 1 year                                   |                  |                      |                      |
| Patientsremaining at risk                | 59               | 63                   | 11                   |
| Event Free Rate (%)                      | 38.2             | 53.7                 | 49.1                 |
| 95% CI                                   | (31.2, 45.3)     | (45.5, 61.9)         | (31.6, 66.7)         |
| 2 year                                   |                  |                      |                      |
| Patients remaining at risk               | NE               | NE                   | NE                   |
| Event Free Rate (%)                      | NE               | NE                   | NE                   |
| 95% CI                                   | NE               | NE                   | NE                   |

ADA=anti-drug antibodies; Atezo + CE = atezolizumab in combination with carboplatin and etoposide;Cl=confidence interval;NE=notestimable;OS=overall survival; PFS = progression-free survival; PBO + CE = placebo in combination with carboplatin and etoposide;

Table 30: IMpower133: OS hazard ratios in ADA-positive and ADA-negative patients for IPW and PSM based on original CCOD

| ADAStatus    | IPW HR (95% CI)      | PSM HR (95% CI)      |
|--------------|----------------------|----------------------|
| ADA-positive | 0.696 (0.381,1.269)  | 0.667 (0.277, 1.604) |
| ADA-negative | 0.687 (0.516, 0.914) | 0.590 (0.389,0.895)  |

ADA = anti-drug antibody; HR = hazard ratio; IPW = inverse probability weighting; PSM propensity score matching.

Table 31: IMpower133: OS hazard ratios in ADA-positive and ADA-negative patients for IPW and PSM based on updated CCOD

| ADAStatus    | IPW HR (95% CI)      | PSM HR (95% CI)      |
|--------------|----------------------|----------------------|
| ADA-positive | 0.841 (0.528, 1.340) | 1.231 (0.547, 2.770) |
| ADA-negative | 0.735 (0.572, 0.945) | 0.600 (0.420, 0.857) |

ADA = anti-drug antibody; HR = hazard ratio; IPW = inverse probability weighting; PSM propensity score matching.

<div style=\"page-break-after: always\"></div>

Table 32: Sensitivity analysis: OS hazard ratios in ADA-positive and ADA-negative patients for IPW and PSM - original CCOD for OS but using updated covariate information

| ADAStatus    | IPW HR (95% CI)     | PSM HR (95% CI)     |
|--------------|---------------------|---------------------|
| ADA-positive | 0.708 (0.382,1.311) | 0.944 (0.395,2.253) |
| ADA-negative | 0.685 (0.515,0.911) | 0.557 (0.377,0.824) |

ADA = anti-drug antibody; HR = hazard ratio; IPW = inverse probability weighting; PSM propensity score matching.

Table 33: IMpower133: PFS hazard ratios in ADA-positive and ADA-negative patients for IPW and PSM based on original CCOD

| ADAStatus    | IPW HR (95% CI)     | PSM HR (95% CI)     |
|--------------|---------------------|---------------------|
| ADA-positive | 0.724 (0.453,1.158) | 0.604 (0.296,1.234) |
| ADA-negative | 0.743(0.588,0.938)  | 0.760 (0.549,1.051) |

ADA = anti-drug antibody; HR = hazard ratio; IPW = inverse probability weighting; PSM propensity score matching.

Treatment beyond progressive disease

Table 34: Summary of disease progression by induction and maintenance phase (safety evaluable population)

|                                 | PBO + CE (Actual) (N=196)   |         | Atezo + CE (Actual) (N=198)   | All Patients (N=394)   | All Patients (N=394)   |
|---------------------------------|-----------------------------|---------|-------------------------------|------------------------|------------------------|
| PD during induction             |                             |         |                               |                        |                        |
| n                               | 16                          |         | 21                            |                        | 37                     |
| Chose to continue treatment     | 6                           | (56.3%) | 11 (52.4%)                    | 20                     | (54.1%)                |
| Other 2L anti-cancer drug       | 4                           | (25.0%) | 4 (19.0%)                     | 8                      | (21.6%)                |
| Noulterior treatment            | 3 (18.8%)                   | 6       | (28.6%)                       | 9                      | (24.3%)                |
| Completed 4 cycles of induction |                             |         |                               |                        |                        |
| n                               | 196                         | 162     | 198                           |                        | 394                    |
| Completed 4 cycles              | 176                         | (89.8%) | (81.8%)                       | 338                    | (85.8%)                |
| Did not complete 4 cycles       | 20                          | (10.2%) | 36 (18.2%)                    |                        | 56 (14.2%)             |
| PD after 4 cycles of induction  | 154                         |         |                               |                        |                        |
| n                               |                             |         | 134                           |                        | 288                    |
| Chose to continue treatment     | 42                          | (27.3%) | 45 (33.6%)                    | 87                     | (30.2%)                |
| Other 2L anti-cancer drug       | 83                          | (53.9%) | 60 (44.8%)                    | 143                    | (49.7%)                |
| No ulterior treatment           | 29                          | (18.8%) | 29 (21.6%)                    | 58                     | (20.1%)                |
| Underwent maintenance treatment |                             |         |                               |                        |                        |
| n                               | 163                         |         | 155                           |                        | 318                    |
| 1-2 doses                       | 67                          | (41.1%) | 51 (32.9%)                    | 118                    | (37.1%)                |
| 3-4 doses                       | 50                          | (30.7%) | 37 (23.9%)                    | 87                     | (27.4%)                |
| 5-6 doses                       | 19                          | (11.7%) | 14 (9.0%)                     | 33                     | (10.4%)                |
| >=7doses                        | 27                          | (16.6%) | 53 (34.2%)                    | 80                     | (25.2%)                |
| PD during maintenance treatment |                             |         |                               |                        |                        |
| n                               | 152                         |         | 132                           |                        | 284                    |
| Chose to continue treatment     | 38                          | (25.0%) | 38 (28.8%)                    | 76                     | (26.8%)                |
| Other 2L anti-cancer drug       | 84                          | (55.3%) | 65 (49.2%)                    | 149                    | (52.5%)                |
| No ulterior treatment           | 30                          | (19.7%) | 29 (22.0%)                    | 59                     | (20.8%)                |
| Ongoing Treatment               |                             |         |                               |                        |                        |
| n                               |                             | 196     | 198                           |                        | 394                    |
| Ongoing Treatment               | 11                          | (5.6%)  | 23                            | 34                     | (8.6%)                 |
| Not Still on Treatment          | 185                         | (94.4%) | (11.6%) 175 (88.4%)           | 360                    | (91.4%)                |

Atezo=Atezolizumab, CE=Carboplatin + Etoposide, PBO=Placebo

<div style=\"page-break-after: always\"></div>

Best Percenl Tumor Shrnkage inSLD from First PD per lnvesliplor AssessmenlAlezo+CE,AlezolizumabTrealed on or afler Firs PD Prolocol: G030081

<!-- image -->

Figure 35: Maximum Percent Post-PD Tumor Shrinkage in SLD from Disease Progression by Investigator Assessment, ATZ+CE arm, ATZ treated on or After First PD

<!-- image -->

<!-- image -->

Figure 36: Maximum Percent Post-PD Tumour Shrinkage in SLD from Disease Progression by Investigator Assessment, PBO + CE, Placebo Treated on or After First PD

Table 35: Time to Event Summary for Overall Survival on or after First PD, atezo treated (intent to treat patients)

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 36: Time to Event Summary for Overall Survival on or after First PD, Placebo Treated (safety evaluable population)

<!-- image -->

|                                                     | PlaceboTreated on or after First PD (N=47)   | Other Anti-cancer Therapy excluding Placebo on or after First PD (N=88)   | No Treatment on or after First PD (N=33)   | All Patients (N=168)   |
|-----------------------------------------------------|----------------------------------------------|---------------------------------------------------------------------------|--------------------------------------------|------------------------|
| Patients with event (8) Earliest contributing event | 24 (51.1%)                                   | 63 (71.6%) 63                                                             | 27 (81.8%)                                 | 114 (67.98) 114        |
| Death                                               | 24                                           |                                                                           | 27                                         |                        |
| Patients without event (&)                          | 23 (48.98)                                   | 25 (28.48)                                                                | 6(18.28)                                   | 54(32.18)              |
| Time Since First PD to Event (Months) Median 958CI  | 6.5 (4.8,12.8) 3.1,12.8                      | 6.0 (4.9, 7.4) 3.6,8.5                                                    | 2.0 (1.1, 3.1) 0.6,3.3                     | 5.2 (4.5, 6.2)         |
| 25%and75g-ile                                       |                                              |                                                                           |                                            | 2.9,8.6                |
| Range                                               | 0.1*to 12.8                                  | 0.7 to 17.0*                                                              | 0.1*to 8.1*                                | 0.1*to 17.0*           |

PD=Progression ofDisease

Atezo=Atezolizumab,CE=Carboplatin+Etoposide,PBO=Placebo

*=Censoredvalue;

= Censored and Event.

Summaries of duration（median andpercentiles)areKaplan-Meier estimates.95sCIs for themedianare computedusing themethodof Brookmeyer and Crowley.

NE =Not estimable.

## Kaplan-Meier Plot of Overall Survival on or after First PD per REClST v1.1, Atezo+CE, Intent-to-Treat Patients Protocol: G030081

Figure 37: Kaplan-Meier Plot of Overall Survival on or after First PD (Intent to-Treat Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Kaplan-MeierPlotofOverallSurvivalonorafterFirstPDperRECiSTv1.1,PBO+CE SafetyEvaluablePatients Protocol:GO30081(DataCut:24APR2018)

<!-- image -->

Atezo=Atezolizumab, CE=Carboplatin + Etoposide. PBO=Placebo

Program:fopt/BlOSTAT/prod/cct30099/go30081/g\\_kmg01\\_unstrat\\_postpd.sas

Group 1: Placebo Treated on or afer First PD. Group 2: Other Anti-Cancer Therapy Excluding Placebo on or after First PD. Group 3: No Treatment on or after First PD.

Output: /opt/BIOSTAT/prodi/cdt30099/s30081m/reports/g\\_kmg01\\_unstrat\\_postpd\\_SE\\_FRSTPDIPBO\\_pdos\\_24APR2018\\_30081.pdf 13FEB2019 18:00

Figure 38: Kaplan-Meier Plot of Overall Survival on or after First PD (Intent to-Treat Population)

## Summary of main study

The following table summarises the efficacy results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 37 : Summary of Efficacy for trial IMpower133

| Title: A Phase I/III, randomised, double-blind, placebo-controlled study of carboplatin plus etoposide with or without atezolizumab (anti-PD-L1 antibody) in patients with untreated extensive-stage small cell lung cancer (IMpower133).   |                                                                                   |                    |                                                                                                           |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|--------------------|-----------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                            | GO30081                                                                           |                    |                                                                                                           |
| Design                                                                                                                                                                                                                                      | Phase I/III, randomised, double-blind, placebo-controlled, two-arm                |                    |                                                                                                           |
|                                                                                                                                                                                                                                             | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:    |                    | Not applicable, event-driven Not applicable Not applicable                                                |
| Hypothesis                                                                                                                                                                                                                                  | Superiority                                                                       |                    |                                                                                                           |
| Treatments groups                                                                                                                                                                                                                           | Arm A (ATZ+CE)                                                                    |                    | Atezolizumab+carboplatin+etoposide until loss of clinical benefit, n=201                                  |
|                                                                                                                                                                                                                                             | Arm B (PBO+CE)                                                                    |                    | Placebo+carboplatin+etoposide until loss of clinical benefit, n=202                                       |
| Endpoints and definitions                                                                                                                                                                                                                   | Co-Primary endpoint                                                               | INV-PFS ITT        | Investigator-assessed progression free survival according to RECIST v1.1 in intention-to-treat population |
|                                                                                                                                                                                                                                             | Co-Primary endpoint                                                               | OS ITT             | Overall survival in intention-to-treat population                                                         |
|                                                                                                                                                                                                                                             | Secondary endpoint                                                                | ORR and DoR in ITT | Overall response rate and duration of response per RECIST v1.1 in intention-to-treat population           |
| Database lock                                                                                                                                                                                                                               | 24 April 2018 final PFS analysis, 24 January 2019 final OS analysis               |                    |                                                                                                           |
| Results and Analysis                                                                                                                                                                                                                        |                                                                                   |                    |                                                                                                           |
| Analysis description                                                                                                                                                                                                                        | Primary Analysis of PFS, ORR and DOR; final analysis of OS                        |                    |                                                                                                           |
| Analysis population and time point description                                                                                                                                                                                              | Intent-to-treat=403, when 360 INV-PFS (89%, final PFS analysis) and 302 OS events |                    |                                                                                                           |
| Descriptive statistics and estimate variability                                                                                                                                                                                             |                                                                                   |                    |                                                                                                           |
|                                                                                                                                                                                                                                             | (75%, final OS analysis) have occurred                                            |                    |                                                                                                           |
|                                                                                                                                                                                                                                             | Treatment group Arm A (ATZ+CE) Arm B (PBO+CE)                                     |                    |                                                                                                           |
|                                                                                                                                                                                                                                             | Number of subjects 201 202 Median OS, months 12.3 10.3                            |                    |                                                                                                           |
|                                                                                                                                                                                                                                             | CI 10.8, 15.8 9.3, 11.3                                                           |                    |                                                                                                           |
|                                                                                                                                                                                                                                             | PFS, months 5.2 4.3                                                               |                    |                                                                                                           |
|                                                                                                                                                                                                                                             | Median                                                                            |                    |                                                                                                           |
|                                                                                                                                                                                                                                             | 95%                                                                               |                    |                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                                | 95% CI                                        | 4.4, 5.6                                | 4.2, 4.5                                |
|--------------------------------|-----------------------------------------------|-----------------------------------------|-----------------------------------------|
|                                | Unconfirmed INV-ORR, number of responders (%) | 149 (74.1)                              | 155 (76.7%)                             |
|                                | 95% CI                                        | 67.5, 80.0                              | 70.3, 82.4                              |
|                                | Median unconfirmed INV-DOR, months            | 4.1                                     | 3.1                                     |
|                                | 95% CI                                        | 3.5, 4.2                                | 2.9, 3.9                                |
| Effect estimate per comparison | OS ITT                                        | Comparison groups                       | ATZ+CE vs. PBO+CE                       |
| Effect estimate per comparison | OS ITT                                        | Stratified Hazard Ratio                 | 0.76                                    |
| Effect estimate per comparison | OS ITT                                        | 95% CI                                  | 0.60, 0.95                              |
| Effect estimate per comparison | OS ITT                                        | p-value (log-rank)                      | 0.0154                                  |
| Effect estimate per comparison | INV- PFS ITT                                  | Comparison groups                       | ATZ+CE vs. PBO+CE                       |
| Effect estimate per comparison | INV- PFS ITT                                  | Stratified Hazard Ratio                 | 0.77                                    |
| Effect estimate per comparison | INV- PFS ITT                                  | 95% CI                                  | 0.62, 0.96                              |
| Effect estimate per comparison | INV- PFS ITT                                  | p-value (log-rank)                      | 0.0170                                  |
| Effect estimate per comparison | Unconfirmed INV-ORR ITT confirmed response    | Comparison groups                       | ATZ+CE vs. PBO+CE                       |
| Effect estimate per comparison | Unconfirmed INV-ORR ITT confirmed response    | Odds Ratio                              | 0.87                                    |
| Effect estimate per comparison | Unconfirmed INV-ORR ITT confirmed response    | 95% CI                                  | 0.55, 1.37                              |
| Effect estimate per comparison | Unconfirmed INV-ORR ITT confirmed response    | p-value (Cochran-Mantel-Haenszel)       | 0.5412                                  |
| Effect estimate per comparison | Unconfirmed INV-DOR ITT                       | Comparison groups                       | ATZ+CE vs. PBO+CE                       |
| Effect estimate per comparison | Unconfirmed INV-DOR ITT                       | Stratified Hazar Ratio                  | 0.73                                    |
| Effect estimate per comparison | Unconfirmed INV-DOR ITT                       | 95% CI                                  | 0.57, 0.94                              |
| Effect estimate per comparison | Unconfirmed INV-DOR ITT                       | p-value (log-rank)                      | 0.0125                                  |
| Notes                          | Both co-primary endpoints have been met       | Both co-primary endpoints have been met | Both co-primary endpoints have been met |

## Clinical studies in special populations

## Table 38 Number of elderly patients investigated in IMpower133

|                   | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|-------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| Controlled Trials | 145/403                                           | 39/403                                            | 2/403                                           |

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The MAH has provided data from the final PFS analysis and interim OS analysis (24-APR-2018) and the final OS analysis (24-JAN-2019) of IMpower133, a pivotal phase I/III, randomised, double-blind, placebo (PBO) controlled study of carboplatin plus etoposide (CE) with or without atezolizumab (ATZ) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC). Co-primary objectives were PFS and OS assessed in the ITT population, hypothesis was superiority of ATZ+CE over PBO+CE.

For sample size calculation, a considerable PFS benefit was assumed (HR of 0.68 and 0.55 for OS and PFS, respectively), planning to recruit 400 all-comer patients. Eligible subjects were stratified by sex (male vs. female), ECOG PS (0 vs. 1), and presence of brain metastases (yes vs. no) and then randomised 1:1 to receive 4 cycles of either ATZ+CE or PBO+CE. After induction, patients continued maintenance therapy with ATZ or PBO, respectively. Treatment continued until disease progression per RECIST v1.1, but patients could be considered for treatment beyond radiographic disease progression if they had evidence of clinical benefit. During the maintenance phase, prophylactic cranial irradiation and palliative thoracic radiation was permitted per local standard-of-care. Dose and scheduling of all drugs was based in previously approved indications.

<div style=\"page-break-after: always\"></div>

The main challenges in relation to the design of the study include maintenance (treatment effect cannot be differentiated from induction); treatment beyond progressive disease (considering patients on the PBO+CE arm would continue on PBO+/-CE); not allowing consolidation thoracic radiotherapy; and not considering the choice between cisplatin and carboplatin for the backbone chemotherapy regimen. INV-assessed PFS is an acceptable co-primary endpoint because the study is double-blinded and OS was the other co-primary objective. The definitions of primary and secondary objectives were also endorsed. Out of 526 screened patients, 403 were randomised into both arms of the trial. The distribution of major protocol deviations between arms is balanced. The proportion of patients with brain metastases (8%) is about half of that in clinical practice (15%), but this was explained as due to the specific inclusion requirements for these patients. The proportion of patients in each of the analysis subpopulations is acceptable and balanced between arms. Overall, the main issue upon the design and conduct of this study is failing to enforce the established tissue requirement, leading to retrospective biomarker availability for less than half of the ITT population. Efficacy data and additional analyses At first data cutoff on 24 April 2018, 238 death events (59%) and 360 PFS events (89%) had occurred, satisfying the predefined data-driven criteria for performing the interim analysis of OS and the final analysis of PFS. Median duration of survival follow-up was 13.9 months in the ITT population. Both co-primary endpoints of the study had been met. OS data showed significant statistical benefit from ATZ+CE (mOS 12.3 months) over PBO+CE (mOS 10.3 months), as indicated by a stratified HR of 0.701 (95% CI 0.54-0.91, p=0.0069). OS results from PBO+CE are comparable to data from most published studies of platinum + etoposide. The MAH has provided results from the exploratory final OS analysis after a median follow-up of 22.9 months (data cutoff 24 January 2019, 302 out of 403 OS events = 75%). The data seem overall consistent with the first interim analysis. Median OS in both arms is unchanged (12.3 months in the ATZ+CE arm and 10.3 months in the PBO+CE arm), although the statistical parameters differ slightly: HR 0.76 (95%CI 0.60, 0.95), p-value=0.0154. PFS was statistically significant (only) after alpha was recycled from the significant OS analysis ('recycling' was introduced with protocol amendment 3). However, the difference in PFS between ATZ+CE (mPFS 5.2 months) and PBO+CE (mPFS 4.3 months) is not striking and hence of only marginal clinical relevance, observing a stratified HR of 0.772 (95% CI 0.62-0.96, p=0.0170). The benefit of adding atezolizumab was not substantially supported by secondary endpoints. Both confirmed and unconfirmed ORR were numerically higher in the PBO+CE arm. DoR was similar in both arms. PRO data 'time to deterioration of lung cancer-related symptoms' did not demonstrate clinically meaningful consistent differences. Forest plots on PFS and OS (including bTMB biomarker) did not identify any particular -appropriately sized- subgroup with considerably higher or lower benefit from ATZ+CE over PBO+CE. The limited number of patients with CNS metastases in the trial limits conclusions regarding efficacy of adding ATZ to CE in this subgroup, so a clarification has been inserted in the SmPC. The practiced sensitivity analyses do not alter the modest statistical benefit indicated from the primary endpoints. IHC as a biomarker to select patients who benefit from immunotherapy across cancers is well established. PD-L1 IHC (Ventana SP263) results are available for 168 patients (42% from ITT), 93 in the PBO+CE arm L1 positivity, defined as staining of ≥1% of tumour cells, was 55% in the ATZ+CE and 11.1 in PBO+CE. In PD-L1 negative patients (n=75), median OS is 10.5 in ATZ+CE and 8.8

and 75 in the ATZ+CE arm. PDPBO+CE arm and 56% in the ATZ+CE arm. In PD-L1 positive patients (n=93), median OS is 10.6 in in PBO+CE. The addition of atezolizumab to CE demonstrated a greater OS benefit in the PD-L1 negative subgroups compared to the PD-L1 positive subgroups when regarding the lower PD-L1 cutoff of 1%, which lacks any biological rationale. Overall, the provided retrospective OS results are considered inconclusive (see Benefit-Risk section).

<div style=\"page-break-after: always\"></div>

95% of the 198 patients who received ATZ were evaluable for anti-drug antibodies (ADAs). Updated analyses of OS by treatment-emergent ADA status based on the 24 January 2019 cutoff analyses reported an even larger difference for the median OS values between both ADA subgroups (mOS 14.1 months in ADA- subgroup and 10.9 months in the ADA+ subgroup), but the data are limited due to the small sample size of the ADA+ (n=35) subgroup.

Concerning treatment beyond progression, the benefit of maintaining ATZ is not established: 3 out of 49 patients who continued atezolizumab beyond progression exhibited a partial response.

## 2.4.4. Conclusions on the clinical efficacy

IMpower133 has met both its co-primary endpoints (superior OS and INV-assessed PFS from ATZ+CE vs. PBO+CE in ITT), but whether this translates into a compelling clinical benefit to all patients regardless of PD-L1 IHC status is unknown. Overall, in patients with ES-SCLC, a net gain of roughly 1 month in median PFS and 2 months in median OS must be weighed against the known safety risks from combining immunotherapy with chemotherapy.

## 2.5. Clinical safety

## Introduction

As of 17 May 2018, an estimated 16,815 patients have been exposed to atezolizumab either as a single agent or in combination with chemotherapy, immunotherapy, or targeted therapy in ongoing clinical studies.

The safety of atezolizumab monotherapy is based on pooled data in 3,178 patients with multiple tumour types. The most common adverse reactions were fatigue (35.9%), decreased appetite (25.5%), nausea (23.5%), cough (20.8%), dyspnoea (20.5%), pyrexia (20.1%), diarrhoea (19.7%), rash (19.5%), back pain (15.3%), vomiting (15.0%), asthenia (14.5%), arthralgia (13.9%), musculoskeletal pain (13.0%), pruritus (12.6%) and urinary tract infection (11.6%).

Safety data for the use of ATZ+CE in patients with chemotherapy-naïve ES-SCLC in the IMpower133 study are presented versus the standard of care control arm (PBO+CE). Safety analyses included all treated patients (defined as all randomized patients who received any amount of any component of study treatment) according to actual treatment received: 198 patients treated with ATZ+CE and 196 patients treated with PBO+CE. Patients who received any amount of atezolizumab were analyzed as part of the ATZ+CE arm even if atezolizumab was given in error.

In addition, safety data from atezolizumab-treated safety evaluable patients (all patients who received any amount of atezolizumab) were pooled and are presented as follows:

- Atezolizumab in combination with platinum-based doublet chemotherapy as 1L treatment in lung cancer, hereinafter referred to as Atezo + Chemo Combo population. The safety analyses for this population are based on safety data from a total of 2421 atezolizumab-treated, safety evaluable patients from IMpower133 (n=198 with SCLC), IMpower130 (n=473 with NSCLC), IMpower131 (n=666 with NSCLC), IMpower132 (n=291 with NSCLC), and IMpower150 (n=793 with NSCLC).
- Single-agent atezolizumab regardless of tumor type, hereinafter referred to as Atezo Mono population. The safety analyses for this population are based on safety data from a total of 3178 atezolizumab-treated, safety evaluable patients from OAK (n=609 with NSCLC), POPLAR (n=142

<div style=\"page-break-after: always\"></div>

with NSCLC), BIRCH (n=659 with NSCLC), FIR (n=137 with NSCLC), IMvigor211 (n=459 with UC), IMvigor210 (n=429 with UC), IMmotion150 (n=103 with RCC), and PCD4989g (n=89 with NSCLC, n=95 with UC, n=17 with SCLC, n=439 with other tumor types).

The severity of all adverse events (AEs) was graded according to the National Cancer Institute Common Terminology Criteria for AEs, Version 4.0 (NCI-CTCAE v4.0) and reported in detail in the electronic Case Report Form (eCRF). Multiple occurrences of the same event in the same patient are counted once at the maximum severity (worst grade) in summary tables.

Verbatim descriptions of AEs were mapped to the Medical Dictionary for Regulatory Activities (MedDRA) thesaurus terms. MedDRA Version 21.0 was used for the individual study of IMpower133, the pooled analysis of Atezo + Chemo Combo studies, and the pooled analysis of Atezo Mono studies.

## Patient exposure

Table 39: Exposure to atezolizumab in patients receiving 1200 mg Q3W (safety evaluable population)

Table 40: Exposure to placebo (safety evaluable population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                            | IMpower133 PBO +CE N-196   |
|----------------------------|----------------------------|
| Treatment duration (M)     |                            |
| n                          | 196                        |
| Mean (SD)                  | 5.0 (3.5)                  |
| Median                     | 4.1                        |
| Min -Max                   | 0-21                       |
| Trealment duralion (M)     |                            |
| n                          | 196                        |
| 0 to s3 months             | 41 (20.9%)                 |
| 3months to ≤6months        | 113 (57.7%)                |
| >6 months to ≤ 12 months   | 30 (15.3%)                 |
| > 12 months                | 12 (6.1%)                  |
| Dose intensity (%)         |                            |
| n                          | 196                        |
| Mean (SD)                  | 92.9 (7.2)                 |
| Median                     | 94.7                       |
| Min - Max                  | 60-102                     |
| Number of doses received   |                            |
| n                          | 196                        |
| Mean (SD)                  | 7.7 (4.8)                  |
| Median                     | 6.0                        |
| Min - Max                  | 1-30                       |
| Total cumulative dose (mg) |                            |
| n                          | 196                        |
| Mean (SD)                  | 0.0 (0.0)                  |
| Median                     | 0.0                        |
| Min - Max                  | 0 -0                       |

Table 41: Exposure to Carboplatin and etoposide treatment (safety evaluable population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Adverse events

AE summary across IMpower133, Atezo+Chemo and Atezo Mono populations:

Table 42: Safety summary (safety evaluable population)

|                                                                                 | PBO + CE (Actual) (N=196)   | PBO + CE (Actual) (N=196)   | Atezo + CE (Actual) (N=198)   | Atezo + CE (Actual) (N=198)   | All Patients (N=394)   | All Patients (N=394)   |
|---------------------------------------------------------------------------------|-----------------------------|-----------------------------|-------------------------------|-------------------------------|------------------------|------------------------|
| Total number of patients with at least one adverse event Total number of events |                             | 189 (96.48) 1861            | 198                           | (100.0%) 2166                 | 387                    | (98.28) 4027           |
| Total number of patients with at least one                                      |                             |                             |                               |                               |                        |                        |
| Treatment-related AE                                                            | 181                         | (92.38)                     | 188                           | 94.98)                        | 369                    | (93.7%)                |
| Any Treatment                                                                   | 181                         | (92.3%)                     | 188                           | 94.9%)                        | 369                    | (93.7%)                |
| Atezolizumab/Placebo                                                            | 98                          | (50.0%)                     | 128                           | 64.6%)                        | 226                    | (57.4%)                |
| Grade3-4AE                                                                      | 125                         | (63.8%)                     | 133                           | 67.2*)                        | 258                    | (65.5%)                |
| Treatment-related Grade 3-4 AE                                                  | 110                         | (56.1%)                     | 112                           | 56.6%)                        | 222                    | (56.3%)                |
| Grade 5 AE                                                                      | 11                          | 5.6%)                       | 4                             | 2.0%)                         | 15                     | (3.8%)                 |
| Treatment-related Grade 5 AE                                                    | 3                           | 1.5)                        | 3                             | 1.5*)                         | 6                      | 1.5*)                  |
| Serious AE                                                                      | 68                          | (34.7%)                     | 74                            | 37.48)                        | 142                    | (36.0%)                |
| AE leading to withdrawal from treatment                                         | 6                           | 3.1)                        | 22                            | 11.1*)                        | 28                     | 7.1%)                  |
| Any Treatment                                                                   | 6                           | 3.1)                        | 22                            | 11.18)                        | 28                     | 7.18)                  |
| Atezolizumab/Placebo                                                            | 5                           | 2.6%)                       | 21                            | 10.68)                        | 26                     | 6.6)                   |
| Carboplatin                                                                     | 1                           | 0.5)                        | 5                             | 2.58)                         | 6                      | 1.5)                   |
| Etoposide                                                                       | 2                           | 1.0%)                       | 8                             | 4.0%)                         | 10                     | 2.5)                   |
| AE leading to any dose modification/interruption                                | 119                         | (60.7%)                     | 138                           | 69.7%)                        | 257                    | (65.28)                |
| Any Treatment                                                                   | 119                         | (60.7%)                     | 138                           | 69.7%)                        | 257                    | (65.28)                |
| Atezolizumab/Placebo                                                            | 102                         | (52.0%)                     | 117                           | 59.18)                        | 219                    | (55.6%)                |
| Carboplatin                                                                     | 96                          | (49.0%)                     | 111                           | 56.1*)                        | 207                    | (52.58)                |
| Etoposide                                                                       | 95                          | (48.58)                     | 113                           | 57.1%)                        | 208                    | (52.8%)                |

Includes adverse events occurring on or after the start date of treatment. Percentages are based on N in the columm headings. Multiple occurrences of the same AE in an individual are counted only once. For frequency counts of \"Total number of events\" row, multiple occurrences of the same AE in an individual are counted separately. For \"Grade 3-4 AE\" and \"Treatment-related Grade 3-4 AE\", multiple occurrences of the same AE within Grade 3-4 is counted at the highest grade for an individual.

Atezo=Atezolizumab, CE=Carboplatin + Etoposide, PBO=Placebo

Data Cutoff: 24APR2018

<div style=\"page-break-after: always\"></div>

## Common AEs reported in ≥10% patients:

Table 43: Adverse Events by Preferred Term with Incidence Rate of at Least 10% in either Arm/Population (Safety Evaluable Population)

|                                                                                 | IMpower133        | IMpower133       |                            |                     |
|---------------------------------------------------------------------------------|-------------------|------------------|----------------------------|---------------------|
| MedDRA Preferred Term                                                           | PBO+CE (N=196)    | Atezo+CE (N=198) | Atezo+Chemo Combo (N=2421) | Atezo Mono (N=3178) |
| Total number of patients with at least one adverse event Total number of events | 189 (96.4) 1861   | 198 (100%) 2166  | 2388 (98.6%) 35088         | 3051 (96.0%) 33365  |
| ANAEMIA                                                                         | 69 (35.2%)        | 86 (43.4%)       | 1063 (43.9%)               | 505 (15.9%)         |
| NAUSEA                                                                          | 64 (32.7%)        | 75 (37.9%)       | 914 (37.8%)                | 747 (23.5%)         |
| NEUTROPENIA                                                                     | 69 (35.2%)        | 74 (37.4%)       | 642 (26.5%)                | 36 (1.1%)           |
| ALOPECIA                                                                        | 68 (34.7%)        | 73 (36.9%)       | 843 (34.8%)                | 37 (1.2%)           |
| DECREASED APPETITE                                                              | 36 (18.4%)        | 54 (27.3%)       | 655 (27.1%)                | 810 (25.5%)         |
| FATIGUE                                                                         | 49 (25.0%)        | 54 (27.3%)       | 778 (32.1%)                | 1142 (35.9%) 652    |
| CONSTIPATION                                                                    | 58 (29.6%)        | 51 (25.8%)       | 869 (28.8%)                | (20.5%)             |
| VOMITING                                                                        | 33 (16.8%)        | 39 (19.7%)       | 477 (19.7%)                | 480 (15.1%)         |
| NEUTROPHIL COUNT DECREASED                                                      | 46 (23.5%)        | 37 (18.7%)       | 336 (13.9%)                | 5 (0.2%)            |
| DIARRHOEA                                                                       | 31 (15.8%)        | 35 (17.7%)       | 685 (28.3%)                | 624 (19.6%)         |
| THROMBOCYTOPENIA                                                                | 31 (15.8%)        | 33 (16.7)        | 451 (18.6%)                | 82 (2.6%)           |
| ASTHENIA                                                                        | 20 (10.2%)        | 25 (12.6%)       | 478 (19.7%)                | 461 (14.5%)         |
| LEUKOPENIA                                                                      | 19 (9.7%)         | 25 (12.6%)       | 171 (7.1%)                 | 9 (0.3%)            |
| PLATELET COUNT DECREASED                                                        | 29 (14.8%)        | 25 (12.6%)       | 366 (15.1)                 | 37 (1.2%)           |
| HEADACHE                                                                        | 23 (11.7%)        | 24 (12.1%)       | 297 (12.3%)                | 352 (11.1%)         |
| DYSPNOEA                                                                        | 18 9.2%)          | 20 (10.1%)       | 464 (19.2%)                | 653 (20.5%)         |
| HYPOTHYROIDISM                                                                  | 1 ( 0.5%)         | 20 (10.1%)       | 218 (9.0%)                 | 137 (4.3%)          |
| PYREXIA                                                                         | 16 （ 8.2%)        | 20 (10.1%)       | 385 (15.9%)                | 638 (20.1%)         |
| WEIGHT DECREASED                                                                | 10 （ 5.1%)        | 20 (10.1%)       | 222 (9.2%)                 | 277 (8.7%)          |
| ARTHRALGIA                                                                      | 13 6.6%)          | 18 9.1%)         | 406 (16.8%)                | 442 (13.9%)         |
| COUGH                                                                           | 25 (12.8%)        | 18 9.1%)         | 444 (18.3%)                | 660 (20.8%)         |
| WHITEBLOODCELLCOUNTDECREASED                                                    | 25 (12.8%)        | 18 9.1%)         | 178 (7.4%)                 | 25 (0.8%)           |
| BACK PAIN                                                                       | 19 (9.7%)         | 8.6%)            | 283 (11.7)                 | 487 (15.3%)         |
| INSOMNIA                                                                        | 13                | 17               | 250 (10.3%)                | 281 (8.8%)          |
| RASH                                                                            | 6.6%) 12 6.1%)    | 15 7.6%) 14 7.1) | 335 (13.8%)                | 358 (11.3)          |
| OEDEMA PERIPHERAL                                                               | 7 3.6%)           | 13 6.6%)         | 216 (8.9%)                 | 332 (10.4%)         |
|                                                                                 |                   | 13               | 201                        |                     |
| URINARY TRACT INFECTION                                                         | 6 3.1)            | 6.68)            | (8.3%)                     | 338 (10.6%)         |
| HYPOMAGNESAEMIA                                                                 | 9 4.6%)           | 12 6.1%)         | 301 (12.4%)                | 131 (4.1%) (12.6%)  |
| PRURITUS MYALGIA                                                                | 9 4.6%) 8 ? 4.1%) | 12 6.1%)         | 233 (9.6%)                 | 401 194 6.1%)       |
| NEUROPATHYPERIPHERAL                                                            | 5 2.6%)           | 8 8 4.0%) 4.0%)  | 254 368 (15.2%) (10.5%)    | 101 3.2%)           |
| PERIPHERALSENSORY NEUROPATHY                                                    | 2 (1.0%)          | 8 4.0%)          | 302 (12.5%)                | 43 (1.4%)           |

Investigator text for AEs encoded using MedDRA v21.o. Percentages are based on N in the column headings. For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once. For frequency counts of \"Total number of events\" rows, the multiple occurrences of the same AE in an individual are counted separately. All treatment emergent AEs are

A+B + GO29436 (IMPOWER150） Arm A+B + GO29438 (IMPOWER132) Arm A + GO30081 (IMPOWER133） Arm A.AteZo Mono: GO28915 (OAK) + GO28753 (POPLAR)+ GO28754 (BIRCH)+ GO28625 (FIR)+ GO27831 (PCD4989g -A11 CohortS）+ GO29293 (IMVIGOR210）+ GO29294 (IMVIGOR211）+ WO29074 (IMMOTION150 Arm B). Clinical cut-off dateS: GO27831:31MAR2016, GO28625:07JAN2015， GO28753:01DEC2015， GO28754:01DEC2015, GO30081:24APR2018，WO29074:170CT2016.

Table 39: Adverse Events with a Difference of at Least 5% between the PBO + CE and Atezo + CE arms (Safety Population)

| MedDRA Preferred Term                                                                                                      | PBO+CE (Actual) (N=196)                         | Atezo + CE (Actual) (N=198)                        | All Patients (N=394)                     |
|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|----------------------------------------------------|------------------------------------------|
| Total number of patients with at least one adverse event Totalnumberofevents ANAEMIA NAUSEA DECREASEDAPPETITE HYPOKALAEMIA | 189 (96.4%) 1861 69(35.2%) 64(32.7%) 36 (18.4%) | 198 (100.0%) 2166 86(43.4%) 75 (37.9%) 54 ( 27.3%) | 387 (98.2%) 4027 155 (39.3%) 139 (35.3%) |
|                                                                                                                            |                                                 | 8                                                  | 90(22.8%)                                |
|                                                                                                                            | 18 ( 9.2%)                                      | 4.0%)                                              | 26 ( 6.6%)                               |
| HYPOTHYROIDISM                                                                                                             | 1 (0.5%)                                        | 20 ( 10.1%)                                        | 21 (5.3%)                                |

Includes adverse events occurring on or after the start date of treatment.

For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once.

Atezo=Atezolizumab,CE=Carboplatin + Etoposide,PBO=Placebo Data Cutoff: 24APR2018

<div style=\"page-break-after: always\"></div>

Table 45 Adverse Events by Preferred Term, Difference of at Least 5% between IMpower133 Arm A and atezo+Chemo Combo Patients (Safety Evaluable Population)

| MedDRA Preferred Term                                                           | IMpower133 Atezo+CE (N=198)   | IMpower133 Atezo+CE (N=198)   |                    | Atezo+Chemo Combo (N=2421)   |
|---------------------------------------------------------------------------------|-------------------------------|-------------------------------|--------------------|------------------------------|
| Total number of patients with at least one adverse event Total number of events | 2166                          | 198 (100%)                    | 2388 (98.6%) 35088 | 2388 (98.6%) 35088           |
| NEUTROPENIA                                                                     |                               | 74(37.4%)                     | 642                | (26.5%)                      |
| DIARRHOEA                                                                       | 35                            | (17.7%)                       | 685                | (28.38)                      |
| ASTHENIA                                                                        | 25                            | (12.6%)                       | 478                | (19.7%)                      |
| LEUKOPENIA                                                                      | 25                            | (12.6%)                       | 171                | (7.1%)                       |
| DYSPNOEA                                                                        | 20                            | (10.1%)                       | 464                | (19.2%)                      |
| PYREXIA                                                                         | 20                            | (10.1%)                       | 385                | (15.9%)                      |
| ARTHRALGIA                                                                      | 18                            | (9.1%)                        | 406                | (16.8%)                      |
| COUGH                                                                           | 18                            | 9.1%)                         | 444                | (18.3%)                      |
| RASH                                                                            | 14                            | (7.1%)                        | 335                | (13.8%)                      |
| HYPOMAGNESAEMIA                                                                 | 12                            | 6.1%)                         | 301                | (12.4%)                      |
| MYALGIA                                                                         | 8                             | 4.0%)                         | 254                | (10.5%)                      |
| NEUROPATHYPERIPHERAL                                                            | 8                             | (4.0%)                        | 368                | (15.28)                      |
| PERIPHERALSENSORYNEUROPATHY                                                     | 8                             | 4.0%)                         | 302                | (12.5%)                      |
| ALANINEAMINOTRANSFERASEINCREASED                                                | 7                             | (3.5%)                        | 207                | (8.6%)                       |
| EPISTAXIS                                                                       | 3                             | (1.5%)                        | 209                | (8.6%)                       |

headings. For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once. For frequency counts of \"Total number of events\" rows, the multiple occurrences of the same AE in an individual are counted separately. All treatment emergent (IMPOWER133) Arm A. C1inical cut-off dateS: GO29436:22JAN2018， GO29437:20APR2018, GO29438:22MAY2018，G029537:15MAR2018,G030081:24APR2018.

Table 46: Treatment-Related Adverse Events Reported as Related to Any Treatment in ≥ 20% of Patients in Either Arm/Population (Safety Evaluable Population)

| MedDRA Preferred Term                         | IMpower133 Atezo + CE (N = 198)   | Atezo+ Chemo Combo (N = 2421)   |
|-----------------------------------------------|-----------------------------------|---------------------------------|
| Total number of patients with at least one AE | 188 (94.9%)                       | 2279 (94.1%)                    |
| Anaemia                                       | 77 (38.9%)                        | 946 (39.1%)                     |
| Neutropenia                                   | 72 (36.4%)                        | 625 (25.8%)                     |
| Nausea                                        | 63 (31.8%)                        | 794 (32.8%)                     |
| Alopecia                                      | 69 (34.8%)                        | 821 (33.9%)                     |
| Fatigue                                       | 42 (21.2%)                        | 628 (25.9%)                     |
| Decreased appetite                            | 41 (20.7%)                        | 495 (20.4%)                     |
| Diarrhoea                                     | 19 (9.6%)                         | 484 (20.0%)                     |

AE = adverse event, Atezo = Atezolizumab, CE = carboplatin + etoposide, MedDRA = Medical Dictionary for Regulatory Activities

<div style=\"page-break-after: always\"></div>

## G3-4 AEs:

Table 47: Grade 34 adverse events reported in ≥5% of patients in any treatment arm (safety evaluable population)

| MedDRAPreferredl Term      | PBO+CE (Actual) (N=196)   | Atezo +CE (Actual) (N=198)   | AllPatients (N=394)   |
|----------------------------|---------------------------|------------------------------|-----------------------|
| NEUTROPENIA                | 49(25.0%)                 | 45 (22.7%)                   | 94(23.9%)             |
| NEUTROPHIL COUNT DECREASED | 33 (16.89)                | 31( 15.7%)                   | 64 (16.29)            |
| ANAEMIA                    | 26(13.3%)                 | 31 15.79)                    | 57 (14.5%)            |
| THROMBOCYTOPENIA           | 17(8.7%)                  | 20 10.1%)                    | 37(9.4%)              |
| HYPONATRAEMIA              | 13(6.66)                  | 6 4.59)                      | 22 (5.66)             |
| FEBRILENEUTROPENIA         | 12 (6.1%)                 | 7 1 3.5%)                    | 19(4.8%)              |
| LEUKOPENIA                 | 8 (4.16)                  | 10 5.1%)                     | 18 (4.66)             |

<div style=\"page-break-after: always\"></div>

Table 48: Grade 3-4 adverse events with incidence rate of at least 2% in either arm/population (safety evaluable population)

|                                                                                    | IMpower133        | IMpower133        |                            |                     |
|------------------------------------------------------------------------------------|-------------------|-------------------|----------------------------|---------------------|
| MedDRA System Organ ClasS MedDRA Preferred Term                                    | PBO+CE (N=196)    | Atezo+CE (N=198)  | Atezo+Chemo Combo (N=2421) | Atezo Mono (N=3178) |
| Totalnumberofpatientswithatleastoneadverseevent                                    | 136 (69.4)        | 136 (68.7%)       | 1702 (70.3%)               | 1564 (49.2%)        |
| Overall total number of events                                                     | 345               | 375               | 5073                       | 3366                |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS                                               |                   |                   |                            |                     |
| Totalnumberofpatientswithatleastoneadverse event                                   | 80 (40.8%)        | 81 (40.9%)        | 880 (36.3%)                | 218 (6.9%)          |
| Totalnumber ofevents                                                               | 150 49 (25.0%)    | 152 45 (22.7%)    | 1573                       | 257 11 (0.3%)       |
| NEUTROPENIA ANAEMIA                                                                | 26 (13.3%)        | 31 (15.7%)        | 414 (17.1) 415 (17.1%)     | 160 5.0%)           |
| THROMBOCYTOPENIA                                                                   | 17 (8.7%)         | 20 (10.1%)        | 162 (6.7%) 2.9%)           | 21 0.7%) 0          |
| LEUKOPENIA                                                                         | 8 (4.1%) 12       | 10 (5.1%)         | 70 （                       |                     |
| FEBRILE NEUTROPENIA                                                                | (6.1%)            | 7 (3.5%)          | 137 (5.7%)                 | 8 (0.3%)            |
| INVESTIGATIONS                                                                     |                   |                   |                            |                     |
| Total number of patients with at least one adverse event                           | 40 (20.4%)        | 38 (19.2%)        | 445 (18.4%)                | 189 (5.9%)          |
| Total number of events                                                             | 83                | 85                | 891                        | 274 2               |
| NEUTROPHIL COUNT DECREASED                                                         | 33 (16.8%)        | 31 (15.7%)        | 229 (9.5%)                 | (<0.1%)             |
| PLATELET COUNT DECREASED                                                           | 8 (4.1)           | 7 (3.5%)          | 110 (4.5%)                 | 6 (0.2%)            |
| WHITE BLOOD CELL COUNT DECREASED                                                   | 9 (4.6%)          | 7 (3.5%)          | 90 (3.7%)                  | 5 (0.2%)            |
| GASTROINTESTINALDISORDERS Total number of patients with at least one adverse event | 11 (5.6%)         | 18 (9.1%)         | 257 (10.6%)                | 242 (7.6%           |
| Totalnumber of events                                                              | 17                | 22                | 342                        | 319 36              |
| DIARRHOEA                                                                          | 2 (1.0%)          | 4 (2.0%)          | 85 (3.5%)                  | (1.1)               |
| VOMITING                                                                           | 5 2.6%)           | 3 1.5)            | 43 (1.8%)                  | 26 0.8%)            |
| NAUSEA                                                                             | 1 (0.5%)          | 1 （0.5%)          | 53(2.2%)                   | 35 (1.1%)           |
| METABOLISM AND NUTRITION DISORDERS                                                 |                   |                   |                            |                     |
| Totalnumberofpatientswithatleastoneadverseevent                                    | 19 (9.7%)         | 18 (9.1%)         | 273 (11.3%)                | 308(9.7%)           |
| Totalnumber of events                                                              | 28                | 25                | 367                        | 387                 |
| HYPONATRAEMIA                                                                      | 13 (6.6%)         | 9 (4.5%)          | 60 （2.5%)                  | 98 (3.1)            |
| HYPERGLYCAEMIA                                                                     | 1 (0.5%)          | 4 (2.0%)          | 39 (1.6%)                  | 32 (1.0%)           |
| DECREASED APPETITE                                                                 | 0                 | 2 (1.0%)          | 49 (2.0%)                  | 35 (1.1%)           |
| HYPOKALAEMIA                                                                       | 3 (1.5%)          | 0                 | 51 (2.1%)                  | 32 (1.0%)           |
| INFECTIONS AND INFESTATIONS                                                        |                   |                   |                            |                     |
| Total number of patients with at least one adverse event                           | 15 (7.7%)         | 15 (7.6%)         | 355 (14.7%)                | 347 (10.9%)         |
| Total number of events                                                             | 16                | 19                | 437                        | 419                 |
| PNEUMONIA URINARY TRACT INFECTION                                                  | 5 (2.6%) 2 (1.0%) | 6 (3.0%) 2        | 132 (5.5%)                 | 89                  |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                               |                   | (1.0%)            | 24 (1.0%)                  | 72                  |
| Totalnumber ofpatientswithatleastoneadverse event                                  | 8(4.1%) 8         | 12 (6.1%)         | 272 (11.2%) 308            | 265 (8.3%) 315      |
| Total number of events ASTHENIA                                                    | 4 (2.0%)          | 13 5 (2.5%)       | 78 (3.2%)                  | 63 (2.0%)           |
| FATIGUE                                                                            | (0.5%)            | 5 (2.5%)          | 105 (4.3%)                 | 109(3.4%)           |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS                                    |                   |                   |                            |                     |
| Totalnumberof patientswithatleastoneadverseevent                                   | 16 (8.2%)         | 12 (6.1%)         | 242 (10.0%)                | 323 (10.2%)         |
| Total number of events                                                             | 20                | 13                | 303                        | 415 (3.7%)          |
| DYSPNOEA PULMONARY EMBOLISM                                                        | 2 (1.0%) (1.5%)   | 3 (1.5%) 2 (1.0%) | 59(2.4%) 50 (2.1%)         | 117 59 (1.9%)       |
| INJURY，POISONING AND PROCEDURAL COMPLICATIONS                                      |                   |                   |                            |                     |
| Totalnumberof patientswithat least oneadverseevent Total number of events          | 4(2.0%)           | 7 (3.5%)          | 51 (2.1%)                  | 49 9(1.5%)          |
| INFUSION RELATED REACTION                                                          | 4 (0.5%)          | 8 4 (2.0%)        | 56 12 (0.5%)               | 52 7 (0.2%)         |
| VASCULARDISORDERS                                                                  |                   |                   |                            |                     |
| Totalnumberof patientswithat leastoneadverseevent                                  | (2.0%)            | 5 (2.5%)          | 114 (4.7%)                 | 103 (3.2%)          |
| Total number of events HYPERTENSION                                                | 5 3 (1.5)         | 5 3 (1.5)         | 130 61 (2.5%)              | 107                 |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                               | 8 (4.1%)          | 12 (6.1)          | 272 (11.2%)                | 265 (8.3%)          |
| Total number patientswithatleastoneadverseevent Totalnumber of events              | 8                 | 13                | 308                        | 315                 |
| ASTHENIA FATIGUE                                                                   | 4 (2.0%) (0.5%)   | 5 (2.5%) 5 (2.5%) | 78 (3.2%) 105 (4.3%)       | 63 (2.0%) 109(3.4%) |
| RESPIRATORY， THORACIC AND MEDIASTINAL DISORDERS                                    |                   |                   |                            |                     |
| Totalnumber ofpatients withatleast oneadverseevent                                 | 16 (8.2%)         | 12  (6.1%)        | 242 (10.0%)                | 323 (10.2%)         |
| Totalnumber of events                                                              | 20                | 13                | 303                        | 415 117 (3.7%)      |
| DYSPNOEA PULMONARY EMBOLISM                                                        | 2 (1.0%) 3 (1.5%) | 3 (1.5%) 2 (1.0%) | 59 (2.4%) 50 (2.1%)        | 59 (1.9%)           |
| INJURY，POISONING AND PROCEDURAL COMPLICATIONS                                      |                   |                   |                            |                     |
| Total number of patients with at least one adverse event Totalnumber of events     | 4(2.0%)           | (3.5%)            | 51 (2.18)                  | 49(1.5%)            |
|                                                                                    | 4                 | 8                 | 56                         | 52                  |
| INFUSION RELATED REACTION                                                          | (0.5%)            | 4(2.0%)           | 12 (0.5%)                  | (0.2%)              |
| VASCULARDISORDERS                                                                  |                   |                   |                            |                     |
|                                                                                    | 4 (2.0%)          | 5 (2.5%)          | 114 (4.7%)                 | 103 (3.2%)          |
| Totalnumber of events HYPERTENSION                                                 | 5                 | (1.5%)            | 130                        | 107                 |
| Total number of patients with at least one adverse event                           | 3 (1.5%)          | 5 3               | 61 (2.5%)                  | 42 (1.3%)           |

highest grade 5 and other AEs of highest grade 3-4 are included in the overal1 and Soc total number rows counting for grade 3-4 in thistable.Forfrequencycounts bypreferredterm,multiple occurrences of the same AE inanindividualare countedonlyonce.For frequency counts of \"Total number of events\"rows，the multiple occurrences of the same AE in an individual are counted separately. WO29074 (IMMOTION150 Arm B).C1inical cut-0ff dateS:GO27831:31MAR2016，GO28625:07JAN2015，G028753:01DEC2015，G028754:01DEC2015, GO29293:04JUL2016，G028915:07JUL2016, GO29294:13MAR2017，GO29436:22JAN2018，GO29437:20APR2018，G029438:22MAY2018，G029537:15MAR2018， GO30081:24APR2018，WO29074:170CT2016.

<div style=\"page-break-after: always\"></div>

## Adverse drug reactions

The MAH has submitted a table with the pooled adverse drug reactions from atezolizumab in monotherapy (n=3178) and in combination therapy (n=2759).

Table 49: Data from combination therapy comes from the following studies:

| Study                 | Description                                                                                                                                                                                                                             |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| GO29436 (IMpower150)  | Atezolizumab in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)                |
| GO29438 (IMpower132)  | Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
| GO29537 (IMpower130)  | Atezolizumab in Combination With Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)                                                  |
| GO30081 (IMpower133)  | Carboplatin + Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)                                                                                                  |
| WO29074 (IMmotion150) | Atezolizumab as monotherapy or in combination with Bevacizumab compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma                                                                             |
| WO29637 (IMmotion151) | Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)                                                                                                        |
| WO29522(IMpassion130) | Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer                                                           |

The table below reflects the ADRs from the pooled safety data for atezolizumab including study IMpower133.

Table 50: Frequency of ADRs reported with atezolizumab based on a pooled safety data set

| Atezolizumab monotherapy (n=3178)    | Atezolizumab monotherapy (n=3178)    | System Organ Class ADR               | Atezolizumab in combination therapy* (n=2759)   | Atezolizumab in combination therapy* (n=2759)   |
|--------------------------------------|--------------------------------------|--------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Frequency (All Grades)               | Incidence% (All Grades)              | System Organ Class ADR               | Frequency (All Grades)                          | Incidence% (All Grades)                         |
| Infections and infestations          | Infections and infestations          | Infections and infestations          | Infections and infestations                     | Infections and infestations                     |
| very common                          | 368 (11.6%)                          | Urinary tract infection a            | -                                               | -                                               |
| -                                    | -                                    | Lung infection b                     | very common                                     | 377 (13.7%)                                     |
| Blood and Lymphatic System Disorders | Blood and Lymphatic System Disorders | Blood and Lymphatic System Disorders | Blood and Lymphatic System Disorders            | Blood and Lymphatic System Disorders            |
| -                                    | -                                    | Anaemia                              | very common                                     | 916 (33.2%)                                     |
| -                                    | -                                    | Neutropenia d                        | very common                                     | 930 (33.7%)                                     |
| common                               | 116 (3.7%)                           | Thrombocytopenia c                   | very common                                     | 586 (21.2%)                                     |
| -                                    | -                                    | Leukopenia e                         | very common                                     | 322 (11.7%)                                     |
| -                                    | -                                    | Lymphocyte count decreased           | common                                          | 55 (2.0%)                                       |
| Immune System Disorders              | Immune System Disorders              | Immune System Disorders              | Immune System Disorders                         | Immune System Disorders                         |
| common                               | 51 (1.6%)                            | Infusion related reaction f          | -                                               | -                                               |
| Endocrine Disorders                  | Endocrine Disorders                  | Endocrine Disorders                  | Endocrine Disorders                             | Endocrine Disorders                             |
| uncommon                             | 11 (0.3%)                            | Adrenal insufficiency j              | -                                               | -                                               |

<div style=\"page-break-after: always\"></div>

| uncommon                                         | 10 (0.3%)                                        | Diabetes mellitus i                              | -                                                | -                                                |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| uncommon                                         | 30 (0.9%)                                        | Hyperthyroidism h                                | -                                                | -                                                |
| rare                                             | 2 (<0.1%)                                        | Hypophysitis k                                   | -                                                | -                                                |
| common                                           | 164 (5.2%)                                       | Hypothyroidism g                                 | very common                                      | 420 (15.2%)                                      |
| Metabolism and nutrition disorders               | Metabolism and nutrition disorders               | Metabolism and nutrition disorders               | Metabolism and nutrition disorders               | Metabolism and nutrition disorders               |
| very common                                      | 810 (25.5%)                                      | Decreased appetite                               | very common                                      | 678 (24.6%)                                      |
| common                                           | 138 (4.3%)                                       | Hypokalemia                                      | common                                           | 202 (7.3%)                                       |
| -                                                | -                                                | Hypomagnesaemia                                  | common                                           | 259 (9.4%)                                       |
| common                                           | 169 (5.3%)                                       | Hyponatremia                                     | common                                           | 145 (5.3%)                                       |
| common                                           | 103 (3.2%)                                       | Hyperglycaemia                                   | -                                                | -                                                |
| Nervous System Disorders                         | Nervous System Disorders                         | Nervous System Disorders                         | Nervous System Disorders                         | Nervous System Disorders                         |
| -                                                | -                                                | Dizziness                                        | very common                                      | 292 (10.6%)                                      |
| -                                                | -                                                | Syncope                                          | common                                           | 46 (1.7%)                                        |
| uncommon                                         | 5 (0.2%)                                         | Guillain-Barré syndrome                          | -                                                | -                                                |
| uncommon                                         | 14 (0.4%)                                        | Meningoencephalitis n                            | -                                                | -                                                |
| rare                                             | 1 (<0.1%)                                        | Myasthenic syndrome o                            | -                                                | -                                                |
| -                                                | -                                                | Peripheral neuropathy l                          | very common                                      | 740 (26.8%)                                      |
| -                                                | -                                                | Headache                                         | common                                           | (17.0%)                                          |
| very 469 Cardiac Disorders                       | very 469 Cardiac Disorders                       | very 469 Cardiac Disorders                       | very 469 Cardiac Disorders                       | very 469 Cardiac Disorders                       |
| rare                                             | 2 (<0.1%)                                        | Myocarditis p                                    | -                                                | -                                                |
| common                                           | 102 (3.2%)                                       | Vascular Disorders Hypotension                   | -                                                | -                                                |
| Respiratory, Thoracic, and Mediastinal Disorders | Respiratory, Thoracic, and Mediastinal Disorders | Respiratory, Thoracic, and Mediastinal Disorders | Respiratory, Thoracic, and Mediastinal Disorders | Respiratory, Thoracic, and Mediastinal Disorders |
| very common                                      | 660 (20.8%)                                      | Cough                                            | very common                                      | 554 (20.1%)                                      |
| very common                                      | 651 (20.5%)                                      | Dyspnoea                                         | very common                                      | 481 (17.4%)                                      |
| common                                           | 73 (2.3%)                                        | Hypoxia                                          | -                                                | -                                                |
| common                                           | 101 (3.2%)                                       | Nasal congestion                                 | -                                                | -                                                |
| common                                           | 87 (2.7%)                                        | Pneumonitis q                                    | -                                                | -                                                |
| common                                           | 141 (4.4%)                                       | Nasopharyngitis                                  | -                                                | -                                                |
| -                                                | -                                                | Dysphonia                                        | common                                           | 155 (5.6%)                                       |
| Gastrointestinal Disorders                       | Gastrointestinal Disorders                       | Gastrointestinal Disorders                       | Gastrointestinal Disorders                       | Gastrointestinal Disorders                       |
| common                                           | 268 (8.4%)                                       | Abdominal pain                                   | -                                                | -                                                |
| common                                           | 34 (1.1%)                                        | Colitis s                                        | -                                                | -                                                |
| -                                                | -                                                | Constipation                                     | very common                                      | 745 (27.0%)                                      |
| very common                                      | 626 (19.7%)                                      | Diarrhoea r                                      | very common                                      | 814 (29.5%)                                      |
| common                                           | 82 (2.6%)                                        | Dysphagia                                        | -                                                | -                                                |
| very common                                      | 747 (23.5%)                                      | Nausea                                           | very common                                      | 1031 (37.4%)                                     |
| uncommon                                         | 18 (0.6%)                                        | Pancreatitis u                                   | -                                                | -                                                |
| - very common                                    | - 477 (15.0%)                                    | Stomatitis                                       | common very common                               | 259 (9.4%) 527 (19.1%)                           |
| common                                           | 131 (4.1%)                                       | Vomiting Oropharyngeal pain t                    | -                                                | -                                                |
| -                                                | -                                                | Dysgeusia                                        | common                                           | 199 (7.2%)                                       |
| Hepatobiliary Disorders                          | Hepatobiliary Disorders                          | Hepatobiliary Disorders                          | Hepatobiliary Disorders                          | Hepatobiliary Disorders                          |
| common                                           | 167 (5.3%)                                       | ALT increased                                    | common                                           | 219 (7.9%)                                       |
| common                                           | 180 (5.7%)                                       | AST increased                                    | common                                           | 203 (7.4%)                                       |
| common                                           | 62 (2.0%)                                        | Hepatitis v                                      | -                                                | -                                                |
| Skin and Subcutaneous Tissue Disorders           | Skin and Subcutaneous Tissue Disorders           | Skin and Subcutaneous Tissue Disorders           | Skin and Subcutaneous Tissue Disorders           | Skin and Subcutaneous Tissue Disorders           |
| very common                                      | 400 (12.6%)                                      | Pruritus                                         | very common                                      | 363 (13.2%)                                      |
| very common                                      | 619 (19.5%)                                      | Rash w                                           | very common                                      | 785 (28.5%)                                      |
| Musculoskeletal and Connective Tissue Disorders  | Musculoskeletal and Connective Tissue Disorders  | Musculoskeletal and Connective Tissue Disorders  | Musculoskeletal and Connective Tissue Disorders  | Musculoskeletal and Connective Tissue Disorders  |
| very common                                      | 441 (13.9%)                                      | Arthralgia                                       | very common                                      | 535 (19.4%)                                      |
| very common                                      | 487 (15.3%)                                      | Back pain                                        | very common                                      | 373 (13.5%)                                      |
| very common                                      | 414 (13.0%)                                      | Musculoskeletal pain x                           | very common                                      | 510 (18.5%)                                      |
| Uncommon                                         | 13 (0.4%)                                        | Myositis y                                       | -                                                | -                                                |
| Renal Disorders                                  | Renal Disorders                                  | Renal Disorders                                  | Renal Disorders                                  | Renal Disorders                                  |
| -                                                | -                                                | Proteinuria z                                    | common                                           | 215 (7.8%)                                       |
| rare                                             | 3 (<0.1%)                                        | Nephritis aa                                     | -                                                | -                                                |
| General Disorders and Administration             | General Disorders and Administration             | General Disorders and Administration             | General Disorders and Administration             | General Disorders and Administration             |
| very common                                      | 461 (14.5%)                                      | Asthenia                                         | very common                                      | 487 (17.7%)                                      |
| common                                           | 207 (6.5%)                                       | Chills                                           | -                                                | -                                                |
| very common                                      | 1142 (35.9%)                                     | Fatigue                                          | very common -                                    | 1003 (36.4%) -                                   |
| common very common                               | 186 (5.9%) 638 (20.1%)                           | Influenza like illness Pyrexia                   | very common                                      | 473 (17.1%)                                      |

a Includes reports of urinary tract infection, cystitis, pyelonephritis, escherichia urinary tract infection, urinary tract infection bacterial, kidney infection, pyelonephritis acute, urinary tract infection fungal, urinary tract infection pseudomonal.

b Includes reports of pneumonia, bronchitis, lung infection, lower respiratory tract infection, infective exacerbation of COPD, infectious pleural effusion, tracheobronchitis, atypical pneumonia, lung abscess, pyopneumothorax.

<div style=\"page-break-after: always\"></div>

- c  Includes reports of thrombocytopenia and platelet count decreased.
- d  Includes reports of neutropenia, neutrophil count decreased, febrile neutropenia, neutropenic sepsis, granulocytopenia.
- e  Includes reports of white blood cell count decreased and leukopenia.
- f  Includes reports of cytokine release syndrome, hypersensitivity, anaphylaxis.
- g  Includes reports of autoimmune hypothyroidism, autoimmune thyroiditis, blood thyroid stimulating hormone abnormal, blood thyroid stimulating hormone decreased, blood thyroid stimulating hormone increased, euthyroid sick syndrome, goitre, hypothyroidism, myxoedema, thyroid disorder, thyroid function test abnormal, thyroiditis, thyroiditis acute, thyroxine decreased, thyroxine free decreased, thyroxine free increased, thyroxine increased, tri-iodothyronine decreased, tri-iodothyronine free abnormal, tri-iodothyronine free decreased, tri-iodothyronine free increased.
- h  Includes reports of hyperthyroidism, Basedow's disease, endocrine ophthalmopathy, exophthalmos.
- i Includes reports of diabetes mellitus, type 1 diabetes mellitus, diabetic ketoacidosis, ketoacidosis.
- j Includes reports of adrenal insufficiency and primary adrenal insufficiency.
- ak  Incudes reports of hypophysitis and temperature regulation disorder.
- l  Includes reports of neuropathy peripheral, autoimmune neuropathy, peripheral sensory neuropathy, polyneuropathy, herpes zoster, peripheral motor neuropathy, neuralgic amyotrophy, peripheral sensorimotor neuropathy, toxic neuropathy, axonal neuropathy, lumbosacral plexopathy, neuropathic arthropathy, peripheral nerve infection.
- m  Includes reports of Guillain-Barré syndrome and demyelinating polyneuropathy.
- n Includes reports of encephalitis, meningitis, photophobia.
- ao  Incudes reports of myasthenia gravis.
- p  Reported in studies outside the pooled dataset. The frequency is based on the program wide exposure.
- q Includes reports of pneumonitis, lung infiltration, bronchiolitis, interstitial lung disease, radiation pneumonitis.
- r  Includes reports of diarrhoea, defaecation urgency, frequent bowel movements, and gastrointestinal hypermotility.
- s Includes reports of colitis, autoimmune colitis, colitis ischaemic, colitis microscopic, colitis ulcerative.
- t  Includes reports of oropharyngeal pain, oropharyngeal discomfort and throat irritation.
- u Includes reports of autoimmune pancreatitis, pancreatitis, pancreatitis acute, lipase increased, amylase increased.

v

Includes reports of ascites, autoimmune hepatitis, hepatocellular injury, hepatitis, hepatitis acute, hepatotoxicity, liver disorder, drug-induced liver injury, hepatic failure, hepatic steatosis, hepatic lesion, oesophageal varices haemorrhage, varices oesophageal.

w  Includes reports of acne, acne pustular, dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis bullous, dermatitis exfoliative generalised, drug eruption, eczema, eczema infected, erythema, erythema multiforme, erythema of eyelid, exfoliative rash, eyelid

rash, fixed eruption, folliculitis, furuncle, generalised erythema, palmar-plantar erythrodysaesthesia syndrome, rash , rash erythematous, rash generalised, rash macular, rash maculo-papular, rash papular, rash papulosquamous, rash pruritic, rash pustular,

rash vesicular, seborrhoeic dermatitis, skin exfoliation, skin toxicity, skin ulcer, toxic epidermal necrolysis, toxic skin eruption.

- x Includes reports of musculoskeletal pain and myalgia.
- y  Includes reports of myositis, rhabdomyolysis, polymyalgia rheumatica, dermatomyositis, muscle abscess, myoglobin urine present.
- z  Includes reports of proteinuria, protein urine present, haemoglobinurea, nephrotic syndrome.
- aa Includes report of nephritis, Henoch-Schonlein Purpura nephritis.
- -*includes studies GO29436, GO29438, GO29537, GO30081, WO29074, WO29637, WO29522.

## Serious adverse event/deaths/other significant events

## Serious AEs:

## Table 51 : Serious adverse events reported in ≥2% of patients in either treatment arm (safety evaluable patients)

| MedDRA System Organ Class MedDRA Preferred Term          | PBO + CE (Actual) (N=196)   | Atezo + CE (Actual) (N=198)   | All Patients (N=394)   |
|----------------------------------------------------------|-----------------------------|-------------------------------|------------------------|
| Total number of patients with at least one adverse event | 68(34.7%)                   | 74(37.4%)                     | 142 (36.0%)            |
| Overall total number of events                           | 113                         | 129                           | 242                    |
| BLOOD AND LYMPHATICSYSTEMDISORDERS                       |                             |                               |                        |
| Totalnumber of patients withatleastone adverse event     | 27 (13.8%)                  | 17 (8.6%)                     | 44 (11.2%)             |
| Totalnumber of events                                    | 30                          | 23                            | 53                     |
| NEUTROPENIA                                              | 8 4.1%)                     | 7 (3.5%)                      | 15 (3.8%)              |
| FEBRILENEUTROPENIA                                       | 9 4.6%)                     | 5 2.5%)                       | 14 (3.6%)              |
| THROMBOCYTOPENIA                                         | 4 2.0%)                     | 5 （ 2.5%) 0                   | 9 (2.3%)               |
| PANCYTOPENIA                                             | 五 2.0%)                     |                               | 4 (1.0%)               |
| INFECTIONS AND INFESTATIONS                              |                             |                               |                        |
| Total number of patients with at least one adverse event | 20 (10.2%)                  | 16 (8.1)                      | 36(9.18)               |
| Total number of events                                   | 22                          | 21                            | 43                     |
| PNEUMONIA                                                | 7 (3.6%)                    | 9(4.5%)                       | 16 (4.1)               |
| METABOLISMANDNUTRITIONDISORDERS                          |                             |                               |                        |
| Total number of patients with at least one adverse event | 5 (2.6%)                    | 4  (2.0%)                     | 9(2.38)                |
| Total number of events                                   | 6                           | 4                             | 10                     |
| HYPONATRAEMIA                                            | (2.0%)                      | 1 (0.5%)                      | 5( 1.3%)               |

```
For frequency counts by preferred term, multiple occurrences of the same AE in an individual are soumted only once. Atezo=Atezolizumab,CE=Carboplatin +Etoposide,PBo=Placebo Data Cutoff: 24APR2018
```

<div style=\"page-break-after: always\"></div>

Table 40 : Serious adverse events by preferred term occurring in ≥1% in either arm/population (safety evaluable population)

|                                                                                | IMpower133     | IMpower133       |                            |                     |
|--------------------------------------------------------------------------------|----------------|------------------|----------------------------|---------------------|
| MedDRA Preferred Term                                                          | PBO+CE (N=196) | Atezo+CE (N=198) | Atezo+Chemo Combo (N=2421) | Atezo Mono (N=3178) |
| Total number of patients withat least one adverse event Total number of events | 68 (34.7%) 113 | 74 (37.48) 129   | 1073 (44.3%) 2023          | 1309 (41.2%) 2267   |
| PNEUMONIA                                                                      | 7 (3.6%)       | 9 (4.58)         | 144 (5.9%)                 | 98 (3.1%)           |
| NEUTROPENIA                                                                    | 8 4.1%)        | 7 （ 3.5%)        | 34 (1.4%)                  | 0                   |
| FEBRILE NEUTROPENIA                                                            | 9 4.6%)        | 5 ( 2.5%)        | 93 (3.8%)                  | 7 0.2%)             |
| THROMBOCYTOPENIA                                                               | 4 2.0%)        | 5 2.5%)          | 31 (1.3%)                  | 6 0.2%)             |
| ANAEMIA                                                                        | 2 1.0%)        | 3 1.5%)          | 49 (2.0%)                  | 29 0.9%)            |
| DIARRHOEA                                                                      | 1 0.5%)        | 3 1.5%)          | 52 (2.1%)                  | 21 0.7%)            |
| FATIGUE                                                                        | 0              | 3 1.5%)          | 11 (0.5%)                  | 21 (0.7%)           |
| SYNCOPE                                                                        | 0              | 3 (1.5%)         | 10 (0.4%)                  | 12 (0.4%)           |
| VOMITING                                                                       | 3 (1.5)        | 3 (1.5)          | 27 (1.1)                   | 19                  |
| ACUTE KIDNEY INJURY                                                            | 0              | 2 (1.0%)         | 20 (0.8%)                  | 37(1.2%)            |
| ASTHENIA                                                                       | 1 0.5%)        | 2 1.0%)          | 11 (0.5%)                  | 13 (0.4%)           |
| AUTOIMMUNE THYROIDITIS                                                         | 0              | 2 (1.0%)         | 2 (<0.1%)                  | 0                   |
| BRONCHITIS                                                                     | 0              | 2 1.0%)          | 19 0.8%)                   | 7 0.2%)             |
| CHRONICOBSTRUCTIVEPULMONARYDISEASE                                             | 2 1.0%)        | 2 1.0%)          | 35 1.4%)                   | 10 0.3%)            |
| COLITIS                                                                        | 0              | 2 (1.0%)         | 17 0.7%)                   | 16 0.5%)            |
| GENERALPHYSICAL HEALTHDETERIORATION                                            | 1 0.5%)        | 2 1.0%)          | 11 C 0.5%)                 | 11 0.3%)            |
| HAEMOPTYSIS                                                                    | 1 0.5%)        | 2 1.0%)          | 28 1.2%)                   | 20 0.6%)            |
| HYPERGLYCAEMIA                                                                 | 0              | 2 1.0%)          | 5 0.2%)                    | 0.2%)               |
| LEUKOPENIA                                                                     | 1 0.5%)        | 2 1.0%)          | 5 0.2%)                    | 5 0                 |
| LOWER RESPIRATORY TRACT INFECTION                                              | 0              | 2 1.0%)          | 5 0.2%)                    | 15 0.58)            |
| PLEURAL EFFUSION                                                               | 1 0.5%)        | 2 (1.0%)         | 16 0.7%)                   | 40 1.3%)            |
| PYREXIA                                                                        | 0              | 2 （ 1.0%)        | 45 1.9%)                   | 79 2.5%)            |
| URINARY TRACT INFECTION                                                        | 2 1.0%)        | 2 (1.0%)         | 20 0.8%)                   | 1.9%)               |
| ATRIAL FIBRILLATION                                                            | 2 1.0%)        | 1 0.5%)          | 17 0.7%)                   | 61 9 0.3%)          |
| DYSPNOEA                                                                       | 2 1.0%)        | 1 0.5%)          | 32 1.3%)                   | 89 2.8%)            |
| HYPONATRAEMIA                                                                  | 4 2.0%)        | 0.5%)            | 12 0.5%)                   | 20 0.6%)            |
| INFUSION RELATED REACTION                                                      | 2 ( 1.0%)      | 1 0.5%)          | 11 0.5%)                   | 7 (0.2%)            |
| PNEUMONITIS                                                                    | 2 1.0%)        | 1 0.5%)          | 51 (2.1%)                  | 35                  |
| ACUTE RESPIRATORYFAILURE                                                       | 2              | 0                | 5 (0.2%)                   | 3 (<0.1%)           |
|                                                                                | (1.0%)         |                  |                            | 35 (1.1%)           |
| BACK PAIN LUNG INFECTION                                                       | 0 3            | 0 0              | 11 0.5%)                   | 15 (0.5%)           |
| PANCYTOPENIA                                                                   | 1.5) 4 2.0%)   | 0                | 28 1.2%) 7 0.3%)           | 0                   |
| PLATELETCOUNTDECREASED                                                         | 2 1.0%)        | 0                | 6 0.2%) 1.7%)              | 2 (<0.1%)           |
| PULMONARY EMBOLISM SEPSIS                                                      | 2 1.0%)        | 0                | 40 27 (1.1%)               | 42 (1.3%)           |
|                                                                                | 1 0.5%)        | 0                |                            | 41                  |

Investigator text for AEs encoded using MedDRA v2l.o. Percentages are based on N in the column headings. For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once. For frequency counts of \"Total number of events\" rows, the multiple occurrences of the same AE in an individual are counted separately. All treatment emergent AEs are included.Sort order is by decreasing frequency in Atezo+CE treatment arm.

Atezo=Atezolizumab，PBO=Placebo,CE=Carboplatin+Etoposide.Atezo+Chemo Combo:GO29537 (IMPOWER130） Arm A + GO29437 (IMPOWER131） Arm A+B + GO29436 （IMPOWER150）Arm A+B + GO29438 (IMPOWER132） Arm A + GO30081 (IMPOWER133)） Arm A.AteZO Mono: GO28915 (OAK) + GO28753 WO29074 (IMMOTION150 Arm B).C1inical cut-off dateS: GO27831:31MAR2016，GO28625:07JAN2015， G028753:01DEC2015，GO28754:01DEC2015, GO29293:04JUL2016，GO28915:07JUL2016，G029294:13MAR2017，G029436:22JAN2018，G029437:20APR2018，GO29438:22MAY2018，G029537:15MAR2018, GO30081:24APR2018， WO29074:170CT2016.

<div style=\"page-break-after: always\"></div>

## Deaths and primary cause of deaths:

Table 41: All deaths and primary cause of death (safety evaluable population)

|                                               | PBO+CE (N=196)   | Atezo+CE (N=198)   | Atezo+ChemoCombo (N=2421)   | Atezo Mono (N=3178)   |
|-----------------------------------------------|------------------|--------------------|-----------------------------|-----------------------|
| All death                                     |                  |                    |                             |                       |
| n                                             | 130 (66.3%)      | 103 (52.0%)        | 1277 (52.7%)                | 1884 (59.3%)          |
| <=30 days from last study drug administration | 13(6.6%)         | 8(4.0%)            | 235(9.7%)                   | 352 (11.1)            |
| >30 days from last study drug administration  | 117 (59.7%)      | 95 (48.0%)         | 1042 (43.0%)                | 1532 (48.2)           |
| Primary cause of death                        |                  |                    |                             |                       |
| n                                             | 130 (66.3%)      | 103 (52.0%)        | 1277 (52.7%)                | 1884 (59.3)           |
| ADVERSEEVENT                                  | 11 (5.6%)        | 4 (2.0%)           | 143(5.9%)                   | 120(3.8%)             |
| PROGRESSIVEDISEASE                            | 115 (58.7%)      | 90(45.5%)          | 1062 (43.9%)                | 1463 (46.0%)          |
| OTHER                                         | 4(2.0%)          | 9 (4.58)           | 72(3.0%)                    | 301 (9.5%)            |

Deathsdue to other includes unrelatedadverse events outside of reporting window.other Cause of Deathis displayedverbatim. Atezo=Atezolizumab，PBO=Placebo，CE=Carboplatin+Etoposide.Atezo+Chemo Combo:G029537(IMPoWER130）ArmA + GO29437(IMPoWER131）Arm A+B + GO29436 (IMPOWER150）Arm A+B+ GO29438（IMPOWER132）Arm A+ GO30081 (IMPOWER133）Arm A.AteZo Mono:GO28915(OAK)+ GO28753 WO29074 (IMMOTION150 Arm B).C1inical cut-0ff dateS: GO27831:31MAR2016，GO28625:07JAN2015， GO28753:01DEC2015， GO28754:01DEC2015, GO30081:24APR2018,WO29074:170CT2016.

## G5 AEs across IMpower133, Atezo+Chemo and Atezo Mono populations:

Table 42: Grade 5 events by preferred term (safety evaluable population)

|                                                                                                                                         | IMpower133     | IMpower133       |                            |                     |
|-----------------------------------------------------------------------------------------------------------------------------------------|----------------|------------------|----------------------------|---------------------|
| MedDRA SOc/Preferred Term                                                                                                               | PBO+CE (N=196) | Atezo+CE (N=198) | Atezo+Chemo Combo (N=2421) | Atezo Mono (N=3178) |
| Totalnumber of deaths                                                                                                                   | 11 (5.6%)      | (2.0%)           | 144 (5.9%)                 | 120 (3.8%)          |
| BLOODAND LYMPHATIC SYSTEM DISORDERS /NEUTROPENIA                                                                                        | 0              | (0.5%)           | 1 (<0.1%)                  | 0                   |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS/DEATH                                                                              | 0              | (0.5%)           | 15 (0.6%)                  | 19 (0.6%)           |
| INFECTIONS ANDINFESTATIONS/PNEUMONIA                                                                                                    | 3 (1.5%)       | (0.5%)           | 19 0.8%)                   | 12 (0.4%)           |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS / RESPIRATORY FAILURE                                                                   | 0              | (0.5%)           | 3 0.1%)                    | 5 (0.2%)            |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS DISSEMINATED INTRAVASCULAR COAGULATION                                                             | 0              | 0                | 0                          | 1 (<0.1%)           |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS FEBRILE NEUTROPENIA                                                                                | 0              | 0                | 3 0.1%)                    | 1 (<0.1%)           |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS HISTIOCYTOSIS HAEMATOPHAGIC                                                                        | 0              | 0                | 0                          | 1 (<0.1%)           |
| CARDIAC DISORDERS ACUTE CORONARY SYNDROME                                                                                               | 0              | 0                | 0                          | 1 (<0.1%)           |
| CARDIAC DISORDERS ACUTE MYOCARDIAL INFARCTION                                                                                           | 0              | 0                | 0                          | 1 (<0.1%)           |
| CARDIAC DISORDERS CARDIAC ARREST                                                                                                        | 0              | 0                | 7 0.3%)                    | 5 (0.2%)            |
| CARDIAC DISORDERS CARDIAC FAILURE                                                                                                       | 0              | 0                | 0                          | 3 (<0.1%)           |
| CARDIAC DISORDERS CARDIAC FAILURE ACUTE                                                                                                 | 0              | 0                | 1 (<0.1%)                  | 0                   |
| CARDIAC DISORDERS CARDIAC TAMPONADE                                                                                                     | 0              | 0                | 0                          | 1 (<0.1%)           |
| CARDIAC DISORDERS CARDIO-RESPIRATORY ARREST                                                                                             |                | 0                | 2 (<0.1%)                  | 0                   |
| CARDIAC DISORDERS CARDIOPULMONARY FAILURE                                                                                               | 1 (0.5%)       | 0                | 0                          | 0                   |
| CARDIAC DISORDERS                                                                                                                       | 0 0            | 0                | 4 (0.2%)                   | 2 (<0.1%)           |
| MYOCARDIAL INFARCTION CARDIAC DISORDERS MYOCARDIAL ISCHAEMIA                                                                            | 0              | 0                | 0                          | 1 (<0.1%)           |
| DISORDERS                                                                                                                               | 1 (0.5%)       | 0                |                            |                     |
| CARDIAC PERICARDIAL EFFUSION                                                                                                            |                |                  | 0                          | 0                   |
| CARDIAC DISORDERS PERICARDITIS CONSTRICTIVE                                                                                             | 0 0            | 0 0              | 0 1 (<0.1%)                | 1 (<0.1%)           |
| CARDIAC DISORDERS VENTRICULAR TACHYCARDIA                                                                                               | 0              | 0                | (<0.1%)                    | 0                   |
| GASTROINTESTINAL DISORDERS ENTEROVESICAL FISTULA                                                                                        | 0              |                  | 1 0                        | 0                   |
| GASTROINTESTINAL DISORDERS ENTEROCOLITIS                                                                                                |                | 0                |                            | 1 (<0.1%)           |
| GASTROINTESTINAL DISORDERS GASTRIC PERFORATION                                                                                          | 0              | 0                | 0                          | 1 (<0.1%)           |
| GASTROINTESTINAL DISORDERS GASTROINTESTINALHAEMORRHAGE                                                                                  | 0              | 0                | 1 (<0.1%)                  | 1 (<0.1%)           |
| GASTROINTESTINAL DISORDERS INTESTINAL ANGINA                                                                                            | 0              | 0                | 1 (<0.1%)                  | 0                   |
| GASTROINTESTINAL DISORDERS INTESTINAL ISCHAEMIA                                                                                         | 0              | 0                | 1 (<0.1%)                  | 0                   |
|                                                                                                                                         |                |                  |                            | 0                   |
| GASTROINTESTINAL DISORDERS INTESTINAL OBSTRUCTION                                                                                       | 0              | 0                | 1 (<0.1%)                  |                     |
| GASTROINTESTINAL DISORDERS INTESTINAL PERFORATION                                                                                       | 0              | 0                | 0                          | 1 (<0.1%)           |
| GASTROINTESTINAL DISORDERS LARGE INTESTINAL OBSTRUCTION                                                                                 | 0              | 0                | 0                          | 1 (<0.1%)           |
| LARGE INTESTINE PERFORATION                                                                                                             | 0              | 0                | 1 (<0.1%)                  | 1 (<0.1%)           |
| GASTROINTESTINAL DISORDERS                                                                                                              | 0              | 0                | 1 (<0.1%)                  | 0                   |
| GASTROINTESTINAL DISORDERS PROCTITIS ULCERATIVE GASTROINTESTINAL DISORDERS SMALL INTESTINAL PERFORATION                                 | 0              | 0                | 1 (<0.1%) 0                | 0                   |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS / GENERAL PHYSICAL HEALTH DETERIORATION                                            | 1 (0.5%) 0     | 0                |                            | 3 (<0.1%)           |
|                                                                                                                                         |                |                  | 0                          |                     |
| GASTROINTESTINAL DISORDERS SUBILEUS                                                                                                     | 0              | 0 0              | 0                          | 1 (<0.1%) 1 (<0.1%) |
| GENERAL DISORDERS AND ADMINISTRATIONSITE CONDITIONS SUDDEN DEATH GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS ULCER HAEMORRHAGE |                |                  |                            | 1 (<0.1%)           |
| HEPATOBILIARY DISORDERS HEPATIC CIRRHOSIS                                                                                               | 0 0            | 0 0              | 1 (<0.1%) 0                | 0                   |
|                                                                                                                                         | 0              | 0                | 0                          | 2 (<0.1%)           |
| HEPATOBILIARY DISORDERS HEPATIC FAILURE                                                                                                 |                |                  |                            |                     |
| HEPATOBILIARY DISORDERS HEPATIC HAEMATOMA                                                                                               | 0              | 0                | 0                          | 1 (<0.1%)           |
| HEPATOBILIARY DISORDERS HEPATIC FUNCTION ABNORMAL                                                                                       | 0              | 0                | 1 (<0.1%)                  | 0                   |
|                                                                                                                                         | 0              | 0                | 1 (<0.1%)                  | 0                   |
| HEPATOBILIARY DISORDERS HEPATITIS ACUTE                                                                                                 |                |                  |                            |                     |
| HEPATOBILIARY DISORDERS HEPATOTOXICITY                                                                                                  | 0              | 0                | 1 (<0.1%)                  | 0                   |
| INFECTIONS AND INFESTATIONS EMPYEMA                                                                                                     | 0              | 0                | 0                          | 1 (<0.1%)           |
| INFECTIONS AND INFESTATIONS INFLUENZA INFECTIONS AND INFESTATIONS LOWER RESPIRATORY TRACT INFECTION                                     | 0 0            | 0 0              | 2 (<0.1%) 0                | 0 1                 |
| INFECTIONS AND INFESTATIONS LUNG INFECTION                                                                                              | 0              | 0                | (<0.1%)                    |                     |

<div style=\"page-break-after: always\"></div>

| INFECTIONS AND INFESTATIONS NEUTROPENIC SEPSIS                                                                                            | 0        | 0   | (<0.1%)   | 0           |
|-------------------------------------------------------------------------------------------------------------------------------------------|----------|-----|-----------|-------------|
| INFECTIONS AND INFESTATIONS PULMONARY SEPSIS                                                                                              | 1 (0.5%) | 0   | 0         | 2 (<0.1%)   |
| INFECTIONS AND INFESTATIONS RESPIRATORY TRACT INFECTION                                                                                   | 0        | 0   | 0         | 1 (<0.1%)   |
| INFECTIONS AND INFESTATIONS SEPSIS                                                                                                        | 1 (0.5%) | 0   | 6 0.2%)   | 8 0.3%)     |
| INFECTIONS AND INFESTATIONS SEPTIC SHOCK                                                                                                  | 1 (0.5%) | 0   | 4 0.2%)   | 5 0.2%)     |
| INFECTIONS AND INFESTATIONS STAPHYLOCOCCAL SEPSIS                                                                                         | 0        | 0   | 1 (<0.1%) | 0           |
| INJURY， POISONING AND PROCEDURAL COMPLICATIONS HEAD INJURY                                                                                | 0        | 0   | 0         | 1 (<0.1%)   |
| INJURY, POISONING AND PROCEDURAL COMPLICATIONS HIP FRACTURE                                                                               | 0        | 0   | 1 (<0.1%) | 0           |
| INJURY, POISONING AND PROCEDURAL COMPLICATIONS OVERDOSE                                                                                   | 0        | 0   | 0         | 1 (<0.1%)   |
| INJURY, POISONING AND PROCEDURAL COMPLICATIONS SUBDURAL HAEMATOMA                                                                         | 0        | 0   | 1 (<0.1%) | 0           |
| INVESTIGATIONS GENERALPHYSICALCONDITION ABNORMAL                                                                                          | 0        | 0   | 0         | 1 (<0.1%)   |
| METABOLISMANDNUTRITIONDISORDERS DECREASED APPETITE                                                                                        | 0        | 0   | 1 (<0.1%) | 0           |
| METABOLISM AND NUTRITION DISORDERS FAILURE TO THRIVE                                                                                      | 0        | 0   | 0         | 1 (<0.1%)   |
| NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)/ TUMOUR                                                               | 0        | 0   | 2 (<0.1%) | 0           |
| EMBOLISM                                                                                                                                  |          |     |           |             |
| NERVOUS SYSTEM DISORDERS CEREBRAL ARTERY EMBOLISM                                                                                         | 0        | 0   | 0         | 1 (<0.1%)   |
| NERVOUS SYSTEM DISORDERS CEREBRAL HAEMORRHAGE                                                                                             | 0        | 0   | 0         | 2 (<0.1%)   |
| NERVOUS SYSTEM DISORDERS CEREBRAL INFARCTION                                                                                              | 0        | 0   | 0         | 1 (<0.1%)   |
| NERVOUS SYSTEM DISORDERS CEREBROVASCULARACCIDENT                                                                                          | 0        | 0   | 3 (0.1%)  | 2 (<0.1%)   |
| NERVOUS SYSTEM DISORDERS GUILLAIN-BARRE SYNDROME                                                                                          | 0        | 0   | 1 (<0.1%) | 0           |
| NERVOUS SYSTEM DISORDERS HAEMORRHAGE INTRACRANIAL                                                                                         | 0        | 0   | 2 (<0.1%) | 0           |
| NERVOUS SYSTEM IDISORDERS ISCHAEMIC STROKE                                                                                                | 0        | 0   | 0         | 2 (<0.1%)   |
| NERVOUS SYSTEM DISORDERS SEIZURE                                                                                                          | 0        | 0   | 1 (<0.1%) | 0           |
| PSYCHIATRIC DISORDERS/ ASSISTED SUICIDE                                                                                                   | 0        | 0   | 0         | 1           |
| PSYCHIATRIC DISORDERS / COMPLETED SUICIDE                                                                                                 | 0        | 0   | 3 (0.1%)  | (<0.1%)     |
| RENALANDURINARY DISORDERS/1 ACUTE KIDNEY INJURY                                                                                           | 0        | 0   | 1 (<0.1%) | 0           |
| RENAL AND URINARY DISORDERS / RENAL FAILURE                                                                                               | 0        | 0   | 0         | 1 (<0.1%)   |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS ACUTE RESPIRATORY FAILURE                                                                 | 1 (0.5%) | 0   | 1 (<0.1%) | 0           |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS ASPIRATION                                                                                | 0        | 0   | 3 (0.1%)  | 0           |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS CHRONIC OBSTRUCTIVE PULMONARY                                                             | 0        | 0   | 5 (0.2%)  | 0           |
| DISEASE                                                                                                                                   |          |     |           |             |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS                                                                                           | 0        | 0   | 1 (<0.1%) | 1 (<0.1%)   |
| DYSPNOEA RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS HAEMOPTYSIS                                                                      | 1 (0.5%) | 0   | 8 (0.3%)  | 0           |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS INTERSTITIAL LUNG DISEASE                                                                 | 0        | 0   | 2 (<0.1%) | 0           |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS PNEUMONIA ASPIRATION                                                                      | 0        | 0   | 1 (<0.1%) | 2 (<0.1%)   |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS PNEUMONITIS                                                                               | 0        | 0   | 4 (0.2%)  | 1 (<0.1%)   |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS PNEUMOTHORAX                                                                              | 0        | 0   | 0         | 1 (<0.1%)   |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS PULMONARY EMBOLISM                                                                        | 0        | 0   | 12 (0.5%) | 2 (<0.1%)   |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS PULMONARY HAEMORRHAGE                                                                     | 0        | 0   | 2 (<0.1%) | 1 (<0.1%)   |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS PULMONARY H HYPERTENSION                                                                  | 0        | 0   | 0         | 1 (<0.1%)   |
|                                                                                                                                           |          |     | 1         | 0           |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS PULMONARY OEDEMA                                                                          | 0 0      | 0 0 | (<0.1%) 0 | 1 (<0.1%)   |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS RESPIRATORY DISORDER RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS RESPIRATORY DISTRESS | 0        | 0   | 1 (<0.1%) | 2 (<0.1%)   |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS TOXIC EPIDERMAL NECROLYSIS                                                                         | 0        | 0   | 0         | (<0.1%)     |
|                                                                                                                                           |          |     | 1         | 1           |
| VASCULAR RDISORDERS AORTIC DISSECTION                                                                                                     | 0        | 0   | (<0.1%)   | 0           |
| VASCULAR DISORDERS EMBOLISM                                                                                                               | 0        | 0   | 1 (<0.1%) | 2 (<0.1%)   |
| VASCULAR DISORDERS HAEMODYNAMIC INSTABILITY                                                                                               | 0        | 0   | 1 (<0.1%) | 0           |
| VASCULAR DISORDERS INTERNAL HAEMORRHAGE                                                                                                   | 0        | 0   | 0         | 1 (<0.1%)   |
| VASCULAR DISORDERS JUGULAR VEIN THROMBOSIS VASCULARDISORDERS SUPERIORVENACAVASYNDROME                                                     | 0 0      | 0 0 | 0 1       | 1 (<0.1%) 0 |

(&lt;0.1%)

Investigator text for AEs encoded using MedDRA v21.o. Percentages are based on N in the column headings. For frequency counts

\"Total number of deaths\" rows, the multiple occurrences of the same AE in an individual are counted separately. All treatment by preferred term, multiple occurrences of the same AE in an individual are counted only once. For frequency\\_counts of

emergent AEs are included.Sort order is by decreasing frequency inAtezo+CE treatment arm.

Atezo=Atezolizumab，PBO=Placebo，CE=Carboplatin+Etoposide.Atezo+Chemo Combo:GO29537 (IMPOWER130） Arm A + GO29437 (IMPoWER131）Arm A+B + GO29436 (IMPOWER150) Arm A+B +GO29438 (IMPOWER132） Arm A + GO30081 (IMPOWER133) Arm A.AteZo Mono:GO28915 (OAK) + GO28753 (POPLAR)+ GO28754 (BIRCH)+ GO28625 (FIR)+ GO27831 (PCD4989g -A11 CohortS）+ GO29293 （IMVIGOR210）+GO29294 (IMVIGOR211）+ WO29074 (IMMOTION150 Arm B).C1inical cut-0ff dateS:GO27831:31MAR2016，GO28625:07JAN2015，GO28753:01DEC2015，GO28754:01DEC2015, GO29293:04JUL2016，GO28915:07JUL2016，（ GO29294:13MAR2017，GO29436:22JAN2018，GO29437:20APR2018, G029438:22MAY2018，GO29537:15MAR2018, GO30081:24APR2018， WO29074:170CT2016.

## AESIs to atezolizumab across IMpower133, Atezo+Chemo Combo and Atezo Mono populations:

Table 43: Summary of AESIs for atezolizumab (safety evaluable population)

|                                                    | IMpower133     | IMpower133   | IMpower133       |                            |     |                     |
|----------------------------------------------------|----------------|--------------|------------------|----------------------------|-----|---------------------|
|                                                    | PBO+CE (N=196) |              | Atezo+CE (N=198) | Atezo+Chemo Combo (N=2421) |     | Atezo Mono (N=3178) |
| Total number of patients with at least one AESI    | 48 (24.5%)     |              | 79(39.9%)        | 1164 (48.1)                |     | 1098 (34.6%)        |
| Totalnumberof AESI events                          |                | 71           | 146              | 2395                       |     | 2186                |
| Totalnumberofpatientswithatleastone                |                |              |                  |                            |     |                     |
| Treatment-related AESI                             | 36             | (18.4%)      | 64 (32.3%)       | 975 (40.3%) (36.38)        | 794 | (25.0%)             |
| Atezo-relatedAESI                                  | 0              |              | 61 (30.8%)       | 880                        | 794 | (25.0%)             |
| Grade 3-4 AESI                                     | 5              | (2.68)       | 16 (8.1%)        | 250 (10.3%)                | 248 | (7.8%)              |
| Treatment-related Grade 3-4 AESI                   | 4              | (2.0%)       | 14 (7.1%)        | 213 8.8%)                  | 173 | (5.4%)              |
| Atezo-relatedGrade 3-4 AESI                        | 0              |              | 14 (7.1%)        | 194 8.0%)                  | 173 | (5.4%)              |
| Grade 5 AESI                                       | 0              |              | 0                | 11 0.5%)                   | 4   | ( 0.1%)             |
| Treatment-related Grade 5 AESI                     | 0              |              | 0                | 11 0.5%)                   | 2   | (<0.1%)             |
| Atezo-relatedGrade5 AESI                           | 0              |              | 0                | 10 0.4%)                   | 2   | (<0.1%)             |
| Serious AESI                                       | 7              | 3.6%)        | 13 (6.6%)        | 173 7.1%)                  | 151 | (4.8%)              |
| Treatment-related serious AESI                     | 5              | 2.6%)        | 11 (5.6%)        | 155 6.48)                  | 127 | (4.0%)              |
| Atezo-related serious AESI                         | 0              |              | 11 (5.6%)        | 149 6.28)                  | 127 | 4.0%)               |
| AESI leading to any Treatment withdrawal           | 2              | 1.0%)        | 8 4.0%)          | 134 5.5%)                  | 58  | 1.8%)               |
| AESI leading to Atezo withdrawal                   | 0              |              | 7 (3.5%)         | 122 5.0%)                  | 58  | 1.8%)               |
| AESI leading toTreatment modification/interruption | 11             | 5.6%)        | 22 (11.1$)       | 299 (12.4%)                | 210 | 6.6%)               |
| AESI Treated with Systemic Corticosteroids         | 6              | 4.68)        | 21 (10.6%)       | 373 (15.4)                 | 247 | (7.8%)              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Immune-Related Rash                                        | 20 (10.2%)   | 37 (18.7%)   | 616 (25.48) 277   | 620 (19.58)   |
|------------------------------------------------------------|--------------|--------------|-------------------|---------------|
| Immune-Related Hypothyroidism                              | 1 (0.5%)     | 25 (12.6%)   | (11.4%)           | 164 (5.2%)    |
| Immune-Related Hepatitis (Diagmosis and Lab Abnormalities) | 9 4.6%)      | 14 (7.1%)    | 345 (14.38)       | 343 (10.8%)   |
| Immune-Related Hepatitis (Lab Abnormalities)               | 9 4.68)      | 14 7.1%)     | 315 (13.0%)       | 315 9.98)     |
| Immune-Related Hyperthyroidism                             | 5 2.68)      | 11 5.6%)     | 91 3.8%)          | 30 0.9%)      |
| Infusion-Related Reactions                                 | 10 5.1)      | 11 5.6%)     | 70 2.98)          | 34 1.1)       |
| Immune-Related Pneumonitis                                 | 5 2.68)      | 4 2.0%)      | 134 5.5%)         | 87 2.7%)      |
| Immune-Related Colitis                                     | 0            | 3 1.5%)      | 38 1.6%)          | 34 1.1)       |
| Immune-Related Severe Cutaneous Reactions                  | 0            | 2 1.0%)      | 19 0.8%)          | 22 0.7%)      |
| Rhabdomyolysis                                             | 0            | 2 1.0%)      | 5 0.2%)           | 5 0.2%)       |
| Immune-Related Diabetes Mellitus                           | 0            | 1 0.5%)      | 16 0.7%)          | 11 0.3%)      |
| Immune-Related Guillain-Barre Symdrome                     | 0            | 1 0.5%)      | 2 (<0.1%)         | 5 0.2%)       |
| Immune-Related Hypophysitis                                | 0            | 1 0.5%)      | 7 0.3%)           | 2 (<0.1%) 3   |
| Immune-RelatedNephritis                                    | 1 (0.5%)     | 1 0.5%)      | 12 0.5%)          | (<0.1%)       |
| Immune-Related Pancreatitis                                | 2 (1.0%)     | 1 0.5%)      | 17 0.7%)          | 18 0.6%)      |
| Autoimmune Hemolytic Anemia                                | 0            | 0            | 6 0.2%)           | 4 0.1%)       |
| Immune-Related Adrenal Insufficiency                       | 2 (1.0%)     | 0            | 18 0.7%)          | 12 0.4%)      |
| Immune-Related Encephalitis                                | 0            | 0            | 3 0.1%)           | 2 (<0.1%)     |
| Immune-Related Hepatitis (Diagmosis)                       | 0            | 0            | 44 1.8%)          | 62 2.0%)      |
| Immune-RelatedMeningitis                                   | 0            | 0            | 7 0.3%)           | 11 0.3%)      |
| Immune-Related Meningoencephalitis                         | 0            | 0            | 10 0.4%)          | 13 0.4%)      |
| Immune-Related Myasthenia Gravis                           | 0            | 0            | 0                 | 1 (<0.1%)     |
| Immune-Related Myocarditis                                 | 0            | 0            | 1 (<0.1%)         | 0             |
| Immune-Related Myositis                                    | 0            | 0            | 6 0.2%)           | 8 0.38)       |
| Inmune-Related Ocular Inflammatory Toxicity                | 0            | 0            | 7 0.3%)           | 16 0.5%)      |
| Immune-Related Vasculitis                                  | 1 (0.5%)     | 0            | 6 0.2%)           | 7 0.2%)       |
| Systemic Immune Activation                                 | 0            | 0            | 1 (<0.1%)         | 2 (<0.1%)     |

Table 56: Summary of safety information for important AESIs for atezolizumab (IMpower 133 safety evaluable population)

<!-- image -->

|                                               | Severlty          | Severlty         | Severlty   |                     |                                                  |                                             | All Grades AESls                   | All Grades AESls requlring the   |
|-----------------------------------------------|-------------------|------------------|------------|---------------------|--------------------------------------------------|---------------------------------------------|------------------------------------|----------------------------------|
| Important AESI (Atezo +CE N=198) (39.9%)      | All Grades        |                  | Grade 5    | Resolved All Grades | Medlan time to onset All Grades (months) (range) | Median duratlon All Grades (months) (range) | leading to atezolizumab withdrawal | use of cortleosterolds (ImAEs)   |
|                                               | Alezu 1CE         | Alezo +CE        | Alezo +CE  | Alezo 1CE           | Alezo 1CE                                        | Alezu tCE                                   | Alezu tCE                          | Alezo1CE                         |
| Immune-Related                                |                   |                  |            |                     |                                                  |                                             |                                    |                                  |
| Hypothyroidism                                | 25 (12.6%)        | 0                | 0          | 8 (32.09)           | 4.21 (1.7-11.3)                                  | NE (0-12*)                                  | 0                                  | 1 (0.6%)                         |
| Hepatitis (Diagnoss & I abaratory Ahnnrmalty? | 14 (7.1%)         | 3(1.5%)          | 0          | 10 (71.4%)          | 1.49 (0.2-6.5)                                   | 0.7 (0*-4)                                  | 1(0.5%)                            | 6 (2.0%)                         |
| Hepatis (Disgnosis)                           | 0                 | 0                | 0          | 0                   | NE (NE-NE)                                       | NE (NE)                                     | 0                                  | 0                                |
| Hepatiis (Laboralory Abnomaliyi               | 14 (7.1%)         | 3(1.5%)          | 0          | 10 (71.4%)          | 1.49 (0.2 6.5)                                   | 0.7 (0*.4)                                  | 1 (0.5%)                           | 6 (2.0%)                         |
| Hyperthynediem                                | 11 (5 6%)         |                  |            | 10 (90 95)          | 2 10 (0 3-4 6)                                   |                                             | I                                  | 1 (10 5%)                        |
| Infiusion-Related Reaciong                    | 11 (5.6%)         | 4 (20%)          |            | 11 (1008)           | 072 (0.0-33)                                     |                                             | 4 (2 0%)                           |                                  |
| Pneumonik                                     | 4 [2.0%]          | 1 (0.5%)         |            | 2 (40.0%)           | 2 18 (0.5-4.0)                                   | NF (-II°)                                   | I                                  | 2(1.0%)                          |
| Colitis Guilain-Bare Syndrome                 | 3 (1.5%) 1 [0.6%) | 2 (1.0%) 1[0.5%) | 0 0        | 3 (100%) 0          | 0.95 (0.3.1.6) 3.65 (3.6.3.6)                    | 0.7 (0-1) NE (4*.4*)                        | 0                                  | 3(1.5%) 0                        |
| Pancrealis                                    | 1 (0.5%)          | 1 (0.5%)         | 0          | 1(100%)             | 0.13 (0.1-0.1)                                   | 0.6 (1-1)                                   | 0                                  | 0                                |
| Diahetes Melihus                              | 1 (05%)           |                  |            |                     | 276 (7 8.7 8)                                    | NF (18*-48*)                                | I                                  | 1 (11 .58)                       |
| Hypophysitis                                  | 1 (0.5%)          | 0                | 0          | 1(100%)             | 17.54 (17.5-17.5)                                | 0.5 (0·0)                                   |                                    | 0                                |
| Nephritis                                     | 1 (0.5%)          | 1(0.5%)          | 0          | 1(100%)             | 9.40 (9.4-9.4)                                   | 0.6 (1-1)                                   | 1(0.5%)                            | 1(0.5%)                          |
| Adrenal lnsulfitiency                         | 0                 |                  |            | 0                   |                                                  |                                             | 0                                  |                                  |
|                                               |                   | 0                | 0          |                     | NC (NC NC)                                       | NC (NC)                                     |                                    | 0                                |

<div style=\"page-break-after: always\"></div>

## Immune-related AEs

Immune-related hypothyroidism across IMpower133, Atezo+Chemo Combo and Atezo Mono Populations:

Table 57: Summary of immune-related hypothyroidism (safety evaluable population)

|                                                              |                            | Impower133     | Impower133       |                           |                             |
|--------------------------------------------------------------|----------------------------|----------------|------------------|---------------------------|-----------------------------|
| AE of Special Interest Medical Concept MedDRA Preferred Term | Grade                      | PBO+CE (N=196) | Atezo+CE (N=198) | Atezo+ChemoCombo (N=2421) | Atezo Mono (N=3178)         |
| EUTHYROID SICK SYNDROME                                      | - Any Grade 1 or 2         | 0 0            | 0 0              | 1 (<0.1%) 1 (<0.1%)       | 1 (<0.1%) 1 (<0.1%)         |
| GOITRE                                                       | Any Grade 1 or 2           | 0 0            | 0 0              | 2 (<0.1%) 2 (<0.1%)       | 0 0                         |
| MYXOEDEMA                                                    | Any_Grade                  | 0 0            | 0 0              | 0 0                       | 1 (<0.1%) 1 (<0.1%)         |
| MYXOEDEMA COMA                                               | 1 or2 一 Any Grade 3 or 4   | 0 0            | 0 0              | 1 (<0.1%) 1 (<0.1%)       | 0 0                         |
| THYROID FUNCTION TEST ABNORMAL                               | Any Grade 1 or 2           | 0 0            | 0 0              | 0 0                       | 1 (<0.1%) 1 (<0.1%)         |
| THYROIDITIS ACUTE THYROXINEDECREASED                         | Any_Grade 1 or 2 Any_Grade | 0 0 0          | 0 0 0            | 0 0 0                     | (<0.1%) 1 (<0.1%) 1 (<0.1%) |
| THYROXINEFREEDECREASED                                       | 1 or 2 Any_Grade or2       | 0 0 0          | 0 0 0            | 0 2 (<0.1%) 2 (<0.1%)     | 1 (<0.1%) 0 0               |
| THYROXINE INCREASED                                          | Any Grade 1 or2            | 0 0            | 0 0              | 2 (<0.1%) 2 (<0.1%)       | 0 0                         |
| TRI-IODOTHYRONINEABNORMAL                                    | Any _Grade                 | 0              | 0                | 1 (<0.1%)                 | 0                           |
|                                                              | 1 or2                      | 0              | 0                | 1 (<0.1%)                 | 0 0                         |
| TRI-IODOTHYRONINE DECREASED                                  | Any_Grade 1 or 2           | 0 0            | 0 0              | 1 (<0.1%) 1 (<0.1%)       | 0                           |
| TRI-IODOTHYRONINE FREEDECREASED                              | Any Grade                  | 0              | 0                | (<0.1%)                   | 0                           |
|                                                              | 1 or 2                     | 0              | 0                | (<0.1%)                   | 0                           |

Investigator text for Aes encoded using MedDRA v21.o. All counts represent patients. Multiple occurrences of the same AE in one individual are counted once at the highest grade for this patient. To the'AE of Special Interest Medical Concept' Overall row column headings. All treatment emergent Aes are included. Adverse events with missing grade are not included. Sort order is by decreasing frequency in Atezo+cE treatment arm.

Atezo=Atezolizumab, PBO=Placebo, CE=Carboplatin+Etoposide.Atezo+Chemo Combo: GO29537 (IMPOWER130) Arm A + GO29437 (IMPOWER131） Arm

(POPLAR)+ GO28754(BIRCH)+GO28625（FIR）+ GO27831(PCD4989g-A11 Coh0rtS）+ GO29293（IMVIGOR210)+ GO29294 (IMVIGOR211）+ WO29074 (IMMOTION150 Arm B).Clinical 1Cut-0ff dateS: G027831:31MAR2016，G028625:07JAN2015，GO28753:01DEC2015，GO28754:01DEC2015, GO29293:04JUL2016，G028915:07JUL2016， ：GO29294:13MAR2017，GO29436:22JAN2018，GO29437:20APR2018，GO29438:22MAY2018，GO29537:15MAR2018， GO30081:24APR2018， WO29074:170CT2016.

Immune-related hepatitis across IMpower133, Atezo+Chemo Combo and Atezo Mono Populations:

Table 58: Summary of immune-related hepatitis (safety evaluable population)

|                                                                    |       |            | IMpower133     | IMpower133       |                            |                     |
|--------------------------------------------------------------------|-------|------------|----------------|------------------|----------------------------|---------------------|
| AE ofSpecialInterestMedicalConcept MedDRA Preferred Term           | Grade |            | PBO+CE (N=196) | Atezo+CE (N=198) | Atezo+Chemo Combo (N=2421) | Atezo Mono (N=3178) |
| IMMUNE-RELATEDHEPATITIS(DIAGNOSIS) -Overall-                       |       | Any Grade  | 0 0            | 0                | 44 (1.8%)                  | 62 (2.0%)           |
|                                                                    | 1     | or2        |                | 0                | 24 (1.0%)                  | 35 (1.1%)           |
|                                                                    | 3     | or4        | 0              | 0                | 17 (0.7%)                  | 25 (0.8%)           |
|                                                                    | 5     |            | 0              | 0                | 3(0.1%)                    | 2 (<0.1%)           |
| IMMUNE-RELATEDHEPATITIS(LABABNORMALITIES) Overall                  |       | -Any Grade | 9 4.6%)        | 14 (7.1%)        | 315 (13.0%)                | 315 (9.9%)          |
|                                                                    | 1     | or2        | 9 4.6%)        | 11 5.6%)         | 228 (9.4%)                 | 6.48)               |
|                                                                    | 3     | or4        | 0              | 3 (1.5%)         | 86 (3.6%)                  | 204 111 3.5%)       |
|                                                                    | 5     |            | 0              | 0                | (<0.1%)                    | 0                   |
| IMMUNE-RELATED HEPATITIS(DIAGNOSIS AND LAB ABNORMALITIES) -Overall |       | Any Grade  | 9 4.6%)        | 14 7.1%)         | 345 (14.3%)                | 343 (10.8%)         |
|                                                                    | 1     | or2        | 9 4.6%)        | 11 ( 5.6%)       | 241 (10.0%)                | 213 (6.7%)          |
|                                                                    | 3     | or 4       | 0              | 3 1.5%)          | 100 (4.1%)                 | 128 (4.0%)          |
|                                                                    | 5     |            | 0              | 0                | 4 (0.2%)                   | 2 (<0.1%)           |

patients. Multiple occurrences of the same AE in one individual are counted once at the highest grade for this patient. To the 'AE of Special Interest Medical Concept'overall row counts,a patient contributes only with the AE occurring with the highest grade within the Soc.Percentages are based on N in the column headings.All treatment emergent AEs are included.Adverse events with missing grade are not included.Sort order is by decreasing frecquency in Atezo+CE treatment arm.Atezo=Atezolizumab,PBO=Placebo,CE=Carboplatin+Etoposide.Atezo+Chemo Combo:GO29537（IMPoWER130)ArmA+ GO29437 B).C1inical CUt-0ff dateS:GO27831:31MAR2016，G028625:07JAN2015，GO28753:01DEC2015，GO28754:01DEC2015，G029293:04JUL2016，GO28915:07JUL2016， GO29294:13MAR2017，G029436:22JAN2018，G029437:20APR2018，G029438:22MAY2018,G029537:15MAR2018，G030081:24APR2018，WO29074:170CT2016.Pr0gram:

<div style=\"page-break-after: always\"></div>

Immune-related hyperthyroidism across IMpower133, Atezo+Chemo Combo and Atezo Mono Populations:

Table 59: Summary of immune-related hyperthyroidism (safety evaluable population)

|                                                              |                                   | IMpower133         | IMpower133           |                                                            |                                                   |
|--------------------------------------------------------------|-----------------------------------|--------------------|----------------------|------------------------------------------------------------|---------------------------------------------------|
| AE of Special Interest Medical Concept MedDRA Preferred Term | Grade                             | PBO+CE (N=196)     | Atezo+CE (N=198)     | Atezo+Chemo Combo (N=2421)                                 | Atezo Mono (N=3178)                               |
| IMMUNE-RELATEDHYPERTHYROIDISM - Overall                      | - Any Grade 1 or2 3 or4 Any Grade | 5 (2.6%) 5 2.6%) 0 | 11 (5.6%) 11 5.6%) 0 | 91 (3.8%) 87 (3.6%) 4 (0.2%) 91 (3.8%) 87 4 (0.2%) 3.6%) 0 | 30 (0.9%) 29 (0.9%) 1 (<0.1%) 27 (0.8%)           |
| HYPERTHYROIDISM                                              | 1 or 2 3 or 4                     | 5 2.6%) 0 5 2.6%)  | 11 5.6%) 11 0 (5.6%) |                                                            | 26 (0.8%)                                         |
| BASEDOW'SDISEASE                                             | - Any Grade 1 or 2 - Any Grade    | 0 0 0 0            | 0 0 0 0              | 0 0                                                        | 1 (<0.1%) 1 (<0.1%) 1 (<0.1%) 1 (<0.1%) 1 (<0.1%) |
| ENDOCRINEOPHTHALMOPATHY EXOPHTHALMOS                         | 1 or2  Any Grade 1 or2            | 0 0                | 0 0                  | 0 0 0                                                      | (<0.1%) (<0.1%)                                   |

Investigator text for AEs encoded using MedDRA v21.0. All counts represent patients. Multiple occurrences of the same AE in one r     , n o i s g counts,a patient contributes onlywith the AE occurring withthe highest grade within the Soc.Percentagesare based on N inthe column headings. All treatment emergent AEs are included. Adverse events with missing grade are not included. Sort order is by decreasing frequency in Atezo+cE treatment arm.

Atezo=Atezolizumab,PBO=Placebo，CE=Carboplatin+Etoposide.Atezo+Chemo Combo:GO29537 (IMPOWER130） Arm A + GO29437 (IMPOWER131） Arm WO29074 (IMMOTION150 Arm B).C1inical cut-off dateS: GO27831:31MAR2016,G028625:07JAN2015，GO28753:01DEC2015，GO28754:01DEC2015, GO29293:04JUL2016，G028915:07JUL2016, ：GO29294:13MAR2017，GO29436:22JAN2018，GO29437:20APR2018，G029438:22MAY2018，GO29537:15MAR2018, GO30081:24APR2018，WO29074:170CT2016.

Immune-related pneumonitis across IMpower133, Atezo+Chemo Combo and Atezo Mono Populations:

Table 60: Summary of immune-related pneumonitis (safety evaluable population)

|                                                              |              | power122        | power122         |                            |                     |
|--------------------------------------------------------------|--------------|-----------------|------------------|----------------------------|---------------------|
| AL of apecial Intoreat Medical Conoept MedDRA Freferred Teim | Grade        | FBOICE (N=196)  | AteEOICE (N=190) | AtesolChemo Combo (N=2421] | Atezo Mono (N=0170) |
| INMINE-RETATED PNEUMONTTIS -Overall                          | 一 Any Grade  | 3 [ 2.64] 1.5%) | 3 4 (2.04) 1.54) | 134 95 5.561 3.95)         | 87 (1.95) (2.74)    |
|                                                              | Or 2         |                 |                  |                            | 59                  |
|                                                              | 0r 4         | 2 1.05)         | 1 0.55)          | 33 1.45)                   | 27 (0.05)           |
|                                                              | 5            | 0               | 0                | 6 0.261                    | 1 (<0.16)           |
| FNEUMONITIS                                                  | Any Grade    | 4 2.061         | 4 (2.06)         | 114 4.761                  | 70 ( 2.26)          |
|                                                              | 1 2          | 2 1.05)         | 3 1.54)          | 80 3.341                   | 44 (1.4)            |
|                                                              | 3 0r 4       | 2 1.09)         | 1 0.51)          | 30 1.29)                   | 25 (0.85)           |
|                                                              | 5            | 0               | 0                | 4 ( 0.26]                  | 1 (c0.16)           |
| AIWEOLAR.IUNG DISEASE                                        | Any_Grade    | 0               | 0                | 1 (c0.16)                  | 0 0                 |
| BRONCHIOLITIS                                                | 1 or 2       | Q               | 0                | 1 (0.16)                   | 2 (<0.15)           |
|                                                              | Any Grada    | 0               | 0                | [<0.1]                     |                     |
|                                                              | 1 or 2       |                 | 0                | 1 [40.14]                  | 2 (40.14)           |
| INTERSTITIAL LUNG DISEASE                                    | Any_Grade    | 0               | 0                | 8 (0.35)                   | 4 (0.19)            |
|                                                              | 1 0r 2       | 0               | 0                | 4 ( 0.25)                  | 3 (00.15)           |
|                                                              | 0r 4         | Q               | 0                | 2 [40.16)                  | 1 (40.16)           |
|                                                              | 5            |                 | 0                | (40.16)                    |                     |
| LING INFIIIRATION                                            | ■ Any _Grade |                 | 0                | 7 0.34)                    | 7 0.24)             |
|                                                              | 1 Or 2       | 0               | 0                | 7 ( 0.35)                  | 6 0.29)             |
|                                                              | 3 0r 4       | 0               | 0                | 0                          | 1 (20.16)           |
| FULHONARY FIEROSIS                                           | Any_Grade    | 0               | 0                | 1 (00.16]                  |                     |
|                                                              | 1 or2        | 0               | 0                | 1 [40.16]                  | 0                   |
| PUTHONARY RADTATTON TNTURY                                   | Any Grads    | 0               | 0                | 1 (40.16)]                 |                     |
|                                                              | 1 or 2       |                 | 0                | 1 [40.14)                  | 0                   |
| RADIATION PNEUHONITIS                                        | -Rny _Grade  | 1 0.5%)         | 0                | 5 [0.20)                   | 4 (0.15)            |
|                                                              | 1 2          | 1 0.561         | 0                | 4 10.25]                   | 0.15)               |
|                                                              |              |                 | 0                | 1 [<0.14)                  |                     |

3 or 4

<div style=\"page-break-after: always\"></div>

Immune-related colitis across IMpower133, Atezo+Chemo Combo and Atezo Mono Populations:

Table 61: Summary of immune-related colitis (safety evaluable population)

|                                                              |                    | IMpower133     | IMpower133                                  |                   |                     |
|--------------------------------------------------------------|--------------------|----------------|---------------------------------------------|-------------------|---------------------|
| AE of Special Interest Medical Concept MedDRA Preferred Term | Grade              | PBO+CE (N=196) | Atezo+CE Atezo+Chemo Combo (N=198) (N=2421) |                   | Atezo Mono (N=3178) |
| IMMUNE-RELATED COLITIS Overall                               |                    |                |                                             |                   |                     |
|                                                              | 1 or2              | 0              |                                             |                   |                     |
|                                                              | Any Grade          |                | 3 1.5%)                                     | 38 (1.6%)         | 34 (1.1)            |
|                                                              |                    | 0              | 1 0.5%)                                     | 14 (0.6%)         | 16 ( 0.5%)          |
| COLITIS                                                      | 3 or 4             | 0 0            | 2 1.0%) 2                                   | 24 (1.0%)         | 18 ( 0.6%)          |
|                                                              | - Any Grade        |                | 1.0%)                                       | 31 (1.3%)         | 30 0.9%)            |
|                                                              | 1or2               | 0              | 0 2                                         | 11 0.5%)          | 15 (0.5%)           |
|                                                              | 3 or 4             | 0              | 1.0%)                                       | 20 0.8%)          | 15 (0.5%)           |
| AUTOIMMUNE COLITIS                                           | Any Grade          | 0              | 0.5%)                                       | 5 0.2%)           | 2 (<0.1%)           |
|                                                              | 1 or 2             | 0              | 1 1 (0.5%)                                  | 2 (<0.1%)         | 0 2 (<0.1%)         |
|                                                              | 3 or 4             | 0              | 0                                           | 3 (0.1%)          | 1 (<0.1%)           |
| COLITIS ISCHAEMIC                                            | - Any Grade        | 0              | 0                                           | 0                 |                     |
|                                                              | 3or4               | 0              | 0                                           | 0                 | 1 (<0.1%)           |
| COLITIS MICROSCOPIC                                          |                    | 0              | 0                                           | 2                 | 1                   |
|                                                              | - Any Grade 1 or 2 |                |                                             | (<0.1%) 1 (<0.1%) | (<0.1%) 1 (<0.1%)   |
|                                                              |                    | 0              | 0                                           |                   | 0                   |
|                                                              | 3 or 4             | 0              | 0                                           | 1 (<0.1%)         |                     |
| COLITIS ULCERATIVE                                           |                    | 0              | 0                                           | 0                 | 1 (<0.1%)           |
|                                                              | - Any Grade        |                |                                             |                   |                     |
|                                                              | 3 or4              | 0              | 0                                           | 0                 | (<0.1%)             |

e    ii individual are counted once at the highest grade for this patient. To the 'AE of Special Interest Medical Concept' Overall row counts,a patient contributes only with the AE occurring with the highest grade within the Soc. Percentages are based on N in the column headings.All treatment emergent AEs are included.Adverse events with missing grade are not included.Sort order is by decreasing frequency in Atezo+CE treatment arm.

Atezo=Atezolizumab，PBO=Placebo，CE=Carboplatin+Etoposide.Atezo+Chemo Combo:GO29537 (IMPOWER130） Arm A + GO29437 (IMPOWER131） Arm A+B + GO29436 (IMPOWER150） Arm A+B + GO29438 (IMPOWER132） Arm A + GO30081 (IMPOWER133） Arm A.AteZO Mono:GO28915 (OAK) + GO28753 (POPLAR) + GO28754\\_(BIRCH) + GO28625\\_(FIR) + GO27831 (PCD4989g - A11 Coh0rtS) + GO29293 (IMVIGOR210) + GO29294 (IMVIGOR211)+ WO29074 (IMMOTION150 Arm B).\\_Clinical cut-off dateS: GO27831:31MAR2016, G028625:07JAN2015， GO28753:01DEC2015， GO28754:01DEC2015, GO29293:04JUL2016，G028915:07JUL2016, GO29294:13MAR2017，GO29436:22JAN2018，GO29437:20APR2018，GO29438:22MAY2018，GO29537:15MAR2018, GO30081:24APR2018，WO29074:170CT2016.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

Table 62: Summary of clinically relevant laboratory shifts from baseline

<!-- image -->

|                                      | PBO+CE         | Atezo+CE       |
|--------------------------------------|----------------|----------------|
| Hematology                           |                |                |
| Hemoglobin (high)                    | 3/194 (1.5%)   | 3/193 (1.6%)   |
| Hemoglobin (low)                     | 36/194 (18.6%) | 32/193 (16.6%) |
| Lymphocytes Abs (hlgh)               | 0              | 1/193 (0.5%)   |
| Lymphocytes Abs (low)                | 16/195 (8.2%)  | 26/193 (13.5%) |
| Neutrophils, Total, Abs (low)        | 92/196 (46.9%) | 87/192 (45.3%) |
| Platelet (low)                       | 32/195 (16.4%) | 39/193 (20.2%) |
| Intemational normalized ratio (hlgh) | 0              | 1/95 (1.1%)    |
| White Blood Cell Count (high)        | 0              | 1/193 (0.5%)   |
| White Blood Cell Count (low)         | 39/195 (20.0%) | 45/193 (23.3%) |
| Chemistry                            |                |                |
| Albumin (low)                        | 0              | 2/187 (1.1%)   |
| Alkaline phosphatase (high)          | 4/193 (2.1%)   | 2/193 (1.0%)   |
| ALT (high)                           | 2/194 (1.0%)   | 6/193 (3.1%)   |
| AST (high)                           | 3/193 (1.6%)   | 2/192 (1.0%)   |
| Calclum (high)                       | 2/195 (1.0%)   | 3/192 (1.6%)   |
| Calclum (low)                        | 8/195 (4.1%)   | 5/192 (2.6%)   |
| Creatinine (high)                    | 1/195 (0.5%)   | 8/193 (4.1%)   |
| Glucose (low)                        | 4/195 (2.1%)   | 1/192 (0.5%)   |
| Magneslum (hlgh)                     | 5/191 (2.6%)   | 5/185 (2.7%)   |
| Magnesium (low)                      | 7/191 (3.7%)   | 2/185 (1.0%)   |
| Phosphorus (low)                     | 4/191 (2.1%)   | 3/183 (1.5%)   |
| Potassium (high)                     | 1/195 (0.5%)   | 2/193 (1.0%)   |
| Potasslum (low)                      | 7/195 (3.6%)   | 6/193 (3.1%)   |
| Sodlum (high)                        | 0              | 1/193 (0.5%)   |
| Sodium (low)                         | 15/195 (7.7%)  | 18/193 (9.9%)  |
| Bilirubin (high)                     | 2/195 (1.0%)   | 3/193 (1.6%)   |

Note: A clinlcally relevant shift Is delined as a shlift from Grade 0, 1, or 2 at basellne to Grade 3 or 4 post-baseline.

Table 63: Thyroid stimulating hormone, safety evaluable patients

<!-- image -->

|                            | Post-    |                      |       |              |      |                |
|----------------------------|----------|----------------------|-------|--------------|------|----------------|
|                            | Baseline |                      |       |              |      |                |
| Treatment:                 | Status   | Normal               |       | High         |      | Low            |
| PBO +CE (Actual) (N=196)   | Normal   | 127/167(76.08)       |       | 7/23(30.48)  |      | 2/6 ( 33.38)   |
|                            | High     | 4.28)                | 11/23 | (47.88)      |      | 0/6（0.08)      |
|                            | Low      | 7/167( 20/167(12.08) | 2/23  | ( 8.78)      |      | 4/6(66.78)     |
|                            | Total    | 154/167(92.28)       | 20/23 | (87.08)      |      | 6/6(100.08)    |
| Atezo + CE （Actual)（N=198) | Normal   | 99/170(58.28)        | 6/15  | (40.08)      | 3/12 | （25.08)        |
|                            | High     | 28/170(16.58)        | 7/15  | (46.78)      | 1/12 | ( 8.381        |
|                            | Low      | 41/170(24.18)        | 1/15  | (6.78)       | 7/12 | 58.38)         |
|                            | Total    | 168/170(98.88)       |       | 14/15(93.38) |      | 11/12 ( 91.78) |

Hy's law: Hy's law cases were defined in the study protocol as elevated ALT or AST ( &gt; 3 x baseline value) in combination with either an elevated total bilirubin ( &gt; 2 x ULN) or clinical jaundice in the absence of cholestasis or other causes of hyperbilirubinemia. One patient in the Atezo + CE arm had laboratory abnormalities suggestive of a Hy's law case. This patient developed changes in liver function tests after 1 cycle of Atezo + CE, which was confounded by his liver metastasis at enrollment. Atezolizumab was permanently discontinued and chemotherapy was interrupted, and the patient received treatment with systemic corticosteroids, after which his liver function tests followed a downward trend. No further atezolizumab re-challenge was conducted. The positive dechallenge and the laboratory improvement after steroid treatment were indicative of an immune-related etiology and not drug induced liver injury. This patient had AESI of transaminases increased.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

Safety in special groups and populations was pooled for the Atezo + Chemo Combo (the 'lung-pool') trials:

## Safety by age:

Table 64: Overview of safety by age (safety evaluable population)

|                                                                      | ntezoichemo Combo (N-2421)   | ntezoichemo Combo (N-2421)   | ntezoichemo Combo (N-2421)   | ntezoichemo Combo (N-2421)   | ntezoichemo Combo (N-2421)   | ntezoichemo Combo (N-2421)   | ntezoichemo Combo (N-2421)   | ntezoichemo Combo (N-2421)   | ntezoichemo Combo (N-2421)   |
|----------------------------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                                                      | 65 (N=1251)                  | 65 (N=1251)                  | =65 (N=1170)                 | 65 - 74 (N=927)              | 65 - 74 (N=927)              | 75 - 84 (N=234)              | >=85 (N=9)                   |                              |                              |
| Total number of patients with at least one AE Total number of Events | 1237(98.9%) 17852            | 1237(98.9%) 17852            | 1151 (98.4%) 17236           | 909(98.1%) 13144             | 909(98.1%) 13144             | 233(99.6%) 3977              | 9(100%) 115                  |                              |                              |
| Total muuber of patients with at least one TreaLmenl-relaled AE      |                              | 1169(93.4%)                  | 1110(94.96)                  | 875                          | (94.46)                      | 226 (96.66)                  | 9 （1006)                     |                              |                              |
| Atezo-related AE                                                     | 668                          | (71.98)                      | 840(71.8*)                   | 650                          | (70.1*)                      | 184 (78.68)                  | 6 (66.78]                    |                              |                              |
| Grade 3-4 AE                                                         | 802                          | (64.1%)                      | 798168.251                   | 617                          | (66.6%)                      | 174 (74.4%)                  | 7 (77.8%)                    |                              |                              |
| Treatment-related Grade 3-4 AE                                       | 673                          | (48'65)                      | 707(60.4%)                   | 542                          | (49'89)                      | 159 16*19)                   | 6 (66.7%)                    |                              |                              |
| Atezo-related Grade 3-4 AE                                           | DEE                          | (26.48)                      | 328(28.08)                   | 255                          | (27.58)                      | 70 (29.98)                   | 3 [33.38)                    |                              |                              |
| Grade5AE                                                             | 61                           | (%6')                        | 831 7.19!                    | 67                           | (7.2%)                       | 14 (6.0%)                    | (22.29)                      |                              |                              |
| Treatment-related Grade 5 NE                                         | 23                           | 1.8%)                        | 277 2.391                    | 63                           | 12.54]                       | 3 11.341                     | 1 (11.1%)                    |                              |                              |
| Atezo-relatcd Grade 5 AE                                             | 16                           | (1.36)                       | 15 ( 1.36)                   | 12                           | (1.36)                       | 3 (1.31) (52.19)             | 0                            |                              |                              |
| Serious AE                                                           | 507                          | (40.5%)                      | 566(48.4%)                   | 439                          | (47.49)                      | 122                          | 5 (55.6%)                    |                              |                              |
| Trealmenl-related serious AE                                         | 281                          | (22.56)                      | 298 (25.55)                  | 238                          | (25.76)                      | 57                           | 3 (33.36)                    |                              |                              |
|                                                                      | 184                          | (14.7%)                      | 176 (15.05)                  | 141                          | (15.2)                       | (24.46) 34 (14.5%)           | 1 (11.1%)                    |                              |                              |
| AE leading to Treatment withdrawal                                   | 264                          | (21.1$)                      | 324 (27.78)                  | 254                          | (27.48)                      | 67 (28.68)                   | 3 (33.38)                    |                              |                              |
| AE leading to Atezo withdrawal                                       | 144                          | (11.5%)                      | 175 (15.0%)                  | 139                          | (40'91)                      | (14.1%)                      | 133.3%)                      |                              |                              |
| AE leading to Treatment modification/interruption                    | 806                          | (64.4%)                      | 802 (68.54)                  | 623                          | (67.24)                      | 173                          | 6 (66.7%)                    |                              |                              |

## Safety by gender:

Table 65: Overview of safety by gender (safety evaluable population)

|                                                   | Atezo+Chemo Combo (N=2421)   | Atezo+Chemo Combo (N=2421)   | Atezo+Chemo Combo (N=2421)   | Atezo+Chemo Combo (N=2421)   |
|---------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                                   | Female (N-812)               | Female (N-812)               | Male (N-1609)                | Male (N-1609)                |
| Total number of patients with at least one AE     |                              | 802(98.88) 13605             | 1586 (98.68) 21483           | 1586 (98.68) 21483           |
| Total number of patients with at least one        |                              |                              |                              |                              |
| Treatment-related AE                              |                              | 779(95.96)                   |                              | 1500(93.2%)                  |
| Atezo-related AE                                  | 603                          | (74.34)                      | 1136                         | (70.6%)                      |
| Grade 3-4 AE                                      | 573                          | (70.66)                      | 1027                         | (63.86)                      |
| Treatment-relatedGrade3-4 AE                      | 508                          | (62.65)                      | 872                          | (54.25)                      |
| Atezo-related Grade 3-4 AE                        | 249                          | (30.7%)                      | 409                          | (25.4%)                      |
| Grade 5 AE                                        | 33                           | (4.18)                       | 111                          | 6.98)                        |
| Treatment-related Grade 5 AE                      | 15                           | (1.84)                       | 35                           | 2.24)                        |
| Atezo-relatedGrade5 AE                            | 10                           | [1.29)                       | 21                           | (1.38)                       |
| Serious AE                                        | 378                          | (46.68)                      | 695                          | (43.28)                      |
| Treatment-related Serious AE                      | 208                          | (25.6%)                      | 371                          | (23.1%)                      |
| Atezo related serious AE                          | 128                          | (15.88)                      | 232                          | (14.48)                      |
| AE leading to Treatment withdrawal                | 186                          | (22.98)                      | 402                          | (25.08)                      |
| AE leading to Atezo withdrawal                    | 90                           | (11.1%)                      | 229                          | (14.29)                      |
| AE leading to Treatment modification/interruption | 582                          | (71.78)                      |                              | 1026 (63.88)                 |

<div style=\"page-break-after: always\"></div>

## Safety by race:

## Table44: Overview of safety by race (safety evaluable population)

|                                                   | Atezo+Chemo Combo (N=2421)   | Atezo+Chemo Combo (N=2421)   | Atezo+Chemo Combo (N=2421)   | Atezo+Chemo Combo (N=2421)   | Atezo+Chemo Combo (N=2421)   | Atezo+Chemo Combo (N=2421)   | Atezo+Chemo Combo (N=2421)   | Atezo+Chemo Combo (N=2421)   |
|---------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                                   | White (N1986)                | White (N1986)                | Black (N-39)                 | Black (N-39)                 | Asian (N293)                 | Asian (N293)                 |                              |                              |
| Total number of Events                            | 1956(98.5%)                  | 1956(98.5%)                  |                              | 39( 100号) 817                | 291(99.38) 4694              | 291(99.38) 4694              | 102 (99.0%) 1533             |                              |
| Total number of patients with at least one        |                              |                              |                              |                              |                              |                              |                              |                              |
| Treatment-related AE                              |                              | 1863(93.86)                  | 37                           | (66*46)                      | 284                          | (96.94)                      | 95(92.29)                    |                              |
| Atezo-related AE                                  | 1385                         | (69.76)                      | 30                           | (76.96)                      | 248                          | (84.66)                      | 76 (73.86)                   |                              |
| Grade 3-4 AE                                      | 1271                         | (64.0%)                      | 26                           | (66.75)                      | 232                          | (79.2%)                      | 71 (68.9%)                   |                              |
| Treatment-related Grade 3-4 AE                    | 1081                         | (54.4%)                      | 23                           | (59.0号)                      | 218                          | (74.4号)                      | 58 (56.3%)                   |                              |
| Atezo-related Grade 3-4 AE                        | 493                          | (24.86)                      | 11                           | (28.29)                      | 126                          | (43.0%)                      | 28 (27.20)                   |                              |
| Grade 5 ME                                        | 126                          | 6.3%1                        | E                            | (7.75)                       | 10                           | 3.4%)                        | 5 (4.9%)                     |                              |
| Treatment-related Grade 5 ME                      | 40                           | 2.0%)                        | 1                            | (2.66)                       | 8                            | 2.76)                        | 1 (1.0%)                     |                              |
| Atezo-relatedGrade 5AE                            | 23                           | ( 1.26)                      | 1                            | (2.66)                       | 6                            | (2.06)                       | 1 (1.09)                     |                              |
| Serious AE                                        | 873                          | (44.0%)                      | 20                           | (51.38)                      | 136                          | (46.46)                      | 44 (42.7)                    |                              |
| Treatment-related serious AE                      | 455                          | (22.9%)                      | 10                           | (25.6号)                      | 68                           | (30.4%)                      | 25 (24.3%)                   |                              |
| Atezo-related serious AE                          | 266                          | (13.4%)                      | 7                            | (17.99)                      | 70                           | (23.9%)                      | 17 (16.5%)                   |                              |
| AE leading to Treatment withdrawal                | 474                          | (23.96)                      | 8                            | (20.56)                      | 81                           | (27.66)                      | 25 (24.39)                   |                              |
| nE leading to Nlezo withdrawal                    | 253                          | (12.7%)                      | 5                            | (12.85)                      | 49                           | (16.7%)                      | 12 (11.7%)                   |                              |
| nE leading to Treatment modification/interruption | 1302                         | (65.6%)                      | 28                           | (71.85)                      | 211                          | (72.0%)                      | 67 (65.0%)                   |                              |

## Safety by region:

Table 67: Overview of safety by region (safety evaluable population)

<!-- image -->

|                                               | Rsia-Pacific (N=264)   | nustralia (N=102)   | Central and South hmerica Europe and Middle East North Hmerica (W-118)   | (N=1315)      | (N=622)     |
|-----------------------------------------------|------------------------|---------------------|--------------------------------------------------------------------------|---------------|-------------|
| Totalmumber of patiento with at least LIIE AE | 263 (99.61)            | 101199.0%)          | 117(99.24)                                                               | 1461618821    | 619 (99.5%) |
| Total number ot Events                        | 4087                   | 1574                | 8891                                                                     | 16250         | 11589       |
| Total number of patienta with at least one    |                        |                     |                                                                          |               |             |
| Troatmont-rolatod An                          | 258 (97.76)            | 99(96.16)           | 110(93.24)                                                               | 1213(92.26)   | 600(96.56)  |
| Ntezo related NE                              | 227 (60'98]            | 69 (49*19)          | 70 165'65)                                                               | 887(67.5%)    | 486 (78.1)  |
| Grade34NG                                     | 602 (79.28)            | 67 [65.76)          | 65 55.1%1                                                                | 808 (61.49)   | 451         |
| TreaLmenL-relaLed Grade 3-4 AE                | 66T (75.46]            | 55 (53.96)          | 53 [44.94)                                                               | 605 (52.18)   | 300 (62.46) |
| Atezo-related Grade 3-4 AE                    | 116                    | 21 [20.6%)          | 1'T                                                                      | 988 1%9*92)   | 168 127.0%) |
| Grade b AE                                    | 11 4.281               | (46*1               | 1'T I4b*+1)                                                              | E1 (b.6%1     | 16.1%1      |
| Treatment-related Grade 5 TE                  | 8                      | 0                   | 6 (5.1]                                                                  | 29 (2.28)     | [1.1$]      |
| Atozn-melatodGradn5AF                         | 6 [2.36]               | 0                   | 4 (3.48)                                                                 | 17 (1.38)     | 4 [0.66]    |
| Serlous NE                                    | 116 (46'51)            | 60 (58.8)           | 41 142'19)                                                               | 552 (42.0%)   | 301 (48.4*) |
| Treatment related serious nE                  | 81 (4L'02)             | 31 [30.4b)          | 21                                                                       | 331 (25.2%)   | 115 (4G'87) |
| ALezu-relaled seriuus AE                      | 66 (25.06)             | 19 (10.66)          | 10 (0.56)                                                                | 205 (15.66)   | 60 (9.66)   |
| AE leadinq to Treatment withdrawal            | F.1. [27.74]           | 24 (49'67)          | 24 [6E'02)                                                               | Z.LF 1%1.'82] | 155         |
| AE leadinq to Atezo withdrawal                | 45 [17.0%]             | 13 112.7%)          | 16 149*81)                                                               | 16T (12.7%)   | Af. 112.b%) |
| nE leading to Treatment                       | 190 (72.0%)            | 69 (67.69)          | 70 (42'65)                                                               | 825 (62.7)    | 454 (73.0*) |

modi fieafion/intermupt.ion

八

<div style=\"page-break-after: always\"></div>

## Safety by ADA status:

Table 68: Safety summary profile by atezolizumab ADA status (ADA-evaluable atezolizumab patients in safety evaluable population)

<!-- image -->

|                                                                                 | ADA- (N=153)   | ADA- (N=153)   | ADA+ (N=35)   | ADA+ (N=35)   |
|---------------------------------------------------------------------------------|----------------|----------------|---------------|---------------|
| Total number of patients with at least one adverse event Total number of events | 153            | (100.0%) 1768  | 35            | (100.0%) 339  |
| Total number of patients with at least one                                      |                |                |               |               |
| Treatment-related AE                                                            | 147            | 96.14)         | 33            | (94.3%)       |
| Any Treatment                                                                   | 147            | 96.14)         | 33            | 94.36)        |
| Atezolizumab/Placebo                                                            | 102            | 66.74)         | 21            | 60.0%)        |
| Grade 3-4 AE                                                                    | 107            | 1%6'69         | 22            | 62.9%)        |
| Treatment-related Grade 3-4 AE                                                  | 89             | 58.241         | 20            | 57.1%)        |
| Grade 5 AE                                                                      | 1              | 0.7%1          | 0             |               |
| Treatment-related Grade 5 AE                                                    | 0              |                | 0             |               |
| Serious AE                                                                      | 54             | 35.341         | 14            | 40.04)        |
| AE leading to withdrawal from treatment                                         | 13             | 8.5%1          | 7             | [ 20.0%)      |
| Any Treatment                                                                   | 13             | 8.541          | 7             | 20.04)        |
| Atezolizumab/Placebo                                                            | 12             | 7.841          | 7             | 20.04)        |
| Carboplatin                                                                     | 4              | 2.64)          | 0             |               |
| Etoposide                                                                       |                | 3.34)          | 2             | 5.74)         |
| AE leading to any dose modification/interruption                                | 107            | 69.941         | 26            | 74.34)        |
| Any Treatment                                                                   | 107            | 69.94)         | 26            | 74.34)        |
| Atezolizumab/Placebo                                                            | 90             | 58.841         | 23            | 65.74)        |
| Carboplatin                                                                     | 86             | 56.24)         | 21            | 60.04)        |
| Etoposide                                                                       | 06             | 58.841         | 19            | 54.34)        |

## Safety related to drug-drug interactions and other interactions

No formal pharmacokinetic (PK) drug-drug interaction studies have been conducted with atezolizumab.

## Discontinuation due to adverse events

Table 69: AEs leading to treatment withdrawal (safety evaluable population)

| AEs leading to withdrawal from:                  | Any treatment   | Any treatment   | Atezolizumab/Placebo*   | Atezolizumab/Placebo*   | Carboplatin or Etoposide**   | Carboplatin or Etoposide**   | All treatment   | All treatment   |
|--------------------------------------------------|-----------------|-----------------|-------------------------|-------------------------|------------------------------|------------------------------|-----------------|-----------------|
| MedDRASystemOrganClass MedDRAPreferredTerm       | PBO+CE N=196    | Atezo+CE N=198  | PBO+CE N=196            | Atezo+CE N=198          | PBO+CE N=196                 | Atezo+CE N=198               | PBO+CE N=196    | Atezo+CE N=198  |
| Total number of patients with at least one AE    | 6 (3.1%)        | 22 (11.1%)      | 5 (2.6%)                | 21 (10.6%)              | 2 (1.0%)                     | 8 (4.0%)                     | 1 (0.5%)        | 4 (2.0%)        |
| GASTROINTESTINAL DISORDERS                       | 2 (1.0%)        | 4 (2.0%)        | 1 (0.5%)                | 4 (2.0%)                | 0                            | 0                            | 0               | 1 (0.5%)        |
| Abdominal distension                             | 0               | 1 ( 0.5%)       | 0                       | 1 (0.5%)                | 0                            | 0                            | 0               | 0               |
| Abdominal pain                                   | 1 (0.5%)        | 0               | 0                       | 0                       | 1 (0.5%)                     | 0                            | 0               | 0               |
| Anal haemorrhage                                 | 0               | 1 ( 0.5%)       | 0                       | 1 ( 0.5%)               | 0                            | 0                            | 0               | 0               |
| Diarrhoea                                        | 1 (0.5%)        | 0               | 0                       | 0                       | 1 (0.5%)                     | 0                            | 0               | 0               |
| Gastritis                                        | 0               | 1(0.5%)         | 0                       | 1(0.5%)                 | 0                            | 0                            | 0               | 0               |
| Illeus                                           | 0               | 1 ( 0.5%)       | 0                       | 1 ( 0.5%)               | 0                            | 1 (0.5%)                     | 0               | 1 (0.5%)        |
| Nausea                                           | 1 (0.5%)        | 0               | 0                       | 0                       | 1 (0.5%)                     | 0                            | 0               | 0               |
| Pancreatitis                                     | 1 (0.5%)        | 0               | 1 (0.5%)                | 0                       | 0                            | 0                            | 0               | 0               |
| Vomiting                                         | 0               | 1 ( 0.5%)       | 0                       | 1 (0.5%)                | 0                            | 0                            | 0               | 0               |
| INJURY,POISONINGANDPROCEDURAL COMPLICATIONS      | 0               | 5 (2.5%)        | 0                       | 5 (2.5%)                | 0                            | 0                            | 0               | 1 (0.5%)        |
| Infusion related reaction                        | 0               | 5 ( 2.5%)       | 0                       | 5 ( 2.5%)               | 0                            | 2 (1.0%)                     | 0               | 1 (0.5%)        |
| INFECTIONSANDINFESTATIONS                        | 1 (0.5%)        | 3 ( 1.5%)       | 1 (0.5%)                | 2 ( 1.0%)               | 0                            | 0                            | 0               | 2 (1.0%)        |
| Pneumonia                                        | 1 (0.5%)        | 1 ( 0.5%)       | 1 (0.5%)                | 1(0.5%)                 | 0                            | 1 (0.5%)                     | 0               | 1 (0.5%)        |
| Lower respiratory tract infection                | 0               | 1(0.5%)         | 0                       | 0                       | 0                            | 1 (0.5%)                     | 0               | 0               |
| Urinary tract infection                          | 0               | 1 (0.5%)        | 0                       | 1 (0.5%)                | 0                            | 1 (0.5%)                     | 0               | 1 (0.5%)        |
| GENERALDISORDERSAND ADMINISTRATIONSITECONDITIONS | 1 (0.5%)        | 2 ( 1.0%)       | 1 (0.5%)                | 2 ( 1.0%)               | 0                            | 0                            | 0               | 0               |
| Asthenia                                         | 1 (0.5%)        | 1 ( 0.5%)       | 1 (0.5%)                | 1 ( 0.5%)               | 0                            | 0                            | 0               | 0               |
| General physical health deterioration            | 0               | 1(0.5%)         | 0                       | 1 (0.5%)                | 0                            | 0                            | 0               | 0               |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS             | 0               | 2 ( 1.0%)       | 0                       | 0                       | 0                            | 1 (0.5%)                     | 0               | 0               |
| Leukopenia                                       | 0               | 1 ( 0.5%)       | 0                       | 0                       | 0                            | 1 (0.5%)                     | 0               | 0               |
| Neutropenia                                      | 0               | 1 ( 0.5%)       | 0                       | 0                       | 0                            | 1 (0.5%)                     | 0               | 0               |
| Thrombocytopenia                                 | 0               | 1 ( 0.5%)       | 0                       | 0                       | 0                            | 1 (0.5%)                     | 0               | 0               |

<div style=\"page-break-after: always\"></div>

| CARDIACDISORDERS                                | 2 (1.0%)   | 0        | 2 (1.0%)   | 0        | 0        |   0 | 1 (0.5%)   |   0 |
|-------------------------------------------------|------------|----------|------------|----------|----------|-----|------------|-----|
| Atrial fibrillation                             | 1 (0.5%)   | 0        | 1 (0.5%)   | 0        | 0        |   0 | 0          |   0 |
| Pericardial effusion                            | 1 (0.5%)   | 0        | 1 (0.5%)   | 0        | 1 (0.5%) |   0 | 1 (0.5%)   |   0 |
| VASCULARDISORDERS                               | 0          | 2 (1.0%) | 0          | 2 (1.0%) | 0        |   0 | 0          |   0 |
| Hypotension                                     | 0          | 1 (0.5%) | 0          | 1 (0.5%) | 0        |   0 | 0          |   0 |
| Superior vena cava syndrome                     | 0          | 1 (0.5%) | 0          | 1 (0.5%) | 0        |   0 | 0          |   0 |
| HEPATOBILIARY DISORDERS                         | 0          | 1 (0.5%) | 0          | 1 (0.5%) | 0        |   0 | 0          |   0 |
| Jaundice                                        | 0          | 1 (0.5%) | 0          | 1 (0.5%) | 0        |   0 | 0          |   0 |
| IMMUNESYSTEMDISORDERS                           | 0          | 1 (0.5%) | 0          | 1 (0.5%) | 0        |   0 | 0          |   0 |
| Anaphylactic reaction                           | 0          | 1 (0.5%) | 0          | 1 (0.5%) | 0        |   0 | 0          |   0 |
| INVESTIGATIONS                                  | 0          | 1 (0.5%) | 0          | 1 (0.5%) | 0        |   0 | 0          |   0 |
| Transaminases increased                         | 0          | 1 (0.5%) | 0          | 1 (0.5%) | 0        |   0 | 0          |   0 |
| NERVOUSSYSTEMDISORDERS                          | 0          | 1 (0.5%) | 0          | 1 (0.5%) | 0        |   0 | 0          |   0 |
| Trigeminal neuralgia                            | 0          | 1 (0.5%) | 0          | 1 (0.5%) | 0        |   0 | 0          |   0 |
| RENALANDURINARYDISORDERS                        | 0          | 1 (0.5%) | 0          | 1 (0.5%) | 0        |   0 | 0          |   0 |
| Tubulointerstitial nephritis                    | 0          | 1 (0.5%) | 0          | 1 (0.5%) | 0        |   0 | 0          |   0 |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | 1 (0.5%)   | 0        | 1 (0.5%)   | 0        | 0        |   0 | 0          |   0 |
| Pneumonitis                                     | 1 (0.5%)   | 0        | 1 (0.5%)   | 0        | 0        |   0 | 0          |   0 |
| SKINANDSUBCUTANEOUSTISSUE DISORDERS             | 0          | 1 (0.5%) | 0          | 1 (0.5%) | 0        |   0 | 0          |   0 |
| Erythema                                        | 0          | 1 (0.5%) | 0          | 1 (0.5%) | 0        |   0 | 0          |   0 |

- *: Atezolizumab/placebo withdrawal irrespective of chemotherapy
- **: Carboplatin or etoposide withdrawal irrespective of other study treatment

Table 70 : AEs leading to dose modification/interruption reported in ≥2% of patients in either treatment arm (safety evaluable population)

|                                                         | Any treatment   | Any treatment    | Atezolizumab/Placebo   | Atezolizumab/Placebo   | Carboplatin   | Carboplatin      | Etoposide    | Etoposide        |
|---------------------------------------------------------|-----------------|------------------|------------------------|------------------------|---------------|------------------|--------------|------------------|
| MedDRA System Organ Class MedDRAPreferredTerm           | PBO+CE N=196    | Atezo + CE N=198 | PBO+CE N=196           | Atezo + CE N=198       | PBO+CE N=196  | Atezo + CE N=198 | PBO+CE N=196 | Atezo + CE N=198 |
| Total number of patients with at least one adverseevent | 119 (60.7%)     | 138 (69.7%)      | 102 (52.0%)            | 117 (59.1%)            | 96 (49.0%)    | 111 (56.1%)      | 95 (48.5%)   | 113 (57.1%)      |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS                    | 64 (32.7%)      | 72 (36.4%)       | 49 (25.0%)             | 61 (30.8%)             | 58 (29.6%)    | 68 (34.3%)       | 55 (28.1%)   | 66 (33.3%)       |
| Neutropenia                                             | 46 (23.5%)      | 53 (26.8%)       | 35 (17.9%)             | 43 (21.7%)             | 43 (21.9%)    | 53 (26.8%)       | 41 (20.9%)   | 50 (25.3%)       |
| Anaemia                                                 | 12 ( 6.1%)      | 19 ( 9.6%)       | 11 ( 5.6%)             | 17 ( 8.6%)             | 10 ( 5.1%)    | 15 ( 7.6%)       | 9 ( 4.6%)    | 16 ( 8.1%)       |
| Thrombocytopenia                                        | 15 (7.7%)       | 13 ( 6.6%)       | 10 ( 5.1%)             | 10 ( 5.1%)             | 12 ( 6.1%)    | 11 (5.6%)        | 12 ( 6.1%)   | 10 ( 5.1%)       |
| Leukopenia                                              | 5 (2.6%)        | 13 ( 6.6%)       | 3 ( 1.5%)              | 13 ( 6.6%)             | 5 ( 2.6%)     | 9 (4.5%)         | 5 (2.6%)     | 9 ( 4.5%)        |
| Febrile neutropenia                                     | 5 (2.6%)        | 3 ( 1.5%)        | 2 ( 1.0%)              | 3 ( 1.5%)              | 5 (2.6%)      | 1 ( 0.5%)        | 4 ( 2.0%)    | 1 ( 0.5%)        |
| INVESTIGATIONS                                          | 42 (21.4%)      | 38 (19.2%)       | 37 (18.9%)             | 27 (13.6%)             | 37 (18.9%)    | 32 (16.2%)       | 38 (19.4%)   | 32 (16.2%)       |
| Neutrophil count decreased                              | 33 (16.8%)      | 25 (12.6%)       | 30 (15.3%)             | 21 (10.6%)             | 30 (15.3%)    | 24 (12.1%)       | 31 (15.8%)   | 22 (11.1%)       |
| Platelet count decreased                                | 10 (5.1%)       | 6 (3.0%)         | 8 (4.1%)               | 3 ( 1.5%)              | 7 (3.6%)      | 6 (3.0%)         | 7 (3.6%)     | 4 ( 2.0%)        |
| Whitebloodcellcountdecreased                            | 10 ( 5.1%)      | 4 ( 2.0%)        | 8 (4.1%)               | 3 ( 1.5%)              | 8 ( 4.1%)     | 4 (2.0%)         | 8 (4.1%)     | 3 ( 1.5%)        |
| Alanine aminotransferase increased                      | 0               | 4 ( 2.0%)        | 0                      | 3 ( 1.5%)              | 0             | 1 (0.5%)         | 0            | 2 (1.0%)         |
| INFECTIONSANDINFESTATIONS                               | 18 ( 9.2%)      | 12 ( 6.1%)       | 17 ( 8.7%)             | 11 ( 5.6%)             | 7 (3.6%)      | 10 (5.1%)        | 8 ( 4.1%)    | 11 ( 5.6%)       |
| Pneumonia                                               | 4 (2.0%)        | 4 (2.0%)         | 3 ( 1.5%)              | 4 (2.0%)               | 1 ( 0.5%)     | 4 ( 2.0%)        | 2 ( 1.0%)    | 4 ( 2.0%)        |
| GENERAL DISORDERS AND ADMINISTRATIONSITECONDITIONS      | 7 (3.6%)        | 16 ( 8.1%)       | 5 (2.6%)               | 10 ( 5.1%)             | 4 ( 2.0%)     | 4 (2.0%)         | 4 ( 2.0%)    | 6 (3.0%)         |
| Fatigue                                                 | 0               | 10 ( 5.1%)       | 0                      | 8 (4.0%)               | 0             | 3 (1.5%)         | 0            | 3 ( 1.5%)        |
| Pyrexia                                                 | 0               | 4 (2.0%)         | 0                      | 2 ( 1.0%)              | 0             | 0                | 0            | 2 ( 1.0%)        |
| INJURY,POISONINGANDPROCEDURAL COMPLICATIONS             | 8 (4.1%)        | 8 (4.0%)         | 6 (3.1%)               | 8 (4.0%)               | 0             | 0                | 2 ( 1.0%)    | 2 ( 1.0%)        |
| Infusion related reaction                               | 6 (3.1%)        | 7 (3.5%)         | 5 (2.6%)               | 7 (3.5%)               | 0             | 0                | 1 ( 0.5%)    | 1 (0.5%)         |

## Post marketing experience

Since the International Birth Date (18 May 2016) through 17 May 2018, an estimated cumulative total of 20,783 patients have received atezolizumab from marketing experience (United States n=18,470; European Union n=987; Japan n=181; Rest of the World n=1,145). No new or unexpected safety findings were identified in the post marketing setting for atezolizumab used as a monotherapy. The combination regimen of atezolizumab with carboplatin and etoposide administrated in study IMpower133 is not approved yet.

## 2.5.1. Discussion on clinical safety

Likely reflecting worse prognosis of SCLC as compared to NSCLC, exposure to ATZ in IMpower133 (median 7 doses) was lower than the other first-line NSCLC studies (median 10 doses). Importantly, exposure to ATZ/PBO and chemotherapy between both arms of the trial was similar, with data that reflect completed induction (4 cycles) and started maintenance phase for 81% of the safety population. AEs were observed in almost all treated subjects from the trial. The proportion of patients with G3-4 AEs was high, although comparable between both arms of treatment (67% ATZ+CE, 64% PBO+CE), as was the rate of serious AEs (37% and 35%, respectively). G5 AEs, however, were more common in the PBO+CE arm (6% vs. 2%). On the other hand, most patients with AEs that prompted permanent treatment withdrawal were in the ATZ+CE arm (22 out of 28). The most common AEs of any grade that occurred in the trial were anaemia (39%), neutropenia (36%), alopecia (36%), nausea (35%), constipation (28%) and fatigue (26%), corresponding to what is expected from carboplatin + etoposide, the backbone of both arms. AEs with a considerably higher frequency in the ATZ+CE arm were hypothyroidism (10% vs. 0.5%), decreased appetite (27% vs. 18%), anaemia (43% vs. 35%) and nausea (38% vs. 33%). Conversely, hypokalaemia occurred more often in the PBO+CE arm (9% vs. 4%). Excluding neutropenia, most AEs from the ATZ+CE arm occurred in a similar proportion of patients from the lung-pool studies (37% vs. 27%). G3-4 events that occurred in the trial were in general related to myelotoxicity and hence most likely associated to carboplatin + etoposide. G3-4 gastrointestinal disorders -such as diarrhoea, vomiting and nausea- occurred more in ATZ+CE (9% vs. 6% in PBO+CE). The incidence of G3-4 neutropenia was comparable in both arms (23% ATZ+CE, 25% PBO+CE), albeit considerably higher than in the lung-pool (17%). Based on the review of the pooled safety data set for atezolizumab in combination with chemotherapy, the following ADRs have been added to the section 4.8 of the SmPC: lymphocyte count decreased, headache, vomiting, AST/ALT increased and asthenia. The majority of serious AEs were also related to myelotoxicity and were observed in a similar proportion of patients from both arms. The proportion of patients with febrile neutropenia was higher in the PBO+CE arm (4.6% vs. 2.5%). The proportion of patients with AESIs in the ATZ+CE arm was noticeably higher than in the PBO+CE arm (40 vs. 25%). Most AESIs were immune-related but only about a quarter of the patients from each arm required systemic corticosteroids. Of these, the most frequent was rash, followed by thyroid disorders and hepatitis. As compared to the lung-pool, the incidence and severity of AESIs in the ATZ+CE arm was slightly lower. As expected from chemotherapy-related myelotoxicity, the majority of clinically relevant shifts occurred in haematology (CBC) parameters. The safety profile from the pooled lung-studies suggests particular sensitivity of elderly and Asian patients to treatment with ATZ+chemotherapy. As compared to PBO+CE (3%), 11% of patients from the ATZ+CE arm required treatment withdrawal due to AEs. The main reasons for permanently discontinuing ATZ in 21 patients from the ATZ+CE arm were infusion-related reactions and gastrointestinal disorders. Similarly, the proportion of patients who required dose modification/interruption of ATZ/PBO in the ATZ+CE arm was higher than in the PBO+CE arm (59% vs. 52%). This difference seems mainly driven by the incidence of leukopenia (6.6% vs. 1.5%). From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics. No changes to the RMP are needed as a result of the new safety data

<div style=\"page-break-after: always\"></div>

submitted as part of the application.

## 2.5.2. Conclusions on clinical safety

Overall, the safety profile from carboplatin + etoposide (CE) in both arms of IMpower133 corresponded to the known safety profile of the individual study drugs in clinical practice. Adding ATZ to CE slightly increases the incidence of G3-4 and serious AEs and led to higher proportions of patients that require dose modification/interruption or permanent treatment withdrawal. Nonetheless, the majority of ADRs from ATZ were manageable and resolved with treatment. The safety profile of ATZ+CE in the IMpower133 study was generally consistent with the safety profile of atezolizumab in combination with platinum-based chemotherapy in the Atezo + Chemo Combo population (lung-pool studies). No new safety concerns arise from the use of ATZ+CE in ES-SCLC patients.

The current RMP is adequate to manage the risks associated with Tecentriq is this new indication.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 9.1 is acceptable.

The CHMP endorsed the Risk Management Plan version 9.1 with the following content:

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                                                                                                                               |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-related hepatitis Immune-related pneumonitis Immune-related colitis Immune-related pancreatitis Immune-related endocrinopathies (diabetes mellitus, hypothyroidism, hyperthyroidism, adrenal insufficiency and hypophysitis) Immune-related neuropathies (Guillain-Barré syndrome, and myasthenic syndrome / myasthenia gravis) Immune-related meningoencephalitis Infusion-related reactions Immune-related myocarditis Immune-related nephritis |
| Important potential risks    | Anti-drug antibodies Embryo-fetal toxicity                                                                                                                                                                                                                                                                                                                                                                                                               |
| Missing information          | Concomitant use with other immuno-modulatory drugs Long term use Concomitant or sequential use of atezolizumab with intra-vesical Bacillus Calmette-Guérin vaccine for the treatment of urothelial carcinoma                                                                                                                                                                                                                                             |

No changes to the list of safety concerns were made as a result of this extension of indication.

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                                                                                                      | Summary of Objectives                                                                                                                                                                                                                                                                                                                        | Safety concerns addressed                                                                                                                                                                                                                             | Milestones                                                                                                                                                                                                                                            | Due dates                                                                                                                                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                             | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                        | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization There are no Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization |
| conditional marketing authorization or a marketing authorization under exceptional circumstances Category 3 - Required additional pharmacovigilance activities                                                                                                                    | conditional marketing authorization or a marketing authorization under exceptional circumstances Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                               | conditional marketing authorization or a marketing authorization under exceptional circumstances Category 3 - Required additional pharmacovigilance activities                                                                                        | conditional marketing authorization or a marketing authorization under exceptional circumstances Category 3 - Required additional pharmacovigilance activities                                                                                        | conditional marketing authorization or a marketing authorization under exceptional circumstances Category 3 - Required additional pharmacovigilance activities                                                                                        |
| GO28915 (OAK) A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared with Docetaxel in Patients with Non-Small Cell Lung Cancer After Failure with Platinum-Containing Chemotherapy Ongoing | To determine if atezolizumab treatment results in an improved OS compared with docetaxel To evaluate safety and tolerability of atezolizumab compared with docetaxel To evaluate incidence of ADAs against atezolizumab and to explore the potential relationship of the immunogenicity response with pharmacokinetics, safety, and efficacy | Anti-drug antibodies                                                                                                                                                                                                                                  | Final CSR                                                                                                                                                                                                                                             | December 2019                                                                                                                                                                                                                                         |
| GO29322: A Phase IB Study of the Safety and Pharmacology of atezolizumab Administered with Ipilimumab or Interferon-Alpha in Patients with Locally Advanced or Metastatic Solid Tumors Ongoing                                                                                    | To evaluate the safety and tolerability of atezolizumab and ipilimumab in combination in patients with advanced or metastatic NSCLC or melanoma. To evaluate the safety and tolerability of atezolizumab and interferon alfa-2b in combination in patients with advanced or metastatic RCC or                                                | Concomitant use with other immunomodulatory drugs                                                                                                                                                                                                     | Final CSR                                                                                                                                                                                                                                             | March 2020                                                                                                                                                                                                                                            |
| WO29635: A Phase IB/II, Open-Label Study of the Safety and Pharmacology of Atezolizumab Administered with or without Bacille Calmette-Guérin in Patients with High Risk Non Muscle-Invasive Bladder Cancer                                                                        | melanoma To evaluate the safety and tolerability of atezolizumab as a single agent and in combination with BCG. To identify the DLTs and to determine the MTD or tolerability at the MAD of BCG in combination with atezolizumab                                                                                                             | Concomitant or sequential use of atezolizumab with intra-vesical BCG vaccine for the treatment of urothelial carcinoma                                                                                                                                | Final CSR                                                                                                                                                                                                                                             | June 2022                                                                                                                                                                                                                                             |
| Ongoing MO39171 (TAIL): Single-Arm Long-Term Safety and Efficacy Study of atezolizumab in previously treated NSCLC Patients Ongoing                                                                                                                                               | To evaluate the long-term safety of atezolizumab on the bases of the following endpoints: The incidence of all serious adverse events (SAEs) related to atezolizumab treatment and the incidence of immune-related adverse events (irAEs) related to atezolizumab                                                                            | Long-term use                                                                                                                                                                                                                                         | Final CSR                                                                                                                                                                                                                                             | May 2022                                                                                                                                                                                                                                              |
| MO29983: An Open-Label, Single Arm, Multicenter, Safety Study of atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract Ongoing                                                                                               | treatment To evaluate the safety of atezolizumab based on the following endpoints: Nature, severity, duration, frequency and timing of adverse events (AEs) and changes in vital signs, physical findings, and clinical laboratory results during and following atezolizumab administration.                                                 | Long-term use                                                                                                                                                                                                                                         | Final CSR                                                                                                                                                                                                                                             | Q1 2023                                                                                                                                                                                                                                               |
| WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of                                                                                                                         | The overall objective is to evaluate the effectiveness of the HCP brochure designed to mitigate important immune-related risks in patients receiving atezolizumab                                                                                                                                                                            | Immune-related hepatitis Immune-related pneumonitis Immune-related colitis Immune-related pancreatitis Immune-related                                                                                                                                 | Protocol submission Interim report                                                                                                                                                                                                                    | February 2018 December 2020                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions Ongoing   | in the European Union. Data from HCP surveys and reporting rates for the important identified immune related risks will be collected and analyzed to evaluate effectiveness of the HCP brochure   | endocrinopathies (diabetes mellitus, hypothyroidism, hyperthyroidism, adrenal insufficiency, and hypophysitis) Immune-related neuropathies (Guillain-Barré syndrome, and myasthenic syndrome / myasthenia gravis) Immune related meningoencephalitis Infusion-related reactions Immune-related myocarditis Immune-related nephritis   | Final Report   | December 2022   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-----------------|

No new studies were added to the pharmacovigilance plan as a result of this extension of indication.

## Risk minimisation measures

| Safety concern             | Risk minimization measures                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-Related Hepatitis   | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and                             |
| Immune-Related Pneumonitis | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions. |
| Immune-Related Colitis     | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization                                                                  | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                                 | Risk minimization measures                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|--------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                | measures: • Educational materials for HCPs • Patient alert cards                                                                                                                                                                                                                                                                                        | educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions.                                                                                                                                                                                                                                             |
| Immune-Related Pancreatitis                                                                                                    | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis,                                                                                    |
| Immune-Related Endocrinopathies (Diabetes Mellitus, Hypothyroidism, Hyperthryroidism, Adrenal Insufficiency, and Hypophysitis) | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | infusion-related reactions. Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis and infusion-related reactions. |
| Immune-Related Neuropathies (Guillain-Barre Syndrome and Myasthenia Gravis)                                                    | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions.                            |

<div style=\"page-break-after: always\"></div>

| Safety concern                     | Risk minimization measures                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-Related Meningoencephalitis | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis and infusion-related reactions. |
| Infusion-Related Reactions         | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition and intervention of the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and                            |
| Immune-Related Myocarditis         | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition of and intervention in the following important immune-related risks: Pneumonitis, hepatitis, colitis, pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and                         |
| Immune-related nephritis           | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 -Undesirable effects Additional risk minimization measures: • Educational materials for HCPs Patient alert cards  | infusion-related reactions. Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: WO40486 (Observational Study) Evaluation of the effectiveness of HCP educational materials which aims to facilitate early recognition of and intervention in the following important immune-related risks: Pneumonitis, hepatitis, colitis,                                                                                            |

<div style=\"page-break-after: always\"></div>

| Safety concern          | Risk minimization measures                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance activities                                                                                                                                    |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                         |                                                                                                                                                                                                                                                                                                                                                         | pancreatitis, endocrinopathies, neuropathies, meningoencephalitis, myocarditis, nephritis, and infusion-related reactions.                                      |
| Immune-related myositis | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.2 Posology and method of administration Section 4.4 Special Warnings and Precautions for Use Section 4.8 Undesirable effects Additional risk minimization measures: • Educational materials for HCPs • Patient alert cards | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                |
| Anti-drug Antibodies    | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.8 Undesirable effects No additional risk minimization measures                                                                                                                                                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study GO28915 (OAK) |
| Embryo-fetal toxicity   | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.6 Fertility, pregnancy and lactation Section 5.3 Preclinical safety data No additional risk minimization measures                                                                                                          | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                                               | Risk minimization measures                                                                                                                                                                                                                                                                                                                                           | Pharmacovigilance activities                                                                                                                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Concomitant use with other immuno-modulatory agents                                                                                          | Routine risk minimization measures: This safety concern considered as missing information is mentioned as one of the exclusion criteria within the Warnings and Precautions and description of studies included in the E.U. SmPC. No Additional risk minimization measures                                                                                           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study GO29322                |
| Long-term use                                                                                                                                | Routine risk minimization measures: Proposed text in E.U. SmPC: None No Additional risk minimization measures                                                                                                                                                                                                                                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Studies: • MO29983 • MO39171 |
| Concomitant or sequential use of atezolizumab with intra-vesical Bacillus Calmette-Guérin vaccine for the treatment of urothelial carcinoma. | Routine risk minimization measures: Proposed measures are described in the E.U. SmPC under the following sections: Section 4.4 Special Warnings and Precautions for Use: Includes language that patients who were administered a live attenuated vaccine with 28 days prior to enrolment were excluded from clinical trials No Additional risk minimization measures | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study WO29635                |

The risk minimisations measures remain unchanged as a result of this extension of indication.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

The new indication has only been reflected in the SmPC for the 1,200 mg strength, however the safety sections have been aligned between the 840 mg and 1,200 mg strengths.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

- No significant changes impacting the readability of the package leaflet are made. The new additions follow the same structure and use similar descriptions and terminology as used in the approved package leaflet.
- The target group of users will be similar between the approved indication (locally advanced or metastatic NSCLC previously treated with chemotherapy) and the applied indication (first-line treatment of adult patients with extensive-stage SCLC), with no significant age difference.
- Moreover, the posology proposed in this application is the same as for the currently approved indication.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The proposed new therapeutic indication in this procedure is in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

SCLC is a deadly tumour accounting for approximately 13-15% of lung cancers and is pathologically, molecularly, biologically and clinically very different from other lung cancers (Gazdar et al, Nat Rev 2017;17:725-37). Most SCLC patients have a history of tobacco use.

## 3.1.2. Available therapies and unmet medical need

SCLC is usually widely metastatic at diagnosis and initially responds to cytotoxic therapy and radiotherapy, but it nearly always rapidly relapses with resistance to further therapies. Despite numerous clinical trials, including at least 40 phase 3 trials since the 1970s, systemic treatment for patients with SCLC (commonly carboplatin or cisplatin + etoposide) has not changed significantly in the past several decades (Früh et al, Ann Onc 2013;24:Supp6). Consequently, the 5-year survival rate remains low (&lt;7% overall), and most patients survive for only 1 year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which major advances have been made using targeted agents and immunotherapy, there are still no approved targeted drugs or immunotherapy for SCLC (Byers and Rudin, Cancer 2015;121:665-72). However, over the past 5 years, there has been a worldwide resurgence of studies on SCLC, including comprehensive molecular analyses, the development of relevant genetically engineered mouse models and the establishment of patient-derived xenografts. These studies have led to the discovery of new potential therapeutic vulnerabilities for SCLC and therefore to new clinical trials. (Gazdar et al, Nat Rev 2017;17:725-37).

## 3.1.3. Main clinical studies

One pivotal, double-blind, placebo-controlled, randomized phase I/III study was submitted by the MAH to support the first-line indication in patients with extensive-stage small cell lung cancer (ES-SCLC). IMpower133 investigated the efficacy and safety of 4 cycles of carboplatin plus etoposide with or without atezolizumab (n=403). Following the induction phase, patients continued maintenance therapy with either atezolizumab or placebo (no re-randomization). The co-primary efficacy endpoints of the trial were INV-assessed PFS and OS in the ITT population.

## 3.2. Favourable effects

The study has met its two co-primary efficacy endpoints. At the primary analysis (data cut-off 24-APR-2018), 59% of OS events had occurred and median follow-up was 13.9 months for all patients. First interim OS analysis showed significant statistical benefit from atezolizumab+CE (mOS 12.3 months) over PBO+CE (mOS 10.3 months), with a stratified HR of 0.701 (95% CI 0.54-0.91, p=0.0069), for a net gain of 2 months of median OS for the ITT.

Final exploratory OS analysis for the ITT (data cut-off 24-JAN-2019, 302 OS events = 75%) seems overall consistent with the first interim OS analysis. Median OS in both arms is unchanged (12.3 months in the atezolizumab+CE arm and 10.3 months in the PBO+CE arm), although HR has decreased [HR 0.76 (95%CI 0.61, 0.96] and the p-value is now 0.0154.

<div style=\"page-break-after: always\"></div>

For the final PFS analysis, 89% INV-declared PFS events are accounted for. PFS from atezolizumab+CE is also superior to PBO+CE, but with a meagre difference: median PFS 5.2 vs. 4.3 months and stratified HR of 0.772 (95% CI 0.62-0.96, p=0.0170). The net gain of median PFS is 0.9 months.

Forest plots on PFS and OS (updated) suggest the treatment effect from atezolizumab+CE was consistent across the majority of subgroups evaluated. The practiced sensitivity analyses do not alter the statistical benefit indicated from the primary endpoints.

## 3.3. Uncertainties and limitations about favourable effects

It is not clear whether the treatment effect is related to the use of atezolizumab during the induction or the maintenance phase.

The benefit of treatment with atezolizumab beyond progressive disease is not established and is therefore left at the discretion of the physician (see section 4.2 of the SmPC).

Patients with brain metastases are underrepresented in the pivotal trial (9%, n=35); only subjects with pre-treated and asymptomatic brain metastases were allowed for enrolment; data are too limited to draw conclusions on this population and this has been reflected in section 5.1 of the SmPC.

Updated analyses of OS by treatment-emergent ADA status based on the 24 January 2019 cutoff analyses reported a large difference for the median OS values between both ADA subgroups (mOS 14.1 months in ADA- subgroup and 10.9 months in the ADA+ subgroup), but the data are limited due to the small sample size of the ADA+ (n=35) subgroup. However, complete ADA analyses across several indications (including SCLC) will be performed by the MAH.

## 3.4. Unfavourable effects

Overall, atezolizumab in combination with CE is well tolerated. Similar rates of AEs were observed in both arms of the trial. The most common AEs of any grade that occurred in the trial were anaemia, neutropenia, alopecia, nausea, constipation and fatigue, likely corresponding to the chemotherapy backbone.

AEs with a considerably higher frequency in the atezolizumab+CE arm were hypothyroidism (10% vs. 0.5%), decreased apetite (27% vs. 18%), anemia (43% vs. 35%) and nausea (38% vs. 33%).

The proportion of patients with G3-4 AEs was high, although comparable between both arms of treatment (67% atezolizumab+CE, 64% PBO+CE), as was the rate of serious AEs (37% and 35%, respectively). The majority of G3-4 and serious AEs were related to myelotoxicity from chemotherapy. G5 AEs were rare: 11 (5.6%) patients from the PBO+CE arm and 4 (2.0%) from the atezolizumab+CE arm.

As expected, AESIs occurred more in the atezolizumab+CE arm than in the PBO+CE arm (40% vs. 25%). The majority of AESIs were immune-related and the most frequent were rash, thyroid disorders and hepatitis. Overall, AESIs were manageable and resolved with treatment.

The main safety concern from adding atezolizumab to CE derives from the high proportion of patients who permanently withdrew from treatment due AEs: 22 (11%) vs. 6 (3%) in the PBO+CE arm.

## 3.5. Uncertainties and limitations about unfavourable effects

There are no uncertainties about the unfavourable effects.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 71 : Effects Table for ATZ+CE vs. PBO+CE in the first line treatment of patients with extensive-stage small cell lung cancer, data cut-off 24 January 2019 for OS (exploratory final analysis) and 24 April 2018 for PFS (primary analysis)

| Effect                                   | Unit                  | ATZ+CE (experimental)   | PBO+CE (control)      | Uncertainties / Strength of evidence       |
|------------------------------------------|-----------------------|-------------------------|-----------------------|--------------------------------------------|
| Favourable Effects                       | Favourable Effects    | Favourable Effects      | Favourable Effects    | Favourable Effects                         |
| *OS ITT (n=403)                          | Months                | 12.3                    | 10.3                  | Stratified HR 0.76 (0.60, 0.95) p = 0.0154 |
| *INV-assessed PFS ITT (n=403)            | Months                | 5.2                     | 4.3                   | Stratified HR 0.77 (0.62, 0.96) p = 0.0170 |
| ¤Unfavourable Effects                    | ¤Unfavourable Effects | ¤Unfavourable Effects   | ¤Unfavourable Effects | ¤Unfavourable Effects                      |
| AESIs                                    | %                     | 39.9                    | 24.5                  |                                            |
| Grade 3-4 AEs                            | %                     | 67                      | 64                    |                                            |
| AEs leading to treatment discontinuation | %                     | 11.1                    | 3.1                   |                                            |

*Co-primary efficacy endpoints

¤Safety population n=394 (ATZ+CE n=198, PBO+CE n=196)

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The need for improving outcomes in ES-SCLC is imperative, but a clinically compelling benefit must be proven against potential risks of add-on treatments. In NSCLC, three different immune checkpoint inhibitors (nivolumab, pembrolizumab and atezolizumab) were approved as monotherapy in the second-line setting before escalating to first-line in combination with backbone chemotherapy (pembrolizumab + carboplatin + paclitaxel was approved by CHMP in July 2018). This is not the case with SCLC, since immunotherapy in any setting has not demonstrated an advantage that supersedes its hazards.

Although IMpower133 has met both its co-primary endpoints (superior OS and PFS from atezolizumab+CE vs. PBO+CE in ITT), with a modest net gain of 0.9 months in median PFS (HR=0.77) and 2 months in median OS (HR=0.76). Furthermore, this benefit is not firmly supported by surrogate endpoints such as ORR and DoR. However, given the high unmet medical need in this population and the lack of any survival improvements in the last years, even a small OS advantage could be accepted as clinically meaningful in this patient population.

A retrospective and limited (42% of the ITT) analysis on PD-L1 IHC status and efficacy does not allow for reliable conclusions regarding this as a predictive biomarker for response to immunotherapy in ES-SCLC.

In regards to safety, adding atezolizumab to standard of care platinum + etoposide did not seem to make it less tolerable or significantly increase its risks, but there are two issues that cannot be overlooked from the atezolizumab+CE arm: a high rate of immune-related adverse events and a considerable proportion of patients who withdrew from treatment due AEs. However no new safety signals have been identified and given the overall tolerability of the combination therapy, the added toxicity would not outweigh a clinical relevant improvement in survival.

## 3.7.2. Balance of benefits and risks

Based on the provided data, the B/R balance is positive.

<div style=\"page-break-after: always\"></div>

## 3.7.3. Additional considerations on the benefit-risk balance

PD-L1 IHC (Ventana SP263) results are available for 168 patients (42% from ITT), 93 in the PBO+CE arm and 75 in the atezolizumab+CE arm. PD-L1 positivity, defined as staining of ≥ 1% of tumour cells, was 55% in the PBO+CE arm and 56% in the atezolizumab+CE arm. In PD-L1 positive patients (n=93), median OS is 10.6 in atezolizumab+CE and 11.1 in PBO+CE. In PD-L1 negative patients (n=75), median OS is 10.5 in atezolizumab+CE and 8.8 in PBO+CE. No reliable conclusions regarding the relationship between PD-L1 IHC status and efficacy can be drawn.

The actual PFS difference was considerably smaller than the expected one.

## 3.8. Conclusions

The overall B/R of atezolizumab in combination with carboplatin + etoposide is positive as first line treatment for all-comer patients with extensive-stage small cell lung cancer.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication to include, in combination with carboplatin and etoposide, first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) for tecentriq; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 9.1 has been agreed.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Additional market protection

Furthermore, the CHMP reviewed the data submitted by the MAH, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers by consensus that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies (see appendix 1).

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Extension of Indication to include, in combination with carboplatin and etoposide, first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) for tecentriq; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 9.1 has been agreed.

<div style=\"page-break-after: always\"></div>

## Summary

Please refer to the Scientific Discussion Tecentriq-H-C-4143-II-0018.